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Abstract 
Human African trypanosomiasis (HAT), a lethal disease caused by infection with 
Trypanosoma brucei rhodesiense or Trypanosoma brucei gambiense, is responsible for an 
estimated 500,000 fatalities every year in sub-Saharan Africa. Veterinary trypanosomiases 
caused by related trypanosome species have also retarded agricultural and economic 
development in one of the world's poorest areas. Current control methods rely heavily on 
flawed trypanocides that have been in use for over 50 years. The inherent limitations of 
existing drugs have been compounded further by reports of increasing rates of treatment 
failure. 
Trypanosomes are incapable of de novo synthesis of the purine ring, and since purines are 
essential for many cellular functions (e.g. nucleic acid synthesis, energy metabolism) this 
means the parasites have an absolute requirement for exogenous purines. Several 
transporters have been identified in T. brucei brucei that allow the salvage of purine 
nucleosides (PI and P2 transporter) and nucleobases (HI, H2, H3 and H4 transporter) from 
the host environment. Whilst mammalian cells can also intemalise purines from their 
surroundings, most can synthesise the purine ring from other precursor molecules and this 
is generally reflected in their less efficient uptake systems. 
The P2 nucleoside transporter has also been shown to facilitate entry of arsenical and 
diamidine trypanocides, and loss of this transporter appears to confer resistance to some of 
these drugs in vitro. Given the need for new drugs in the battle against African 
trypanosomiasis and that, possible role in drug resistance notwithstanding, a purine 
transporter has proven an ideal conduit in the past for empirically-applied chemotherapy, it 
has been proposed that other parasite nucleoside and nucleobase transporters could be 
exploited for entry of rationally designed trypanocides. Furthermore, a large reservoir of 
purine compounds exists as a consequence of their widespread use in many other medical 
conditions - the identification of an effective trypanocide from this resource could 
contribute to rapid and cost-effective deployment. 
This thesis describes the elucidation and comparison of substrate recognition relationships 
for the H2 nucleobase transporter of T. b. brucei and the main nucleobase transporter of 
human erythrocytes. Using standard transport kinetics, application of the Cheng-Prusoff 
equation and a derivation of the Nemst equation, it was possible to determine the Gibbs 
free energy (llGO) for the interactions of purine analogues with each transporter, which 
allowed predictions about the nature of the interactions that are essential for uptake. A 
range of unusual tricyclic and "fleximer" purine analogues was also assayed for ability to 
interact with the various purine transporters in T. b. brucei and human erythrocytes. This 
provided further insights into the extent that the substrate-binding pocket can 
accommodate unusual and large substrates. 
Some of the purine analogues used for the substrate-recognition study also displayed 
limited trypanocidal activity in vitro. More importantly, these results provide a foundation 
for the design and development of purine nucleobase analogues with anti-trypanosomal 
action that are efficiently and selectively accumulated by the parasite. 
One of the main aims of the project was to clone and characterise nucleobase transporters 
from T. b. brucei. The initial functional complementation strategy in nucleobase-transport 
deficient trypanosomes proved unsuccessful due to the presence of an additional, 
previously uncharacterised purine transporter in the trypanosome selection background and 
other technical obstacles. 
Homology searching of the T. b. brucei genome database led to the identification of a 
sequence with substantial similarity to the Adenosine Transporter 1 (ThAT1) gene 
previously shown to be responsible for the P2 nucleoside transport activity. The AT -like 
sequence was cloned, functionally expressed in heterologous systems (Saccharomyces 
cerevisiae and Xenopus oocytes), and characterised as the high-affinity Nucleobase 
Transporter 1 (TbNBTI). This also marked the first time a nucleobase-specific transporter 
had been cloned and characterised from any protozoan. 
Several other AT-like sequences were identified in the genome database and some of these 
were also cloned and partially characterised by heterologous expression in yeast. The AT-
like D sequence was found to encode a very high-affinity nucleoside transporter. 
This project has significantly increased our understanding of the biochemical and 
molecular nature of purine transporters in T. b. brucei. 
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Chapter I Introduction 
1.1 African trypanosomiasis 
1.1.1 The problem 
The diseases caused by parasitic protozoans of the genus Trypanosoma are responsible for 
the devastation oflarge regions of the African continent. In the absence of treatment, or in 
the event of treatment failure, infection of the human bloodstream and central nervous 
system by these parasites leads inexorably to death. As well as the casuahies directly 
attributable to human African trypanosomiasis (HAT), the decimation of the domestic 
cattle population by the related disease known as nagana (the Zulu word for ''poorly'') also 
contributes to the profound poverty and malnutrition experienced in sub-Saharan Africa 
Two distinct types of HAT, also known rather innocuously as "sleeping sickness", can be 
differentiated on the basis of the organism involved, the geographical location and how 
quickly the disease progresses. The causative agent of the East African disease is 
Trypanosoma bruce; rhodesiense and the infection typically runs a rapid course usually 
terminating within six months in the absence of any medical intervention. Meanwhile, 
infection with the related species Trypanosoma bruce; gambiense leads to the chronic 
disease seen in West and Central Africa Gamb;ense disease can persist for up to two years 
before final lethal involvement of the central nervous system (Welburn, et al., 2(01). 
Although HAT can be managed with a combination of timely medical treatment and 
control of the tsetse fly vector, due to several factors the disease has made a comeback in 
recent years. In the last 20-30 years there has been a rise in the number of reported cases 
which has coincided with a drop in the number of people under surveillance (WHO, Report 
on Global Surveillance of Epidemic-prone Infectious Diseases, 2000). This means that the 
number of reported cases does not reflect the real magnitude of the problem. It is estimated 
that up to 60 million people are at risk of infection but less than 7% of these are subject to 
surveillance. Therefore, although 40,000 was the number of official cases in 1999 the 
actual victims are much more likely to number 300,000 - 500,000 (Seed, 2000). 
The direct agricultural toll due to the occurrence of trypanosomiasis in domestic livestock 
is the death of an estimated 3 million cattle annually. T. vivax, T. congolense and T. bruce; 
bruce; are the main causative agents of bovine trypanosomiasis across Africa Infection of 
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cattle is also responsible for a 20% decrease in calving and a 25% decrease in milk 
production (Seed, 2000). As well as the obvious direct loss of livestock and dairy produce 
the presence of animal disease also has other consequences for the development of rural 
communities. Infestation by disease-carrying tsetse flies leads to otherwise farmable land 
being unusable and lack of draught power is also disadvantageous to progress (Kuzoe, 
1993; Seed, 2000). 
Factors which have led to the re-emergence of both human and animal disease are 
numerous. The changing political landscape in many areas with the inevitable concurrent 
conflicts and social upheaval has often led to the collapse of health provision services and 
the cessation of control practices. Existing chemotherapy can be effective but is inadequate 
in terms of toxicity, cost and ease of administration, and is further complicated by an 
increasing number of treatment failures in the field. 
1.1.2 Historical perspectives 
The genus Trypanosoma was inaugurated by Gruby in 1843 with the discovery of the first 
trypanosome in frogs (Trypanosoma sanguinis). Observations by David Bruce that led to 
the association of T. b. brucei, the tsetse fly and the animal disease nagana were preceded 
by the observations of Evans and of Smith & Kilbourne. In 1880, Evans made the 
connection between the animal disease sura and the organism later known as Trypanosoma 
evansi. Meanwhile, the transmission of babesia by the tick was elucidated by Smith & 
Kilbourne in 1893 to provide the first known example of a communicable disease spread 
by insect vectors (Vickerman, 1997). 
Trypanosomes and tsetse flies co-evolved with humans and historical accounts suggest that 
although the cause of the disease was unknown prior to the end of the 19th century, the 
symptoms were well known long before. Slave traders would use the presence of 
characteristic neck swellings to reject slaves who would become ill with "sleepy 
distemper" (Barrett, et al., 2003). The role of the tsetse in causing sickness in animals had 
also been observed in the mid 19th century by the renowned explorer David Livingstone 
who surmised that the flies administered some kind of venom in their bite (Vickerman, 
1997). 
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In 1895, while posted in Zululand in South Africa David Bruce outlined the links between 
the tsetse fly, the trypanosome and the cattle scourge named nagana (Smith, et al., 1998). 
Bruce, who also elucidated the cause of brucellosis, later gave his name to the 
Trypanosoma brucei parasite. Several years later, Bruce also worked on the human disease 
in Uganda identifying the causative agent as the Trypanosoma gambiense (later 
Trypanosoma brucei gamb;ense) parasite that had been isolated from a patient by Dutton 
in 1902 (Vickerman, 1997). 
By the time David Bruce was researching the role of T. b. gambiense in human sleeping 
sickness, the number of people suffering from the disease was reaching epidemic 
proportions. The extent of the epidemic in the early 1900's is now estimated to have 
involved more than one million human cases with approximately three quarters of a 
million deaths in central Africa - and over 250,000 fatalities occurring in Uganda alone 
(Seed, 2000; Smith, et al., 1998). According to the World Health Organization, the 20· 
century went on to witness two other periods of extraordinarily high epidemic levels of 
HAT (WHO, Report on Global Surveillance of Epidemic-prone Infectious Diseases, 2000). 
The second epidemic occurred in the 1920's and 1930's, with an all-time high of 33,562 
human cases reported in Zaire in 1930 (Ekwanzala, et aI., 1996). 
Following the devastating epidemics of the first quarter of the century, the colonial 
powers-that-be enforced enthusiastic control measures that included mass-screening and 
treatment of the population, eradication of tsetse flies using insecticides, the destruction of 
tsetse fly habitat and culling of the animal reservoirs of disease (Seed, 2000). By 1959 the 
number of reported cases in Zaire had fallen to around 1,000 (Ekwanzala, et al., 1996); the 
number of cases in Angola also fell from 5,000 in the 1950's to only 3 reported cases in 
1974 (Smith, et al., 1998). By the 1970's, with 10,000 to 20,000 cases across the tsetse fly 
belt it appeared as if the war on HAT was slowly but surely being won (Seed, 2000). With 
no significant involvement of animal reservoirs in the transmission cycle of T. bruce; 
gamb;ense the eradication of the gambiense disease in particular seemed tantalisingly 
close. 
Unfortunately, the last thirty years have seen the re-emergence of HAT, with epidemics 
caused by T. bruce; gambiense arising in Zaire (now the Democratic Republic of Congo). 
Uganda, Sudan and Angola. 
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Many factors have contributed to this recrudescence. The advent of independence for many 
African countries, bringing with it the almost obligatory accompanying civil unrest and 
conflict, led to the disruption of HAT control strategies. Following independence in Zaire 
in 1960, for example, there was a five year civil war, during which there was no 
surveillance of the population (Ekwanzala, et al., 1996). Despite renewed surveillance 
projects from 1965 to 1990, there were around 5,000 to 10,000 cases of HAT annually. 
The toll has continued to rise throughout the last 15 years compounded by another civil 
war in 1996, and the DRC is now in the unenviable position of being the country worst-
affected by HAT (Smith, et ai., 1998). 
1.1.3 Geography and prevalence 
Figure 1.1. Regions of the African continent at risk :from HAT. Reproduced from WHO 
Report on Global Surveillance of Epidemic-prone Infectious Diseases. 
Thirty-six of the fifty-two nations making up the continent of Africa are affected by 
human-infective Trypanosoma species (Figure 1.1). Four hundred million people live in 
countries considered to be part of the "tsetse belt" and it is estimated that between 55 and 
60 million people are at risk of infection with Trypanosoma (Barrett, 1999). The 
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distribution of rhodesiense and gambiense disease very much depends on the distribution 
of the Glossina species that carry the causative agents. The Rift Valley running through 
Africa roughly divides the areas of occurrence of the two types of HAT - gambiense in 
West and Central Africa and rhodesiense in the East (Welburn, el al., 2001). T. brucei 
gambiense is mainly passed by tsestse flies of the G. palpalis group which inhabit riverine 
territories, while T. brucei rhodesiense parasites are transmitted by wood1and tsetses such 
as G. morsitans, G. pallidipes, and G. swynnertoni (Brown & Neva, 1993). Since tsetse 
flies obviously do not respect international boundaries the regions of endemic and 
epidemic disease often spill indiscriminately across borders. 
The dependence of the disease on tsetse fly transmission means that HAT is almost 
exclusively rural in nature. It also tends to occur in discrete foci usually centring on a few 
villages with almost 300 known active foci (Barrett, et al., 2003). As can be seen from the 
distribution map in Figure 1.1, T. bruce; gambiense is responsible for the on-going 
epidemics in Sudan, Uganda, the DRC and Angola, and is present endemically in several 
other countries. Table 1.1 details the number of official cases present in these four 
epidemic-hit countries in 1976 and 1997 . Uganda is of particular interest since it straddles 
the geographical divide between gambiense and rhodesiense disease areas, and it is the 
only country with known foci of both T. brucei rhodesiense and T. brucei gambiense 
(Hutchinson, et al., 2003). The incidence of T. brucei rhodesiense is lower that that of T. 
brucei gambiense, occurring in Zimbabwe, Zambia, Malawi, Mozambique, Tanzania and 
eastern Uganda (Brown & Neva, 1993). 
Seventy to eighty percent of cases of HAT are estimated to arise in the Democratic 
Republic of Congo (DRC) (Smith, et al., 1998) with over 27,000 cases reported in 1998 
(WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases, 2(00). 
Considering the limitations of the screening and reporting processes the actual number of 
cases may be double the official figure. It is estimated that approximately 2% of the entire 
population of the DRC may be suffering from the disease (Barrett, 1999). According to 
Ekwanzala, et al (1996), the prevalence of sleeping sickness in some foci in the DRC 
approaches a phenomenal 70010. In Bandundu and Equateur provinces, HAT is the most 
significant cause of mortality (WHO Report on Global Surveillance of Epidemic-prone 
Infectious Diseases, 2000). 
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Country Number of eases of Number of cases of 
HAT reported in 1976 HAT re~rted in 1997 
Angola 83 8,610 
Democratic Republic 3,818 25,200 
of Congo 
Sudan 431 737 
Uganda 52 1,300 
Table 1.1. Comparison of the number of reported cases of HAT in four African countries 
in 1976 and 1997. Reproduced from the WHO Report on Global Surveillance of Epidemic-
prone Infectious Diseases (2000). 
Embroiled in civil war since the mid-1970's, Angola has seen an exponential rise in the 
cases of HAT. Despite the weak surveillance systems in place, Angola is second only to 
DRC in terms of the number of officially-recorded HAT cases (Ruiz, et al., 2(02). Over 
12,000 cases were recognised in 2001 but this may have only represented around 10010 of 
the actual incidence (Stich, et al., 2003). A prevalence of 60% has been indicated in some 
areas (Seed, 2000). 
Between 1976 and 1990 there were over 40,000 confmned cases ofHA T in Uganda. In the 
last decade of the 20th century the implementation of more rigorous surveillance and 
control strategies resuked in some improvement of the situation. Fly populations were 
reduced using traps, and a higher proportion of HAT cases were detected while in the 
more-easily-treated early stage of the disease (Smith, et al., 1998). Despite the 
improvements Uganda is still subject to the consequences of civil unrest in the 1980's - a 
new focus of T. bruce; rhodes;ense disease was recently identified in a previously-
unaffected region. The appearance of this Soroti focus is thought to have been the resuh of 
the introduction of cattle from affected areas as part of a re-stocking exercise following the 
resettlement of the region (Hutchinson, et al., 2003). 
A prevalence of 40-60010 has been observed in some villages in southern Sudan with more 
than half of cases in late stage disease at first presentation (Seed, 2(00). Large numbers of 
cases that have already progressed to the advanced stages have been detected in many 
epidemic foci across Africa. 
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1.1.4 The disease 
Parasites are introduced into the mammalian host when an infected tsetse fly takes a blood 
meal. A palpable painful ulcer known as a trypanosomal chancre sometimes develops at 
the site of the bite and is the first sign of infection - these chancres are more common in T. 
bruce; rhodes;ense infection. The chancre is usually self-resolving within a month of 
infection (Barrett, et 01., 2003). Trypanosomes can be isolated from aspirations of animal 
chancres before the parasites have become apparent in the bloodstream. The trypanosomes 
can make their way into the bloodstream via dermal venules in the vicinity of the original 
inoculation or via the lymphatic system - the first specific antibody response usually arises 
at this stage (po hera, 1985). 
In the early stages of the disease the parasites remain confined to the bloodstream, 
lymphatic system and interstitial spaces. The duration of this stage is dependent on the 
infecting species - in East African HAT caused by the more virulent T. bruce; rhodesiense 
the disease progresses beyond the early stage within weeks; in West African HAT the 
disease can persist as a chronic early stage infection for years (Barrett, et 01.,2003). HAT 
in the early stages produces a variety of non-specific symptoms, the most common of 
which is a cycling febrile illness accompanied by general weakness and rapid weight loss. 
Host-mediated reactions lead to anaemia. There is often a swelling of the postcervical 
lymph nodes known as Winterbottom's sign and, in T. bruce; rhodes;ense infections 
particularly, a more diffuse lymphadenopathy (Poltera, 1985). 
Late stage trypanosomiasis is characterised by parasitic invasion of the central nervous 
system. Exactly how the trypanosomes gain entry into the central nervous system has not 
been determined - they must somehow traverse the defensive blood-brain and/or blood-
cerebrospinal fluid barriers that ordinarily protect the brain (Enanga, et 01., 2(02). 
Whatever the mechanism of entry, the invasion and the ensuing host responses lead to a 
diffuse meningoencephalitis and meningomyelitis with a subsequent increase in protein 
and leucocytes in the CSF (Brown & Neva, 1993). The progression of early stage to late 
stage HAT brings with it a host of escalating neurological symptoms. Apathy, personality 
changes and unrelenting headache are often the first signs of CNS involvement. Profound 
disruption of circadian rhythms leads to an inversion of the sleep-wake cycle. Many 
patients exhibit Parkinson's disease-like tremors and dyskinaesia. Without treatment the 
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neurological damage continues and the disease eventually culminates in coma and death 
(Cowan & Heap, 1993). 
If HAT is diagnosed and treated whilst in the early stage or before serious neural damage 
has occurred, prognosis is generally good There is some evidence that once late stage 
disease has progressed past a certain point, the injury to the brain is irrevocable and 
treatment at this time is unlikely to facilitate cure (Barrett, et a1., 2003). 
1.1.5 SUn'eiliaDee aDd diagnosis 
An essential part of trypanosomiasis control is the screening of the at-risk population and 
the treatment of people found to be carrying the disease. This is particularly important in 
regions affected by T. b. gambiense because there is a long, largely asymptomatic period in 
which the patient is infective to feeding tsetse flies. Animal reservoirs are not thought to 
playa significant role in the epidemiology of gambiense disease with human-fly-human 
transmission the most likely scenario. Surveillance and treatment programmes are central 
to the reduction of the human reservoir of disease. 
The World Health Organization launched a programme in 1984 for the prevention and 
control of trypanosomiasis; 22 of the 36 countries at risk from trypanosomiasis are actively 
involved in this programme (WHO web-site). Several countries potentially vulnerable to 
HAT, including Ghana, Nigeria, Sierra Leone and Liberia, do not have any surveillance 
system in place and the current picture of HAT in these countries is unclear. 
Surveillance is defined by the World Heahh Organization as "continuing scrutiny of all 
aspects of the occurrence and spread of a disease that are pertinent to effective contror. 
Mass screening of populations for disease is not commonly undertaken due both to the cost 
and difficuky in the implementation of active programmes (WHO Report on Global 
Surveillance of Epidemic-prone Infectious Diseases, 2000). Despite recognition of the 
importance of surveillance, the infrastructure required to carry out the testing and 
screening often does not exist or the necessary resources are scarce. Other factors can 
impede the functioning of surveillance workers in areas often ravaged by military conflict. 
In one epidemiological study in Angola, for example, some villages were unreachable due 
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to mine-fields (Ruiz, et al., 2002). This provides a stark illustration of how the difficulty of 
HAT surveillance can be exacerbated by local circumstances. 
Since most victims of sleeping sickness will succumb to the disease many miles from the 
nearest hospital or other health services, it is necessary for mobile surveillance teams to 
venture out into the field for the purpose of active case-rmding (WHO Report on Global 
Surveillance of Epidemic-prone Infectious Diseases, 2000; Cattand, et al., 2(01). In the 
study of Ruiz and colleagues in Angola (2002) only 19.3% of patients sought medical 
attention out-with the active surveillance network. The population under threat is not 
compelled to participate in screening and it is estimated that the participation rate is only 
around 50% compared to the 95% participation once seen in compulsory colonial 
screening programmes (Ekwanzala, et al., 1996). 
Given the potential consequences of treatment it is imperative to establish that the 
individual patient is indeed suffering from trypanosomiasis and to determine what stage of 
the disease the patient has progressed to. It is important to try to identify patients while 
they are in the first haemolymphatic stage of the disease since the drug treatments are less 
dangerous. In some regions in the mid-1990's up to 90% ofconfmned cases of HAT were 
first identified when the patients were already in the late stage of the disease (Smith, et al., 
1998). 
A definitive diagnosis of HAT can be reached only after demonstration of parasites in the 
blood, lymph or cerebrospinal fluid but parasitaemias can be extremely low, particularly in 
gambiense disease (Brown & Neva, 1993). Several techniques have been developed to aid 
in the diagnosis of HAT. The card agglutination test for trypanosomiasis (CATT) is a 
serological test for the presence of anti-trypanosomal antibodies which is useful for 
identifying possible cases of HAT but it is not specific enough to be used on its own 
(WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases, 2(00). If 
parasites are not apparent on examination of whole blood smears concentrative techniques 
such as capillary tube centrifugation, quantitative buffy coat analysis, and mini-anion 
exchange columns can be utilised (Barrett, et al., 2003). Figure 1.2 shows a schedule used 
for diagnosis of HAT in Angola. 
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FiKUfe 1.2. Diagnosis of tr,ymmosomiasis. CA IT - card agglutination trypanosomiasis test, 
r -trypanosome positive, to - trypanosome negative, CTC - capillary tube centrifugation, 
m-AECT - mini-anion exchange centrifugation technique. Reproduced from Ruiz, et 01., 
2002. 
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For identification of late stage disease the cerebrospinal fluid must be examined 
necessitating a potentially dangerous, invasive lumbar puncture. Since trypanosomes are 
not often visualised in the CSF from lumbar punctures, increased white cell numbers (>5 
cells/J.1I) and heightened protein levels (>25 mgll00 mI) are used to confirm involvement 
of the CNS (Barrett, et al., 2003). 
1.1.6 Chemotherapy 
Since the ability of trypanosomes to evade the host immune response by periodically 
changing their protein covering has so far prevented viable vaccination strategies 
management of HAT relies on chemotherapy. The main weapons in the "current" arsenal 
against HAT consist of four drugs, three of which have been in use for more than fifty 
years. The use of these four drugs is further complicated since two are only suitable for 
early-stage disease (pentamidine and suramin) and another is only active against T. brucei 
gambiense (difluoromethylornithine (DFMO), also known as eflornithine). Figure 1.3 
shows the chemical structures of suramin, pentamidine, melarsoprol, DFMO, and the 
veterinary trypanocide, hereni!. 
1.6.1.1 Treatment or early-stage disease 
The oldest drug still in use is the polysulphonated naphthylamine suramin. first used in 
1922 (Wang, 1995). Suramin is active against both T. h. rhodesiense and T. h. gamhiense 
and is the preferred treatment for the early-stage East African disease. With six negative 
charges this drug interacts with many different serum components and is actually taken up 
by the trypanosome LDL receptor as a complex with low-density lipoproteins 
(Vansterkenburg, et al., 1993; Kirchhoff, et al., 2000). As with most of the other 
trypanocides, the intracellular target of suramin has not been definitively identified. The 
drug has been shown to inhibit several different trypanosomal enzymes including 
dihydrofolate reductase, thymidine kinase, and those involved in glycolysis. The 
trypanocidal action of suramin is likely to be the result of inhibitory effects on a range of 
enzymes in situ (Wang, 1995). 
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Figure 1.3. Structures of tryj)anocides. Suramin and pentamidine are used against early 
stage disease. Melarsoprol and DFMO are used against late stage sleeping sickness. 
Berenil is the most commonly-used veterinary trypanocide. 
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The recommended suramin regimen includes an initial test-dose of 100-200 mg since the 
drug can precipitate an anaphylactic reaction in a small proportion of patients. Thereafter, 
one gram of drug is delivered by slow, intravenous infusion on day 1, 3, 7, 14 and 21 
(Kirchhoff, et al., 2000). Suramin has a range of toxic side-effects, the most common of 
which is renal damage, resulting in proteinuria - ahhough this is usually mild (Pepin & 
Milord, 1994). 
Pentamidine was first used against HAT in 1940 and continues to be used to treat early-
stage T. brucei gambiense infections (Legros, et al., 2002). It is an aromatic diamidine 
compound that associates with the DNA contained within a trypanosomal organelle known 
as the kinetoplast. The drug possesses a range of activities which could contribute to its 
anti-trypanosomal action but, as with suramin, the trypanocidal mechanisms are not fully 
understood. Pentamidine has been shown to inhibit adenosyl-L-methionine carboxylase, 
mitochondrial topisomerase II, Ca2+ transport, and amino acid transport, as well as 
precipitating a partial degradation of the kinetoplast minicircle network (Wang, 1995; 
pepin & Milord, 1994). Pentamidine also has activity against Leishmania species and has 
proven useful in the treatment of AIDS-related Pneumocystis carinii pneumonia (Wang, 
1995). 
The treatment schedule for pentamidine involves 7-10 intramuscular injections of4 mg per 
kg of body weight either daily or on alternate days (Kuzoe, 1993). The side-effects 
associated with pentamidine are mostly transient in nature and include nausea, tachycardia 
and arterial hypotension. More serious problems can follow treatment with pentamidine: 
damage to the pancreas can lead to diabetes and liver damage can also be triggered 
(Kirchhoff, et al., 2000). 
Another aromatic diamidine closely related to pentamidine is the veterinary trypanocide 
berenil used for the treatment of livestock infected with T. congoiense, T. vivax and T. b. 
brucei (peregrine & Mamman, 1993). The active component of herenil is diminazene 
aceturate which has been shown to be active against human-infective parasites 
(Williamson, 1970). Berenil has never been licenced for human usage but it has been used 
in cases where other drugs were not available or were ineffective (Atouguia & Costa, 
1999; Bacchi, 1993). 
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1.6.1.2 Treatment oflate-sta~e disease 
Arsenic-containing drugs have played a major role in anti-trypanosomal therapy since the 
first treatments were attempted (Williamson. 1970). Most of the arsenical drugs have fallen 
out of usage due to excessive toxicity, development of resistance or other limitations. 
Melarsoprol, a melaminophenyl arsenical active against both T. b. gambiense and T. b. 
rhodesiense, was developed by Friedheim in the 1940's and until the introduction of 
eflornithine was the only available treatment for late-stage HAT (Pepin & Milord, 1994). 
The ability of the drug to cross the blood-brain barrier and reach trypanosomes in the CNS 
is assumed to be due to its lipophilic nature. Levels of melarsoprol in the CNS only reach 
about 2-5% of those seen in plasma and this is thought to be due to the rapid metabolism of 
melarsoprol to melarsen oxide which is less able to traverse the BBB (Enanga, et al., 2002; 
Keiser, et al., 2000). 
Ahhough it is known that parasites are quickly lysed in the presence of the drug, in what 
has become a familiar story regarding trypanocides, the mode of action of melarsoprol has 
not been elucidated. Arsenicals have been shown to inhibit glycolytic enzymes (Van 
Schaftingen. el al., 1987; Denise, el al., 1999) and to inhibit trypanothione reductase by 
forming stable adducts with trypanothione (Fairlamb, et al., 1989) but these effects have 
probably not advanced to an appreciable level prior to the lysis of the parasites. In 1993, a 
study by Carter & Fairlamb revealed that arsenical-resistance in trypanosomes could be 
linked to the absence of the P2 purine nucleoside transporter (see later). This transporter 
was shown to mediate uptake of melarsoprol and related compounds and was also capable 
of transporting diamidines such as pentamidine. 
Due to insolubility in most other solvents, melarsoprol is administered as a 3.6% solution 
in propylene glycol, contributing to the painfulness of the injection. Drug regimens were 
determined empirically and traditionally consist of 3 or 4 series of 4 daily intravenous 
injections (3.6 mglkg) with a period of one week separating each series (Kuzoe, 1993). 
Unsurprisingly, as well as leading to the clearance of parasites from the CNS, 
administration of melarsoprol leads to a host of collateral toxic effects. The most serious 
side-effect is the post-treatment reactive encephalopathy (PTRE) that affects up to 100ft, of 
patients. These reactions are fatal in approximately 50% of patients in whom they occur 
(Kennedy, 2004). Other side-effects include abdominal pain, vomiting, diarrhoea, and 
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damage to the myocardium, kidneys and liver (Kirchhoff, et al., 2000). The administration 
of the anti-inflammatory drug prednisolone throughout the entire treatment course can help 
to reduce the incidence and severity ofPTRE (Ruiz, et al., 2002). 
Difluoromethylornithine (DFMO), also known as eflornithine, was first licensed for use 
against HAT in 1990. It is active against T. b. gambiense and due to its ability to cross the 
BBB continues to be effective even when the disease is at an advanced state. 
Unfortunately, this drug is not very effective against T. b. rhodesiense and so the arsenicals 
remain the only therapeutic option for the late stages of the East African disease. 
As well as being the newest drug DFMO is novel amongst trypanocides because its mode 
of action is known. A suicide inhibitor of ornithine decarboxylase (ODC) originally 
intended for use in neoplastic conditions, DFMO interferes with polyamine synthesis 
leading to a cessation of trypanosome proliferation (Bacchi, et al., 1983; Barrett & Barrett, 
2000; Kirchhoff, et al., 2000). The suspension of normal cell function also affects the 
parasite's ability to change its protein coat. Since the drug does not kill the trypanosome 
cells outright immunocompetency is required to clear the parasites from the bloodstream 
andCNS. 
The reason for the selective action of eflornithine on T. b. gambiense and not on T. b. 
rhodesiense or mammalian cells, despite the fact that ODC is also a valid target in these 
cell types, has also been elucidated. Mammalian ODC has a much shorter half-life than 
trypanosomal ODC, e.g. murine ODe has a half-life of less than one hour compared to the 
> 18 hour half-life of T. b. gambiense ODC (Phillips, et al., 1987; G~ et al., 1990). So 
ahhough mammalian ODC is sensitive to inhibition by DFMO, the rapid turnover of the 
enzyme combined with the relatively short half-life of the drug itself abrogates any 
negative effects on the cells. The natural insensitivity to DFMO observed in T. b. 
rhodesiense would also appear to be due to differences in both turnover and specific 
activity of ODC. Recombinant enzymes from both T. b. rhodesiense and T. b. gambiense 
are inhibited to a similar degree by DFMO, but the specific activity of the T. b. rhodesiense 
enzyme was three times that of its T. b. gambiense counterpart, and the half-life of T. b. 
rhodesiense ODC was approximately 4 hours compared to the 18 hours obtained for the T. 
b. gambiense ODe (Iten, et al., 1997). 
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In terms of toxic side-effects, eflornithine is actually well tolerated by patients. The real 
problem with the administration of the drug is the massive amounts required for each 
patient, the duration of the individual intravenous infusions and the length of the entire 
course. The standard treatment protocol is 4 intravenous 100 mg/kg infusions daily for 14 
days - since the drug is provided commercially as a 200 mglml solution almost 1.5 litres of 
drug solution requires to be infused over the course (WHO, Human African 
Trypanosomiasis - A Guide for Drug Supply, 2002). 
1.6.1.3 Limitations of current chemotheraJ!Y 
The pharmaceutical industry has long been seemingly indifferent to the real need for new 
drugs against neglected diseases such as African trypanosomiasis. In the period 1975-1997 
a total of 1223 drugs were licensed for use globally, but only 13 of these were destined for 
use against tropical diseases (Veeken & Pecou~ 2000). Eflornithine, the only new 
trypanocide to be developed for almost 50 years was not even intended for use against 
HAT. It's clear that profit-driven pharmaceutical companies have more invested in the 
afllictions of the developed nations, such as erectile dysfunction (8 drugs in development), 
obesity (7 drugs) and, ironically, sleep disorders (4 drugs), than they do in the diseases 
suffered by the world's poorest people (1 drug for trypanosomiasis and 1 drug for malaria 
are currently in development) (reported in The Scientist, May 13th 2002). 
Despite this lack of interest from the drug companies, the fact remains that most of the 
trypanocides currently in use are woefully inadequate in terms of toxicity, cost and 
availability, the logistics of treatment and follow-up, and a further complication is 
emerging resistance in the field. 
Although the anti-trypanosomal activity of suramin, pentamidine and melarsoprol were 
discovered empirically, it is quite extraordinary that their mode(s) of action are still 
shrouded in mystery more than 50 years after their inaugural application. Given the 
toxicity of melarsoprol (discussed above), it is highly unlikely that this drug would be 
accepted under the current strict safety guidelines (Fairlamb, 1990). 
The process of simply getting the drugs to the right geographical location can be daunting. 
This highlights the need for socio-economic interventions, such as the rebuilding of 
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infrastructure in post-conflict areas - even the perfect drug is useless if it can't be 
administered to patients. Provided they are available, all of the drugs used against HAT 
require the patient to remain in hospital fOf the entire duration of the course, and adequate 
follow-up consists of a lumbar puncture procedure every six months for two years -
unsurprisingly, patient compliance can be problematic (Atouguia & Costa, 1999). Efforts 
have been made to adapt the empirically designed treatment regimens to reduce the course 
duration and/or quantities of drug administered, both as an attempt to cut costs and to 
reduce toxic effects. A shorter course of melarsoprol was found to be just as effective as 
traditional schedules (Burri, et al., 2000), but attempts to reduce the eflornithine course 
from 14 days to 7 days resulted in less encouraging resuhs (pepin, et al., 2000). Another 
possible path to improving current treatment with the limited resources available is 
combinatorial chemotherapy (Keiser, et al., 2001), but more studies are required. 
It is one thing for pharmaceutical companies to drag their heels on research and 
development of new trypanocidal drugs, but even more worrying is their continuing 
reluctance to even continue production of the four current drugs. Inevitably, this is due, at 
least in part, to the poor profitability of these agents, but environmental groups have also 
lobbied for tighter regulations extending to an outright ban on the use of arsenic (Veeken 
& Pecou~ 2000). By-products of suramin manufacture and the hazardous process of 
fluorination necessary for the production of DFMO have also contributed to the 
unwillingness of companies to continue supplying trypanocides (WHO, Human African 
Trypanosomiasis Treatment and Drug Resisitance Network: Report of the second and third 
meetings, 2001). 
Use of trypanocides in other disease conditions, particularly "Western diseases", can be a 
mixed blessing. It means the drug is more likely to be available and often leads to a more 
concerted effort to establish a mode of action and improve toxicity data (Barrett, 2000). 
But it also leads to an inevitable increase in cost - when pentamidine found an application 
in AIDS-related Pneumocystis carinii pneumonia there was an immediate escalation in 
price. It was necessary for the WHO to intervene in order to secure even a limited supply 
of pentamidine from A ventis for HAT usage at a reasonable cost (Veeken & Pecoul, 2000). 
DFMO would not be available for the treatment of HAT at all if it weren't for an 
ahernative use. In the late 1990's Hoechst, Marion, Roussel withdrew eflornithine due to 
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lack of profit and the remaining stocks were quickly used up (Veeken & Pecoul, 2000). 
The company also donated the license to the WHO, effectively divorcing themselves from 
any responsibility for future production. There was therefore outrage when Vaniqua - a 
depilatory cream with DFMO as the main active component - appeared on the US market 
a few years later (Stich, et al., 2003). The situation of having eflornithine available for a 
purpose as frivolous as hair removal, whilst unavailable for melarsoprol-refractory HAT 
was untenable. Thanks largely to the involvement of the WHO and Medecins Sans 
Frontieres, pentamidine, melarsoprol, and eflornithine will now be manufactured and 
supplied free-of-charge by A ventis until 2006, and Bayer has also pledged supplies of 
suramin (Barrett, et al., 2003). 
Considering that there are only four drugs currently licensed for HAT, and that only 1-2 
(depending on which species of parasite is involved) of these are effective against late-
stage disease, the emergence of drug resistance is extremely disturbing. The existence of 
resistance to aU three of the most commonly used veterinary trypanocides (isometamidium, 
homidium, berenil) has also been acknowledged (Anene, et aI., 2(01). In the treatment of 
early-stage HAT, there have been no significant reports of resistance to pentamidine or 
suramin, with occasional treatment failures assumed to be misdiagnosed early late-stage 
disease (Kaminsky & Maser, 2000). Unfortunately, the number of treatment failures 
following administration of melarsoprol is on the rise - current figures show that 15-30010 
of patients suffer relapse (WHO Report on Global Surveillance of Epidemic-prone 
Infectious Diseases, 2000). Although arsenical resistance can be induced by exposing 
parasites to sub-curative doses in the laboratory, the precise reasons for the treatment 
failures in the field have still not been elucidated. The contribution of host-related filctors 
has not been ruled out, and might include sequestration of parasites in sites not available to 
melarsoprol or a reduced movement across the BBB (Kaminsky & Maser, 2(00). Yet, such 
factors do not easily explain the recent sharp increase in treatment failure rates in specific 
foci. 
Loss or alteration of the P2 adenosine transporter has been implicated in resistance to 
arsenicals and some diamidines due to a decrease in uptake of the drug by the parasite 
(Carter & Fairlamb, 1993). The role of the P2 transporter and other trypanosomal transport 
proteins in drug targeting and drug resistance is discussed in more detail later . 
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Investigation of a limited number of field isolates by the group of Reto Brun and 
colleagues (Brun, et aI., 2001) found that most of the T. b. rhodesiense samples displayed 
significant resistance to arsenicals, both in vitro and in animal models in vivo. Despite a 
clear resistant phenotype, some of the isolates possessed a wild-type P2 transporter. 
Clearly, although the P2 transporter has been linked to resistance, it is not the only 
significant factor. In the same study, a correlation between reduced melarsoprol sensitivity 
of T. b. gambiense isolates and the relapse or cure status of the patient was not apparent 
Given that drug-resistant parasites exhibit a range of very different phenotypes, the 
pathways through which resistance develops may take a while to fully elucidate (Kaminsky 
& Maser, 2000). 
1.1.7 Vector control 
FiiMY 1.4. Tsetse fly. Glossina morsitans. feedin~ on a human arm (WHOffDRlPetana). 
Obtained from hUp://www.who.intltdr/media/image.html (Image ID # 9104108) 
There are seven different tsetse species capable of carrying and transmitting African 
trypanosomes (Figure 1.4). There are barriers to the survival of trypanosomes within the 
invertebrate host - the gut of the insect contains lectins that inhibit colonisation by the 
parasites - and this is reflected in the relatively low proportion of infected flies (2-4%) 
even in endemic areas (Aksoy, et al., 2001; Brown & Neva, 1993). 
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It is estimated that tsetse flies are present over more than 40% of the land area in countries 
at risk from human and/or veterinary trypanosomiasis (Allsop, 2001). As a means of 
disrupting disease transmission, reduction of the tsetse population in areas vulnerable to 
zoonotic T. h. rhodesiense infection has been particularly useful. Historically, vector 
control measures took the form of destruction of tsetse habitat and culling of reservoir 
game animals whose blood formed the tsetse diet (Schofield & Maudlin, 2001). For 
obvious ecological reasons these measures are no longer considered acceptable. 
With the advent of organochlorine compounds such as DDT, application of insecticides by 
aerial or ground spraying became the mainstay of vector control methods from the 1940's 
onwards. Originally, insecticides were applied residually at high concentrations to 
maximise the duration of the anti-tsetse effect, but it soon became clear that this approach 
was harmful to other wildlife in the treated areas (Grant, 2001). A new spraying protocol 
known as the sequential aerial drift technique (SAT) using much lower doses at 
appropriate intervals went a long way to minimising this collateral damage but many 
environmentalists still express concern about the wide-spread use of insecticides (Grant, 
2001). 
A more environmentally friendly approach to vector control is the use of fabric traps and 
targets. As the name suggests, traps can simply incarcerate the flies or can lead to direct 
killing if the material is impregnated with insecticide. In Uganda, the organised use of fly-
traps managed to reduce the tsetse populations by around 95% (Smith, et al.. 1998). 
Targets are simple insecticide-saturated screens designed to attract tsetse flies using visual 
stimuli or olfactory stimuli such as carbon dioxide or acetone (Schofield & Maudlin, 
2001). The use of non-toxic pyrethroid insecticides in animal dips or as pour-on 
formulations in "live-bait" techniques has gained in popularity (Allsop, 2001). Pyrethroid 
insecticides used in this way also prevents ticks and other biting flies from feeding on the 
treated cattle (Grant, 2001). Although the use of insecticides, traps and targets lead to 
reductions in tsetse populations, all tsetse control strategies have sustainability issues. 
Breakdown of spraying programmes or poor maintenance or theft of traps and targets can 
lead tsetse flies to quickly reclaim the cleared areas (Allsop, 2001). 
Ambitious plans to rid Africa of the tsetse/trypanosomiasis scourge by the implementation 
of the sterile insect technique (SIT) have received much publicity. The basis of the 
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technique is the mass release of male flies made sterile by exposure to gamma-radiation. 
The over-abundance of sterile males compared to indigenous male fly populations favours 
the interlopers in terms of mating opportunities, with mating events between these males 
and wild-type females being unproductive (Aksoy, et al., 2001). The technique was 
successfully used to eliminate Glossina austeni from the island of Zanzibar (Vreysen, et 
al .• 2000), but many scientists remain sceptical of the current proposals to clear tsetse from 
the African mainland using the technique (Rogers & Randolph, 2002). 
1.2 Trvpanosomes 
1.2.1 TaIoDomy 
Trypanosomes are eukaryotic, protozoan parasites of the order Kinetoplastidae. The 
possession of only one flagellum distinguishes the Trypanosomatina from their other 
Kinetoplastidae relatives, the biflagellate Bodonina. Whilst many of the Bodonina are free-
living, all the Trypanosomatina are dependent on their parasitic associations with a wide 
range ofmuhicellular organisms. As a resuh, Trypanosomatid parasites are the aetiological 
agents of several diseases of medical and veterinary importance, including of course the 
African trypanosomiases. There are at least nine genera making up the fiunily 
Trypanosomatidae: five which are monoxenous (Leptomonas, Herpetomonas, Crithidia, 
Blastocrithidia and Rhynchoidomonas) meaning they have only one host, usually an 
arthropod or other invertebrate; and four that are heteroxenous (Phytomonas, 
Endotrypanum, Leishmania and Trypanosoma) with different hosts depending on the life-
cycle stage. Phytomonas is a parasite of plants, whilst Endotrypanum, Leishmania, and 
Trypanosoma infect a wide variety of vertebrate species, being transmitted by insect or 
leech vectors (Kreier & Baker, 1987). The full taxonomic classification of the 
Trypanosoma genus is shown in Figure 1.5. 
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Monoxenous Genera 
Leptomonas 
Herpetomonas 
Blastocrithidia 
Crithidia 
Rhynchoidomonas 
Kingdom ~ Protista 
Subkingdom ~ Protozoa 
Phylum ~ Sarcomastigophora 
Subphylum ~ Mastigophora 
Class ~ Zoomastigophorea 
Order ~ Kinetoplastida 
Suborder ~ Trypanosomatina 
Family ~ Trypanosomatidae 
Subgenera 
Duttonella, e.g. T. vivax 
Nannomonas, e.g. T. congo/ense 
Pycnomonas, e.g. T. suis 
Trypanozoon, e.g. T. brucei 
Megatrypanum, e.g. T. minasense 
Herpetosoma, e.g. T. leeuwenhoeki 
Schizotryoanum. e.g. T. cruzi 
Figure 1.5. Taxonomic classification oftrypanosomes. 
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Heteroxenous Genera 
Phytomonas 
Leishmania 
Endotrypanum 
Q rypanosom0 
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Studies of the evolutionary relationships within the Trypanosomatidae have indicated that 
the Trypanosoma genus is monophyletic - that is, they are all descended from a single 
common ancestor (Stev~ et al., 2001). The phylogenetic data shows that T. cruzi (the 
causative agent ofChagas' disease or South American trypanosomiasis) and T. brucei may 
have shared a common ancestor 100 million years ago before the separation of the African 
and South American continents (Stevens, et aI., 1999). The genus Trypanosoma bas 
radiated to colonise virtually every vertebrate group including birds, fish, reptiles and, of 
course, a plethora of mammalian hosts (including marsupials). 
Traditionally the Trypanosoma genus is split into two groups depending on the mode of 
transmission of the parasites: the Stercoraria and the Salivaria (Hoare, 1972). Stercorarian 
trypanosomes inhabit the hind-gut of their insect vectors and transmission is via the 
posterior station occurring when the parasite-laden insect faeces contaminate wounds 
(often caused by the bite of the insect) or mucosal membranes (Vickerman, 1985). The 
most infamous member of the Stercoraria is T. cruz; (Brown & Neva, 1993), which 
belongs to the subgenera Schizotrypanum. Two other subgenera, Megatrypanum and 
Herpetosoma, are also classified as Stercorarlan. The remaining four subgenera 
(Duttonella, Nannomonas, Pycnomonas, and Trypanozoon) make up the Salivarian group 
of trypanosomes, which is largely confined to the African continent. Most of these 
parasites undergo cyclical development in the mid-gut of the tsetse fly and are transmitted 
by the tsetse bite following migration to the salivary glands. All four Salivarian subgenera 
contain significant veterinary pathogens. T. vivax and T. congolense cause disease in a 
range of domestic animals and belong to the Duttonella subgenus and Nannomonas 
subgenus, respectively. The pig pathogen T. suis, meanwhile, belongs to the Pycnomonas 
subgenus. The Trypanozoon subgenus of the Salivaria contains important species such as 
T. evans; and T. equiperdum. These species are of particular interest because ahhough 
classified as Salivarian they are no longer dependent on passage through the insect, and 
consequently are not limited solely to areas infested by tsetse flies. T. evansi is 
mechanically transmitted on the contaminated mouth-parts of various biting flies and T. 
equiperdum is transmitted venereally (Kreier & Baker, 1987). These intriguingly different 
lifestyles notwithstanding, the Trypanozoon subgenus has arguably received the most 
attention since it contains the T. brucei subgroup. 
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As discussed earlier in this chapter, T. b. bruce; is responsible for disease in animals, 
including cattle, while T. brucei gambiense and T. bruce; rhodesiense cause different 
clinical manifestations of HAT. In addition, T. b. rhodesiense is clearly zoonotic in that it 
infects a range of domestic and wild animals forming a reservoir for human-infective 
pathogens (Njiru, el al., 2004). Although T. b. gambiense is largely regarded as a human 
parasite with little or no animal reservoir, there have been reports of the parasite infecting 
animals such as pigs (Mehlitz, et al., 1982). The three subspecies of T. bruce; are 
morphologically indistinguishable from one another and various techniques have been 
devised to allow the proper identification of isolates. 
Isoenzyme analysis established T. b. gambiense as a bonafide subspecies, but it was not 
possible to separate T. b. bruce; and T. b. rhodesiense, giving rise to the hypothesis that T. 
b. rhodesiense represents a "host-range variant" of T. b. brucei (Tait, et al., 1984; Tait, et 
al., 1985; Gibson, 2002). Molecular techniques such as restriction fragment length 
polymorphism (RFLP) (Welburn, et al., 2001) and minisatellite marker analysis 
(MacLeod, et al., 2000) can distinguish T. b. rhodesiense from T. b. brucei. 
For obvious reasons, the factors accounting for the human-infectivity of T. b. gambiense 
and T. b. rhodesiense have come under close scrutiny. T. b. brucei is unable to establish 
infections in man because it is sensitive to a trypanolytic factor (TLF) present in human 
serum, but T. b. gambiense and T. b. rhodesiense both appear to have an innate resistance 
to this serum constituent (Raper, et al., 2001). T. b. rhodesiense has been shown to possess 
a serum resistance associated (SRA) gene that encodes for a molecule related to the variant 
surface glycoproteins making up the protein coat of the trypanosome (De Greef, et al., 
1992; Van Xong, et al., 1998; Milner & Hajduk, 1999). The SRA gene is not found in 
serum-sensitive T. b. brucei, and also is not found in serum-sensitive T. b. rhodesiense 
isolates (De Greef, et aI., 1992). It is unclear exactly how exposure to TLF leads to lysis of 
T. b. brucei and, equally, the mechanism by which the SRA protein prevents lysis in T. b. 
rhodesiense has not been elucidated. However, TLF must be internalised by the 
trypanosome to exert its lytic effect and there is some evidence that this internalisation is 
somehow disrupted in the serum-resistant T. b. rhodesiense parasites (Raper, et aI., 2001). 
T. b. gambiense, a very efficient parasite of humans, is clearly able to resist the action of 
TLF, but the SRA gene has not been identified in this parasite. Other mechanisms are 
obviously involved in the human serum-resistance trait of human-infective parasites. 
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1.2.2 Life-cycles and morphologies 
The trypanosome assumes different morphological forms throughout its life-cycle as it 
adapts to the different environmental conditions encountered. It is usually elongate in 
shape and is highly motile due to the action of the single flagellum and the presence of the 
undulating membrane. This undulating membrane is the result of a fold of the pellicle 
bordered by the attached flagell~ which arises from the posteriorally-located flagellar 
pocket, runs the length of cell and, depending on the life-cycle stage, extends to form the 
free flagellum (Brown & Neva, 1993). The trypanosome also possesses several unusual 
organelles including the kinetoplast that is the defining feature of all the Kinetopiastidae 
(Luke§, et aI., 2(02), and also the glycosome which is the site of the compartmentalised 
glycolytic processes (Opperdoes, et al., 1984; Opperdoes & Michels, 1993). The basic 
morphology of T. b. brucei is illustrated in Figure 1.6. 
In the mammalian bloodstream T. b. brucei exists as a pleiomorphic mixture with 
proliferative long-slender (LS) forms giving rise to non-dividing short-stumpy (SS) forms. 
As the names suggest these two populations can be identified by their different 
morphologies - typically, LS forms are -30 J1m by 1.5 J1ffi, whereas the SS form are -18 
J1m by 3.5 J1m (Kreier & Baker, 1987). The rapidly dividing LS trypanosomes are 
responsible for the establishment and maintenance of the mammalian infection 
Bloodstream T. b. gambiense is shown in Figure 1.7. In the glucose-rich environment of 
the blood the energy metabolism of the trypanosome is dependent solely on glycolyis, and 
this is reflected in the large number of glycosomes (>200 per cell) and the simplified 
mitochondrial architecture (Vickerman, 1985; Opperdoes, et al., 1984). As an organism 
swimming free in the bloodstream, the trypanosome is fully exposed to the mammalian 
immune system. The entire cell surface is covered with a variant surface glycoprotein 
(VSG) coat that shields antigenic membrane components (Donelson & Rice-Ficht, 1985), 
and due to the ability to spontaneously change this protein coat by the process of antigenic 
variation (Barry & McCulloch, 2001) parasites are repeatedly able to evade host responses. 
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Figure 1.6. Morphologies of T. b. rhodesiense. The upper diagram represents the 
trypomastigote stage and the lower diagram illustrates the epimastigote form. Reproduced 
from Mulligan, 1970. 
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Figure 1.7. Bloodstream form Trypanosoma bruce; r:ambjense (WHOrrDRfMolyneux). 
Obtained from http://www.who.int/tdr/mediaiimage.html (Image ill # 9104106) 
A combination of host immune reactions and antigenic variation in the trypanosome is 
responsible for the characteristic fluctuations in parasitaemia and the consequent cycling of 
HAT symptoms. Figure 1.8 shows the different phases encountered during each "wave" of 
parasitaemia. The initial rapidly increasing parasitaemia is due to the rapid proliferation of 
LS trypanosomes - a few variable antigen types (VATs) will predominate during this 
ascending phase. The rate of growth is slowed fIrstly by the differentiation of LS forms to 
the non-proliferative SS forms, and then by the host immune responses targeted against the 
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Figure 1.8. Events during a single "wave" of parasitaemia caused by T. b. brucei. 
Reproduced from Matthews, 1999. 
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predominant VATs. The descending phase of the parasitaemia is characterised by the mass 
clearance of LS and SS forms by the immune system. The next wave of parasitaemia is 
initiated by a small subpopulation of trypanosomes garbed in a new VSG coat (Matthews, 
1999). 
Bloodstream SS forms are pre-adapted for a return to the tsetse fly and in large part this 
involves the reactivation of selected mitochondrial enzymes and the reorganisation of the 
mitochondrial cristae. When the SS forms are ingested by a potential tsetse vector, it is 
essential that they quickly convert to alternative energy sources since glucose is rapidly 
removed from the bloodmeal. The energy requirements of the mid-gut procyclic form of 
the parasite are met by the amino acid proline (Vickerman, 1985), and succinate and 
oxoglutarate can also be utilised (Vickerman, et al., 1988). The change in metabolic 
substrate is also reflected in reduced numbers of glycosomes with a general flattening of 
the retained organelles. The VSG coat is rapidly shed as the ingested SS parasites 
differentiate into the proliferative procyclic trypomastigotes (Vickerman, et al., 1988) and 
it is replaced by a layer of procyclic acidic repetitive proteins (p ARP), or procyclins. There 
are two different types of procyclin molecule: EP and GPEET, named for their signature 
amino acid repeat motifs (Roditi, et al., 1998). 
Procyclics continue to divide rapidly by binary fission with numbers in the mid-gut of the 
tsetse reaching 300,000 (Borst & Fairlamb, 1998). The next stage of trypanosome 
development involves the movement of the procyclics into the ectoperitrophic space and 
forward to the proventriculus. The pro ventricular mesocyclic trypanosomes do not divide 
and become extremely elongated reaching lengths of up to 60 J.Illl (Vickerman, 1985). 
These cells are responsible for the infiltration of the tsetse salivary glands which are 
reached via the oesophagus, proboscis lumen and hypopharynx (Vickerman, et al., 1988). 
The movement of the trypanosomes to the salivary glands is accompanied by 
mitochondrial regression, as once again the trypanosomes start to brace themselves for a 
major change in lifestyle. Once in the salivary glands the trypanosomes enter a new 
proliferative stage as epimastigotes anchored to the wall of the salivary glands by their 
flagellar structures. While still attached the trypanosomes complete their development into 
mammalian-infective forms by the acquisition of the VSG layer and further changes in 
mitochondrial and glycosomal structure. The 12-15 nm-thlck protein coat consists of _107 
copies ofa single GPI-linked VSG unit and there are usually around 15-20 different VATs 
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present in the entire mature metacyclic population (EI-Sayed, et ai. , 2000). Final 
maturation is marked by the detachment of the non-dividing metacyclic into the lumen of 
the gland, with each fly harbouring up to 50,000 metacyclics (Donelson & Rice-Ficht, 
1985). The time taken for the passage of the trypanosome through the fly is usually around 
3-5 weeks (Vickerman, et ai., 1985). The life-cycle continues when the trypanosomes are 
injected into the unfortunate provider of the tsetse's next bloodmeal. 
The complete life-cycle of the trypanosome is illustrated in Figure 1.9. 
IN TSETSE SALIVARY GLANDS 
Premetacyclic 
Migration to tsetse 
salivary glands 
IN TSETSE MIDGUT 
Nascent metacyclic 
IN MAMMALS 
Figure 1.9. Diagrammatic representation of the T. b. brucei life-cycle. Reproduced from 
Vickerman, 1985. 
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1.2.3 Molecular biology of trypanosomes 
The entire DNA content of each individual T. b. bruce; parasite is in the region of 0.1 ng 
(K.reier & Baker, 1987) and the interphase nucleus measures ~3 J.1m in diameter (Ersfeld, et 
01., 1999). The genome is considered to be diploid and may contain more than 12,000 
genes. The haploid nuclear genome of T. b. bruce; is around 35 Mb and is made up of 
several different chromosome types distinguished by their comparative mobilities in pulsed 
field gel electrophoresis (pFGE) (Ersfeld, et 01., 1999). The main megabase chromosomes 
are between I Mb and 6 Mb and are thought to contain the majority of the coding 
sequence. There are eleven pairs of megabase chromosome numbered I-XI on the basis of 
increasing size but there is a wide variation in the actual dimensions of the chromosomes -
even between homologous partners the size discrepancy can be as much as 25%. The 
intermediate chromosomes are between 200 kb and 900 kb and the myriad 
minichromosomes measure 50-150 kb. The functional significance of the 
minichromosomes is uncertain - they are mostly made up of tandem arrays of a 177 bp 
repeat but do contain silent VSG genes and other coding sequences and they show stable 
inheritance (EI-Sayed, et 01., 2000). 
Trypanosomes belong to the order Kinetoplastidae and are defmed as such due to the 
possession of an extranuclear genome contained within the unique kinetoplast organelle. 
Found close to the base of the flagellum, the kinetoplast is associated with the single 
mitochondrion and contains approximately 20% of the total DNA of the organism. It 
consists of an extensive network of concatenated super-coiled minicircles (~I kb) and 
maxicircles (~20 kb). The maxicircle DNA is considered to be analogous to the 
mitochondrial genome of other organisms. The function of the minicircle DNA appears to 
be the provision of guide RNA (gRNA) molecules which are involved in the modification 
of maxicircle transcripts - this process of RNA editing is another novel feature of the 
Kinetoplastidae (El-Sayed, et 01., 2000; Benne, 1994; Sloof & Benne, 1997). 
The phenomenon of antigenic variation that allows survival of the trypanosome in the 
mammalian bloodstream and has thwarted efforts to develop a vaccine against 
Trypanosoma species was mentioned earlier. The study of the molecular mechanisms by 
which the parasite effects the periodic changes in the VSG covering has been one of the 
most studied and most intriguing aspects of trypanosome biology (Donelson & Rice-Ficht, 
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1985; Barry & McCulloch, 2001). The trypanosome genome codes for many different 
VSGs (-1000) that are often expressed in a characteristic sequence with certain VATs 
associated with metacyclic populations and others making an appearance early in the 
infection course (Turner, 1999). The parasites accomplish the complete re-garbing of the 
cell by changing which VSG is expressed from an active expression site located at one of 
the telomeres - only one VSG is actively expressed at anyone time. It is estimated that 
trypanosomes are capable of making 10-6_10-2 switches of VSG per doubling time of 5-10 
hours (EI-Sayed, et al., 2000; Turner & Barry, 1989). 
Figure 1.10 shows the structure of a typical telomeric bloodstream expression site (B-ES). 
It consists of the sequence between the VSG promoter and the characteristic repeats that 
make up the telomere and is between 45-60 kb in length. Between the promoter and the 
actual VSG gene is a series of 76 bp repeats and several expression site associated genes 
(ESAGs) that include the trypanosomal transferrin receptor which is also subject to 
variation (Borst & Fairlamb, 1998). Downstream of the B-ES is a series of 50 bp repeats, 
and then characteristic RIME (ribosomal insertional mobile elements) and ingi motifs that 
vary in size and number. There are thought to be around 20 B-ES present in the 
trypanosome genome, and also another 20 metacyclic expression sites (M-ES) which are 
smaller and simpler in tenns of structural organisation (EI-Sayed, et al,. 2000). 
A range of different molecular switching mechanisms can lead to the expression of a new 
VSG. A silent telomeric B-ES can become active leading to the expression of its 
constituent VSG gene although this process of in situ activation leads to a limited number 
of combinations and is not thought to be the most important route of antigenic variation. 
Various recombinatory processes such as gene conversion, telomere conversion and 
telomere exchange which lead to the integration of new VSG genes into active B-ES are 
probably the most common pathways of antigen switching (EI-Sayed, et al., 2000; Barry & 
McCulloch, 200 1). 
The mechanisms that prevent the expression of the multitude of silent VSG genes and 
allow exclusive transcription of the VSG residing in the active expression site have yet to 
be fully elucidated. There have been reports of a RNA pol I involved in the expression of 
the active VSG (Navarro & Gull, 2001). 
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Figure 1.10. Organisation of the bloodstream expression site (B-ES). Adapted from El-
Sayed, et aI. , 2000. 
Very few promoter sequences have been identified in trypanosomes with genes being 
transcribed as large polycistronic messages which are then processed into individual 
functional transcripts. Consequently, much of the regulation of protein synthesis in T. b. 
brucei is thought to occur at the level of mRNA stability or translationally (Clayton, 2002). 
1.2.4 Purine salvage and metabolism in trypanosomes 
1.2.4.1 Purine metabolic pathways 
In many ways, trypanosomes and other parasites are "metabolically lazy" since they 
require the host to furnish them with energy-rich molecules such as glucose and ready-
made cellular building blocks such as purines (Fair lamb, 1989). In the glucose-rich 
environment of the bloodstream trypanosomes rely totally on glycolysis and do not even 
make full use of the appropriated sugar molecules, generating only 2 ATP from each 
salvaged glucose. This opportunism, brought about by an abundant supply of nutrients, is 
wholly to the parasite's benefit, as it reduces the number of metabolic pathways it needs to 
maintain, alllowing it to concentrate on vital functions such as immune-response evasion 
and rapid proliferation. Moreover, de novo biosynthesis of the purine ring costs three ATP 
molecules, so it is more energy efficient to salvage them instead. 
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Purine salvage in protozoan parasites has received much attention since they are generally 
incapable of the de novo synthesis of purines. Mammalian cells, with a few notable 
exceptions, can construct the purine ring in the form of inosine 5'-monophosphate (IMP) 
from a combination of precursor molecules including formate, glycine, glutamine, 
aspartate and other amino acids (Hammond & Gutteridge, 1984). Radioactive tracer 
studies have identified the origin of the atoms found in the purine ring system following de 
novo synthesis (Figure 1.11). Similar tracer experiments in T b. brucei, combined with 
observations that the parasites cannot survive on media lacking preformed purines, led to 
the conclusion that rapidly proliferating trypanosomes depend on the scavenging of purines 
from their environment to satisfy their high demand for nucleic acid constituents (Hassan 
& Coombs, 1988). 
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Figure 1.11. Origins of the atoms present in the purine ring following de novo synthesis. 
Reproduced from Gutteridge & Coombs (1977). 
The survival oftrypanosomes on media containing anyone of the natural purines indicates 
that there must be pathways for intercoDversion of these molecules and this is indeed the 
case (Hammond & Gutteridge, 1984; Hassan & Coombs, 1988). Figure 1.12 shows the 
main routes of purine metabolism in trypanosomes. 
Trypano oma brucei possesses three different phosphoribosyltransferases with different 
substrate specificities: adenine phosphoribosyltransferase (APRT) , xanthine 
phosphoribosyltransferase (XPRT) and hypoxanthine-guanine phosphoribosyltransferase 
(HGPRT). Only HGPRT has been cloned and characterised in detail (Allen & Ullman, 
1993). These enzymes are responsible for the formation of nucleoside 5'-monophosphates 
from the appropriate base and 5'-phosphoribosyl-l-pyrophosphate (pRPP). Nucleoside 
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Figure 1.12. The main pathways of purine salvage in Trypanosoma brucei. The enzymes responsible for the interconversion of purines are 
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phosphorylases or nucleoside hydroIases are responsible for the release of the free 
nucleobase from scavenged or reutilised nucleosides. Ahhough some studies have reported 
an adenosine kinase activity in Trypanosoma brucei capable of the direct phosphorylation 
of adenosine to AMP (Hassan & Coombs, 1988), most researchers have been unable to 
corroborate these results or have only detected extremely low enzyme activity (El Kouni, 
2003). However, the T. brucei genome project has identified two copies of a gene located 
on chromosome 6 with very high homology to L. donovani adenosine kinase (53% identity 
and 72% similarity). Given the difficulty in detecting the activity of adenosine kinase in 
vivo, the main route of incorporation of purines into nucleotides seems to be via the 
phosphoribosylation of the nucleobase. Once the parasite has succeeded in producing at 
least one nucleoside 5' -monophosphate it possesses the full complement of enzymes 
(adenylosuccinate lyase, adenylosuccinate synthetase, AMP deaminase, IMP 
dehydrogenase, GMP synthetase, GMP reductase) necessary to generate all the others. 
The major aims of rational chemotherapy are to exploit the differences between the host 
and the pathogen to cause maximum harm to the pathogen while minimising toxic effects 
on the patient. The purine salvage pathways of protozoan parasites have long been 
considered excellent targets for new therapeutics. The absolute dependence on exogenous 
purines might be expected to render the parasite particularly susceptible to inhibitors of 
these salvage pathways (El Kouni, 2003). Equally, the presence of de novo synthesis could 
serve to diminish the side-effects experienced by the host, although some cell types may 
still be substantially affected. 
As well as the intrinsic differences in reliance on exogenous purines, the mammalian and 
trypanosomal handling of purines differs at the individual enzyme level too. An XPRT 
activity present in trypanosomes (Fish, et a/., 1982) but absent in mammalian cells presents 
a possible site for selective inhibitory action (EI Kouni, 2003). In addition, the HGPRT of 
African trypanosomes, and other protozoan parasites such as Leishmania spp. and T. cruzi, 
is able to convert pyrazolopyrimidines such as allopurinol into their nucleotide equivalents 
which then exert a toxic effect by their incorporation into RNA (Marr, 1983). 
Despite these clear differences between the trypanosomal and mammalian biochemistry, 
the development of effective chemotherapy aimed at parasite-specific targets in the purine 
salvage pathways may prove to be extremely challenging due to a high degree of 
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redundancy integral to the system. Blocking the xanthine phosphoribosyltransferase 
activity would certainly seem to exert a selective effect on the trypanosome compared to 
the host, but the presence of other functioning conversion enzymes would negate any 
nucleotide deficiency caused. In some other protozoans, the salvage relies more heavily on 
the action of a single enzyme (e.g. the hypoxanthine-guanine-xanthine 
phosphoribosyltransferase in Tritrichomonas foetus) and there has been speculation that 
purine salvage could be more easily blocked in these systems (Somoza, et aI., 1998). In 
order to circumvent the problem of redundancy in trypanosomes it would be necessary to 
administer a cocktail of different inhibitors specific for different enzymes - currently, this 
does not seem practicable and is likely to increase the likelihood of undesirable side-
effects. 
As the "selective inhibitor" approach appears problematic, the "subversive substrate" 
approach becomes more accessible, as multiple pathways are available for the activation of 
nucleoside or nucleobase pro-drugs. Allopurinol is one example in trypanosomatid 
parasites and thioxanthine is another for the apicomplexan parasite Toxoplasma gondii 
(Pfefferkorn, et al., 2001). 
1.2.4.2 Purine tra1JS]JOrt activities 
Although purines can be fed into the salvage pathways from other intracellular processes, 
such as nucleic acid degradation or ATP hydrolysis, the first step in purine salvage is 
usually the uptake of preformed purines from the host milieu. For most purines, this 
requires the action of specific transport permeases present in the plasma membrane of the 
parasite. The uptake of purines by nucleoside and nucleobase transporters in trypanosomes 
has been well studied, particularly in the past 15 to 20 years following revelations about 
the central role they play in parasite viability and their participation in drug uptake. 
Prior to the identification of the first purine transporter gene in 1999, the study of purine 
uptake in Trypanosoma brucei brucei relied almost exclusively on the detection of 
internalised radiolabelled permeants. One early study reported the uptake of purine 
nucleotides by T. b. brucei (Sanchez, et al., 1976), but this was highly controversial since 
the ability to transport these molecules across biological membranes is very rare. The 
consensus opinion seemed to be that the results obtained were due to the activity of a 
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nucleotidase present at the exofacial side of the plasma membrane followed by uptake of 
the resuhant nucleoside. A recent review by Landfear and co-workers, however, reported 
some preliminary findings regarding the possible uptake of AMP by T. b. brucei and the 
related trypanosomatid parasite Leishmania donovani, and so this is one area that may need 
re-examination (Landfear, et aI., 2004). 
James & Born (1980) showed that bloodstream form T. b. brucei and T. congolense could 
accumulate adenosine, guanosine, inosine, hypoxanthine and adenine. The discovery in the 
early 1990's that an adenosine transporter was involved in the uptake of arsenical drugs in 
T. b. brucei led quickly to the characterisation of two separate nucleoside transport 
activities designated PI and P2 (Carter & Fairlamb, 1993). 
The PI transporter displayed very high affinity for eH] adenosine with a Km value of 0.15 
J.1M and could be inhibited by other purine nucleosides but had very little affmity for the 
purine nucleobases. The PI carrier also had a high capacity for its adenosine permeant 
(Vmax value of 1.06 pmol (107 cellsrl S·I) and was responsible for up to 800/0 of the 
adenosine flux in T. b. brucei bloodstream forms (Carter & Fairlamb, 1993; De Koning & 
Jarvis, 1999). Addition of 1 J1M melarsen oxide or melarsoprol failed to inhibit uptake of 
adenosine by the PI transporter (Carter & Fairlamb, 1993), indicating that this transporter 
was not involved in the uptake of these chemotherapeutic agents. The PI transporter was 
shown to be the only adenosine or inosine transporter present in procyclic parasites and 
was the first purine transporter in T. b. brucei to be identified as a nucleoside/proton 
symporter (De Koning, et al., 1998). 
By completely saturating the PI transport activity with unlabelled inosine, the uptake of 
eH] adenosine by the P2 transporter could be studied in isolation. It displayed rigorous 
substrate preference for the 6-aminopurines adenosine and adenine (Km value for 
adenosine uptake of 0.59 J1M; ~ value for inhibition of adenosine uptake by adenine of 
0.38 J.1M) (Carter & Fairlamb, 1993; De Koning & Jarvis, 1999). Its mixed 
nucleosidelnucleobase transport function has been confirmed by the measurement of eH] 
adenine uptake in bloodstream form trypanosomes (De Koning, unpublished) and also 
following expression of the ThAT} gene (see next section) in Xenopus oocytes (Baldwin & 
De Koning, unpublished). As expected, uptake by the P2 transporter accounted for the 
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remaining 20-40% of adenosine flux (Carter & Fairlamb, 1993; De Koning & Jarvis, 
1999). In contrast to the PI transport component, the P2-mediated uptake of adenosine was 
inhibited by the addition of me larsen oxide or melarsopro~ implicating this transporter in 
uptake of trypanocidal agents. The observation that a melarsen-resistant parasite line had 
completely lost the ability to accumulate adenosine via the P2 transporter further endorsed 
the idea that P2 was involved in the selective targeting of melaminophenyl arsenical drugs 
to the parasite (Carter & Fairlamb, 1993). To complicate the situation even further, the P2 
transporter was later shown to also mediate the uptake of the diamidine class of drugs 
which includes pentamidine and herenil (Carter, et ai., 1995; Barrett, et ai., 1995; De 
Koning, 200 I b). 
T. b. bruce; also exhibits several different purine nucleobase transport activities which are 
differentially expressed according to life-cycle stage. The HI hypoxanthine transporter is 
present in the procyclic form of the trypanosome, and was shown to be driven by the 
protonmotive force using similar techniques used to determine the proton-dependence of 
the PI nucleoside transporter (De Koning & Jarvis, I 991a). The HI transporter was 
specific for purine nucleobase permeants with affmities of between 1.8 ~ and 9.3 ~. 
The existence of an additional nucleobase transport component in procyclics was 
discovered in the course of my research project. This transport activity was designated H4 
and is described in Chapter 6, Chapter 1 and in Burchmore, et ai., 2003. 
When T. b. bruce; procyclics were exposed to different purine levels there was a 
concordant change in purine uptake systems. In response to purine starvation first 
hypoxanthine and then adenosine transport components displayed increased capacities as 
indicated by a rise in V max values - the Km values were unchanged. The differential control 
of the purine transporters in T. b. brucei in response to different growth conditions mirrors 
similar phenomena in the monoxenous insect parasite Crithidia spp. (De Koning, et ai .• 
2000). 
Uptake of purine nucleobases in the bloodstream form parasites was found to be due to the 
activity of two distinct transporters, which could be distinguished on the basis of their 
substrate preference, their affinities for their permeant and their differential sensitivity to 
guanosine. The H2 transporter mediated uptake of hypoxanthine with a Km value of 123 
nM, and this transporter was affected by a range of purine nucleobases and pyrimidines, 
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and was inhibited by guanosine with a Ki of 10.9 J,LM. The guanosine-sensitive H2 
component accounted for -90% of hypoxanthine transport, whilst the H3 transporter 
mediated the remaining 10% of transport. The lower affmity H3 hypoxanthine transporter 
was more stringent in its choice of substrate - it accepted the four natural purine 
nucleobases (hypoxanthine, adenine, guanine, and xanthine) with affmities in the range of 
4.7 J.IM to 28.8 J.1M, but was not inhibited by other purines and pyrimidines (De Koning & 
Jarvis, 1997b). 
In addition to the purine transporters described above, T. b. brucei also possesses the high-
affinity Ul uracil transporter that is expressed in procyclics and is also a proton-symporter 
(De Koning & Jarvis, 1998). There is also evidence for the existence of a separate 
transporter in bloodstream forms for S-adenosylmethionine (Goldberg, et al., 1997). 
The proton-dependence of the T. b. bruce; purine transporters is in contrast with the 
transporters in mammalian cells and tissues. Purine uptake in animal cells is by one of two 
mechanisms: facilitated diffusionlequilibrative transport or alternatively sodium-dependent 
active transport (plagemann, et al., 1988; Griffith & Jarvis, 1996). It is hoped that such 
fundamental differences in the function of the transport processes can be exploited to target 
trypanocides selectively to the trypanosome (Landfear, et al., 2004). 
Figure 1.13 shows the range of transporters expressed in T. b. brucei bloodstream forms 
and procyclics. 
1.2.4.3 Molecular biology ofpurine uptake 
The characterisation of transporters in intact parasites using radio labelled permeants was 
obviously necessary in the absence of genetic information but the techniques used had 
many drawbacks, particularly as the multitude of transporters with overlapping 
specificities can confound efforts to dissect the function of the individual transport 
components. 
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Figure 1.13. The complement of nucleoside and nucleobase transporters present in the 
plasma membrane of T. b. bruce; at different life-cycle stages. The PI nucleoside transport 
component is found in both bloodstream form and pro cyclic T. b. bruce; and seems to be 
encoded by the TbNT cluster of genes found on chromosome 2. The P2 transport activity is 
present in bloodstream form parasites only and is encoded by the TbATI gene. The 
expression of the TbNBTI protein is responsible for the pro cyclic H4 hypoxanthine 
transport activity (see Chapter 7 and Burchmore, et al. , 2003). The other transporters 
shown in this figure have been detected biochemically but have yet to be characterised at 
the mo lecular level. 
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The cloning of the ftrst purine nucleoside transporter gene from T. b. brucei heralded a 
new molecular age in the study of purine uptake. The gene encoding the Trypanosoma 
brucei Adenosine Transporter 1 (ThATl) was identified by the functional 
complementation of a Saccharomyces cerevisiae strain defective in normal purine 
synthesis with a T. brucei bloodstream form cDNA library. The yeast S. cerevisiae 
naturally lacks any purine nucleoside uptake ability and the ade2 strain would normally not 
be able to survive on adenosine as the sole purine source. The introduction of ThAT} 
permitted growth under these conditions strongly suggesting that the gene encoded an 
adenosine transporter (MIiser, et 01 .• 1999). Further characterisation of the identified gene 
revealed that indeed it could facilitate the uptake of eH] adenosine. Moreover, this 
adenosine transport was adenine-sensitive but was not appreciably affected by a range of 
other nucleosides and nucleobases. In other words, the ThAT} gene seemed to code for a 
P2-like activity. Most signiftcantly, the activity could be inhibited by melaminophenyl 
arsenicals and the complemented yeast strain became sensitised to the drugs compared to 
the non-complemented controls (Mliser, et 01., 1999). 
Three months after the description of ThATl was published, another group reported the 
cloning of a gene encoding a PI-type activity. In this case, the cloning was accomplished 
by the identification of a expressed sequence tag in the T. brucei genome database with 
homology to the Leishmania donovani nucleoside transporter 1.1 (LdNTl.l) and the 
subsequent screening of a T. brucei cDNA library (Sanchez, et 01., 1999). The functional 
characterisation of the Trypanosoma brucei Nucleoside Transporter 2 (ThNT2) by 
expression in Xenopus oocytes showed that the permease could facilitate transport of eH] 
adenosine and eH] inosine. The uptake of adenosine by the transporter could be inhibited 
by the addition of a range of purine nucleosides to the assay buffer but was unaffected by 
purine nucleobases paralleling the substrate preferences of the PI transporter characterised 
in situ. Southern blots in this initial study strongly suggested the existence of an array of 
closely related genes and this was confll'IIled in a further report identifYing 5 more NT2-
like genes present at the NT2 locus (Sanchez, et 01., 2001). The predicted amino acid 
sequences of ThNT3, ThNT4, ThNT5, ThNT6 and TbNT7 exhibited> 8()oA, identity to 
TbNT2. Expression in Xenopus oocytes revealed that ThNT5, ThNT6 and TbNT7 encoded 
permeases capable of mediating transport of typical PI nucleoside substrates. Intriguingly, 
expression of TbNT5, and to a lesser degree ThNT6 and TbNT7, conferred some 
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hypoxanthine transport ability on the oocytes. No substrates were identified for TbNT3 and 
TbNT4. 
As part of this project Trypanosoma bruce; Nucleobase Transporter 1 (ThNBTJ), the first 
nucleobase-specific trypanosomal transporter gene to be identified, was cloned and its 
function was characterised (see Chapter 7; Burchmore, et 01., 2003). An almost identical 
transporter was cloned by Henriques and co-workers (Henriques, et 01.,2003) and the first 
Leishmania nucleobase transporter was also recently cloned and characterised (Sanchez, et 
01.,2004). 
1.2.5 The role or transporters in drug tal'leting and drug resistance 
Like the purine salvage enzymes, the purine transporters of T. b. brucei have potential as 
drug targets because they are essential for parasite survival and have been shown to be 
functionally different from the purine transporters possessed by the host. However, 
chemotherapeutic strategies aimed at inhibiting the uptake of purines and thus depriving 
the parasite of essential nutrients would require all the transporters to be blocked 
simuhaneously. It has been shown that parasites that have lost a single purine transporter 
(i.e. the ThATJ gene knockout) suffered no perceivable loss of viability (Matovu, et 01., 
2003). With the range of purine transporters with different substrate preferences and 
affinities present in T. b. brucei it would likely be very difficuh to achieve total 
suppression of uptake - and of course the purine salvage enzymes would be able to convert 
any purine substrate that evaded the transport blockade. Furthermore, adenine may be able 
to diffuse across the membrane to some degree, and trypanosomes that are subjected to 
absolutely purine-free conditions in vitro undergo a reversible growth arrest rather than cell 
death for the first few days at least (De Koning, et 01., 2000; Natto, et 01., submitted). 
The purine transporters, along with other transporter and receptor classes in T. b. brucei, 
have garnered interest for their potential or actual ability to act as gateways for 
trypanocides. Figure 1.14 shows the different pathways through which existing 
trypanocides can enter the trypanosome. Although lipophilic drugs can diffuse across the 
plasma membrane to gain access to their intracellular targets they can be limited by their 
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lack of selectivity with drugs flooding into host cells as well as into the parasite target. The 
entry ofDFMO into host cells by passive diffusion (Bitonti, et al., 1986) is not problematic 
Figure 1.14. Uptake of trypanocidal drugs. Reproduced from De Koning, 2001a. 
because pronounced differences in the properties of the host and parasite ODe account for 
the selectivity of the drug. Other drugs require specific transport processes to allow their 
entry into cells and/or across other membranes such as the BBB, and their selective action 
can often be mediated at the level of uptake. Suramin is taken up as a complex with LDL 
by receptor-mediated endocytosis mediated by the trypanosomal LDL receptor 
(Vansterkenburg, et aI., 1993). The P2 purine nucleoside transporter has already been 
shown to be involved in the selective uptake of existing trypanocidal agents, as discussed. 
The purine transporters of T. b. brucei could be further exploited to facilitate the selective 
and concentrative accumulation of novel trypanocides, whether these are subversive purine 
substrates intended to disrupt normal incorporation of purines into nucleic acids, or 
molecules engineered to be taken up by the purine transporters, but with a intracellular 
target unrelated to purine salvage (El Kouni, et al., 2003; Landfear, 2001; Wallace, et al., 
2002). 
There have been many studies reinforcing the link between the P2 transporter and the 
uptake of arsenical drugs. Observations that arsenical-resistant parasites accumulated lower 
levels of diamidines and other drugs gave an indication that resistance could be due to 
44 
Chapter L Introduction 
reduced uptake of the trypanocides (Fromme I & Balher, 1987). The original P2 transport 
study showed that an arsenical-resistant strain had lost the P2 transport function (Carter & 
Fairlamb, 1993). Following the identification of the TbAT} gene it was discovered that an 
arsenical-resistant strain contained several point mutations in the gene which resulted in 
the alteration of the transporter protein at 6 amino acid positions (Maser, et al., 1999). The 
altered P2 transporter was unable to mediate normal uptake of adenosine, adenine and its 
presence in yeast led to a reduced sensitivity to arsenicals compared to that seen when the 
wild-type transporter was expressed (M!ser, et al., 1999). A study of parasite isolates 
derived from patients in whom melarsoprol therapy had failed to bring about a cure 
showed that many possessed similar point mutations in the TbAT} sequence (Matovu, et 
al.,2001). 
Although several studies have also implicated the P2 transporter in the uptake of diamidine 
drugs (Carter, et al., 1995; Barrett, et al., 1995; Barrett & Fairlamb, 1999), the situation 
has been somewhat complicated with the discovery that alternative transporters are also 
involved in the intemalisation ofa number of these drugs (De Koning, 2001b). Barrett and 
co-workers demonstrated that a herenil-resistant T. equiperdum line possessed a P2 
transport activity with reduced affinity for its substrates (Barrett, et al., 1995). On the other 
hand, the arsenical-resistant parasites described by Carter & Fairlamb (1993) as having lost 
the P2 transport function were hardly resistant to pentamidine at all (Fairlamb, et al., 
1992). Although adenosine uptake by the P2 transporter could be inhibited by pentamidine, 
a tOO-fold excess of adenosine failed to inhibit uptake of pentamidine, and other diamidine 
drugs could only partially inhibit uptake of radio labelled pentamidine (Carter, et al., 1995). 
The P2 activity introduced into yeast by the expression of the ThAT} gene also could not 
be inhibited with pentamidine (Mliser, et al., 1999). 
The existence of two additional pentamidine transporters, designated as the high affmity 
pentamidine transporter (RAPT) and the low affinity pentamidine transporter (LAPT) are 
now known to be responsible for the conflicting data regarding uptake of diamidines in 
Trypanosoma species (De Koning, 2001b). The high level of cross-resistance between the 
arsenicals and the veterinary diamidine berenil is a consequence of the two drugs sharing 
the same main route of uptake through the P2 transporter (De Koning, et al., 2004; Wito1a, 
et al., 2004), although there is some evidence for a residual uptake of arsenicals via the 
HAPT (Matovu, et 01., 2003). The surprisingly low levels of cross-resistance observed for 
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melarsoprol and pentamidine (Fairlamb, el aJ., 1992) are explained by the transport of 
pentamidine by HAPT and LAPT even in the absence of the P2 transporter (De Koning, 
2001 b). 
Given the scarcity of effective trypanocides and the dearth of novel anti-trypanosomallead 
compounds, the importance of understanding both normal and aberrant targeting of the 
essential HAT chemotherapeutics melarsoprol and pentamidine to the par&Ue cannot be 
understated. The inherent limitations of these drugs, however, call for the development of 
new or re-engineered trypanocides. Since the uptake of drugs by the trypanosome is likely 
to be important for selective action an increased understanding of how the many different 
purine transporters of TrypanosolllQ bruce; function at the molecular and biocbemicallevel 
must also be imperative. 
This Ph. D. project was initiated with the issues stated above very much in mind. The main 
focus of the project was to improve our knowledge of previously-identified transport 
components with particular emphasis on nucleobase-specific transporters, but ab;o to 
catalogue transporter genes emerging from the T. bruce; genome project. The initial aiJm 
were to quantitatively characted<le the substrate recognition motifs of the T. bruce; H2 
transporter and the human erythrocyte nucleobase transporter. This also led us to 
investigate some of the compounds used in this study as potential trypanocides. 
Circumstances also allowro us to investigate some novel purine compounds for 
trypanocidal activity. Another primary aim was to clone T. bruce; purine permease genes 
and characterise their function in an heterologous system, again with an emphasis on the 
identification of genes responsible for nucleobase-specific transporters. 
46 
CbapterTwo 
Materials and Metbods 
Chapter II Materials and Methods 
2.1 Parasite strains 
Two strains of Trypanosoma brucei brucei were used during the project. It is a peculiarity 
of African trypanosome research that biochemical studies have tended to focus on the 
EA TRO 427 strain, while the molecular analyses, including the genome sequencing 
project, have been carried out on the TREU 927 strain; the work described here has mostly 
kept to this custom, except where noted. Both bloodstream form parasites and procyclic 
form parasites were used for various stages of the study. Stabilates were maintained on-site 
as liquid nitrogen stocks and these were prepared as described in Appendix A. 
2.2 Bacterial strains 
The JMI09 and TOP 1 0 strains of Escherichia coli were used for routine cloning and 
subcloning of T. b. bruce; genomic sequences. E. coli JM109 (endAl, recAl, gyrA96, thi, 
hsdRl7 (rK-IllK+), relA1, supE44, A(lac-proAB), F' [traD36, proAB, lacrUM15]) 
competent cells were purchased from Promega initially but were subsequently prepared 
"in-house" using the method described in section 2.14.7, below. E. coli TOPIO (F-, mcrA, 
A(mrr-hsdRMS-mcrBC), +80lacZAMI5, AlacX74, deoR, recA1, araD139, A(ara-Ieu)7697, 
galU, g~ rpsL (StrR), endAl, nupG) electrocompetent cells were also prepared in the 
laboratory (see section 2.14.8). 
2.3 Yeast strains 
Saccharomyces cerevisiae M0887.1 (Oillissen, et aI., 2000) was used as a heterologous 
expression system for the cloned T. b. bruce; nuc1eobase transporters. This strain is anfcy2 
mutant and thus does not possess a functional endogenous uptake system for adenine, 
guanine, hypoxanthine or cytosine (Ho~ 1997). The strain has also been engineered by 
replacement of the ura3 gene with a truncated version, thus generating uracil auxotrophy. 
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2.4 Chemicals 
2.4.1 Purine analogues and radlolabelled compounds 
[s-3H] hypoxanthine (I.IS TBq/mmol) was purchased from Amersham Pharmacia Biotech, 
UK. [2,S_3H] adenine (1.2 TBq/mmol) was obtained from NEN, USA. [2,8-3H] adenosine 
(1.2 TBq/mmol) was manufactured by Perkin Elmer. [2,8-3H] inosine (592 GBq/mmol) 
and eH] allopurinol (44.4 GBq/mmol) were both purchased from Moravek. 
Natural purines and purine analogues were purchased from Sigma (adenine, hypoxanthine, 
guanine, xanthine, thymine, uracil, adenosine, guanosine, inosine, acycloguanosine, 
allopurino~ 6-thioguanine, 2-aminopurine, 8-azaguanine, 7-deazaguanine, 2,6-diamino-
purine, ARA-hypoxanthine, inosine, 6-methoxypurine, I-methyladenine, 3-methyladenine, 
purine, theophylline, 8-azaadenine, and lumazine, ), Fluka (1-methylguanine and 9-methyl-
guanine), Aldrich (aminopurino~ 1,3-dideazapurine, 6-benzyloxypurine, 6-chloropurine, 1-
deazapurine, 2,6-dichloropurine, 6-dimethylaminopurine and 4(3H)-pyrimidone), and ICN 
(7-azaindole). 9-deazaadenine was a kind gift from John A. Secrist In of the Southern 
Research Institute. 9-deazaguanine was generously provided by Howard Cottam of the 
University of California, San Diego. The novel purine compounds described in Chapter 
Five were synthesised by Katherine Seley and colleagues at the Georgia Institute of 
Technology, Atlanta. 
2.4.2 Other chemical I'88gents 
Alamar Blue reagent was purchased from Trek Diagnostic Systems Ltd. All other 
chemicals were purchased from Sigma at the highest grade available unless stated 
otherwise. 
2.4.3 Oligonucleotides and molecular biologv enzymes 
All oligonucleotides were synthesised by MWG Biotech. T4 DNA ligase, Taq DNA 
polymerase, Pfu DNA polymerase, dNTPs, and all restriction enzymes were purchased 
from Promega. Calf intestinal alkaline phosphatase (ClAP) was from Boehringer 
Mannheim. The pGEM-T Easy Vector system was obtained from Promega. 
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2.5 Growth and maintenance of parasites 
2.5.1 Bloodstream form trypanosomas In vitro 
Bloodstream form T. b. brucei were maintained in liquid culture using HMI-9 medium plus 
20% heat-inactivated foetal calf serum (FCS), and culture conditions of37 °C and 5% CO2 
(Hirumi & Hirumi, 1989). Cultures were initiated by inoculating 5 ml ofHMI-9 medium 
with a tiny aspiration of the "buffy coat layer" of infected rodent blood (see section 2.8.1). 
The cuhures were then passaged regularly into fresh HMI-9 medium. This method was 
appropriate for producing a small quantity of parasites, but an in vivo route had to be taken 
to obtain large numbers of bloodstream form parasites. 
2.5.2 Bloodstteem form manOfOmH in vivo 
Aduh female Wistar rats were injected intra-peritoneally with T. b. brucei EATRO 427 or 
IREU 927 bloodstream forms (from capillary tube blood stocks in 10.5% DMSO stored in 
liquid nitrogen). Parasitaemia was monitored by daily examination of blood smears from 
tail venepuncture. Estimation of total parasite numbers was by a method developed by 
Herbert & Lumsden (1976) based on number oftrypanosomes per microscope field. The 
blood was collected when peak parasitaemia was reached (between 5 x 108 and 1 X 109 
parasites per millilitre of blood). 
2.5.3 Procycllc form ttvpalJOfomes In vitro 
Procyclic form T. b. brucei was conveniently maintained at 25°C in SDM79 medium 
supplemented with 10010 FCS (Brun & Sch6nenberger, 1979) or purine-free trypanosome 
medium (PFTM) supplemented with 5% dialysed FCS (De Koning, et aI., 2000). Large 
numbers ofprocyclics were simple to cultivate by scaling up cuhure volumes. 
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2.6 Growth and maintenance of Saccharomyces cerevls/ae 
S. cerevisiae MG887.1 was maintained on solid yP AD medium at 30 °C. It was necessary 
to streak a fresh plate every 4-5 days. S. cerevisiae MG887.1 was made chemically-
competent by the method described in section 2.14.13. 
2.7 Growth and maintenance of Escherichia coIl 
Non-recombinant E. coli JM109 and E. coli TOPI0 was grown on solid Luria-Bertani (LB) 
medium or in LB broth at 37 °C overnight. 
2.8 Transport assays in trvpanosomatids 
2.8.1 Collection and purification of bloodstream fonn T. b. brucei from 
experimental rodents 
At peak parasitaemia the blood was removed by cardiac puncture under terminal 
anaesthesia using a syringe loaded with a small volume ofCBSS (Carter's balanced saline 
solution) containing 100 D/ml heparin. The whole blood was centrifuged at 1,250 x g for 
15 minutes to separate the different components. The white, parasite-containing "buffy 
coat" layer forms at the intersection between the red blood cells and the plasma. This layer 
was carefully removed using a plastic Pasteur pipette and resuspended in a small volume of 
PSG (Phosphate buffered saline with glucose, pH 8.0). The pre-washed DEAE (DE-52, 
Whatman) cellulose was poured to a depth of 5 cm into a glass-wool-plugged 50 ml 
syringe with plunger removed. The cellulose column was equilibrated with 200 ml of PSG. 
The "buffy coat" suspension was loaded onto the column and ran through with PSG. Blood 
cell surfaces are negatively charged and these cells remained within the column adsorbed 
to the cellulose while the less-negatively charged trypanosomes were collected in the flow-
through (Lanham, 1968, and Lanham & Godfrey, 1970). The purification was carried out 
as rapidly as possible since pH 8.0, although necessary for the correct functioning of the 
column, is quite a hostile environment for the parasites. 
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2.8.2 PreD8I1If!on of cells for uptak, assav 
Bloodstream form trypanosomes collected from the cellulose column were washed twice in 
the trypanosome assay buffer for 10 minutes at 800 x g, and then suspended at 108 cellslml. 
The cells were usually left at room temperature for 15-20 minutes before use in the assay. 
Procyclic form trypanosomes for transport assays were grown in 100 ml cultures to mid-
log stage. The cuhures were then harvested and washed in the trypanosome assay buffer as 
described above for bloodstream forms. 
Cell viability and motility were checked under a phase-contrast IDlCroSCOpe at the 
conclusion of each experiment. 
2.8.3 Transport _win tlypanosomat/d$ 
Uptake of radio labelled permeants in T. b. bruce; was determined using a rapid-stop/oil-
spin technique previously described by De Koning & Jarvis (1 997a). The molar 
concentration of the radiolabel was adjusted according to the transporter of interest to 
allow isolation of particular activities. Radiolabel concentrations varied from 15 nM to 1 
J!M as appropriate. One hundred microlitres of the trypanosome suspension (_10' cells) 
was mixed with 100 f.11 assay buffer containing tritiated permeant only or mixed with 
various concentrations of inhibitor. After a predetermined incubation time at room 
temperature, uptake was stopped by addition of an ice-cold millimolar solution of 
unlabelled permeant and centrifugation (30 seconds; 12,000 x g) through an oil layer [7:1 
(v/v) mix of di-n-butyl phthalate (BDH) and light mineral oil (Sigma)]. The centrifugation 
step thus separated the parasites from the radio label. The microfuge tubes were then flash-
frozen in liquid nitrogen and the bottom, containing the cell pellet. cut off and collected in 
a numbered scintillation vial. The cells were solubilised in 2% SDS (30 minutes; room 
temperature), mixed with 3 ml Ecoscint scintillation fluid and the accumulated 
radioactivity measured in the 1450 Microbeta Liquid Scintillation and Luminescence 
Counter (perkinEImer Lifesciences). 
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Some test compounds were used from stock solutions in 100% DMSO. Final DMSO 
concentrations in the assays never exceeded 1 %, which did not affect uptake kinetics. 
2.9 Transport assays in human erythrocytes 
2.9.1 Pl8paratlon of cells for uptake aSHY 
Whole human blood from heahhy volunteers was sourced from the Bloodbank. 
Heparinised blood was stored at 4 °C until needed. 
The whole blood was centrifuged at 800 x g for 10 minutes and the red cells were washed 
twice in erythrocyte assay buffer (see Appendix A) and resuspended at a haematocrit ratio 
of approximately 25%. The erythrocytes were counted in a haemocytometer; typical 
densities were 2-3 x 109 cells/mI. The integrity of the cells was checked at the conclusion 
of each experiment. 
2.9.2 Transport assaYS In human elVtlJI'Ocvtes 
Uptake of [2,8-3H] adenine by human erythrocytes was also measured by the oil-stop 
method, using 100% dibutylphthalate for the oil layer and 2-3 x 108 erythrocytes per assay 
point. The final concentration of radio labelled adenine in the assay was 1 JIM. The uptake 
was stopped by addition of ice-cold 2 mM papaverine solution (an inhibitor of 
equilibrative transport). After centrifugation, the oil layer was aspirated and the inside of 
the tube wiped with absorbent paper to remove traces of radiolabel. Cell pellets were 
solubilised in 250 J.11 1% Triton xlOO and the haemoglobin was precipitated with 0.5 mI 
5% trichloroacetic acid. Following further centrifugation (10 minutes, 13,000 x g), the 
supernatant was transferred to scintillation vials, mixed with 3 mI scintillation fluid and 
counted for radioactivity, as in section 2.8.3. 
Some test compounds were used from stock solutions in 100% DMSO. Again, with final 
DMSO concentrations in the assays never exceeding 1 %, uptake kinetics were not 
significantly affected. 
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2.10 Transport assavs In Saccharomyces cerevlslae 
2.10.1 Preparation of cells for uptake assay 
A yeast starter cuhure was grown at 30 °C in 5 ml of synthetic complete medium minus 
uracil (SC-URA) for 6 hours. The starter cuhure was then used to inoculate a 50 ml 
overnight culture. 
The yeast cells were harvested by centrifugation at 1,800 x g for 5 minutes at 4 °C. The 
pellet was washed twice in ice-cold yeast assay buffer, before resuspension at 1-2 x 101/m1. 
The cells were allowed to acclimatise to room temperature for 10 minutes before use in the 
assay. 
2.10.2 Transport assays In Saccharomyces cerevisiae 
Uptake of radio labelled penneants in Saccharomyces cerevisiae MG887.1 transformants 
was determined using a virtually identical rapid-stop/oil-spin technique to that described 
for the trypanosome assays (section 2.8.3). One hundred microlitres of the yeast 
suspension (107 cells) was mixed with 100 J.LI yeast assay buffer containing tritiated 
permeant and various concentrations of inhibitor. After a predetermined incubation time, 
uptake was stopped by addition of an ice-cold millimolar solution of unlabelled permeant 
and centrifugation through an oil layer [7:1 (v/v) mix of di-n-butyl phthalate and light 
mineral oil]. The microfuge tubes were then flash-frozen in liquid nitrogen and the bottom 
containing the cell pellet cut off into a numbered scintillation vial. The cells were 
solubilised in 2% SDS (30 minutes; room temperature), mixed with 3 ml scintillation fluid 
and the accumulated radioactivity measured in the liquid scintillation counter. 
Some test compounds were used from stock solutions in 100% DMSO. Final DMSO 
concentrations in the assays never exceeded 1 %, which did not affect uptake kinetics. 
54 
Chapter II. Materials and Methods 
2.11 Transport aasava in Xenopus laevls oocytes 
This work was carried out by Stephen Baldwin's laboratory at the University of Leeds. 
2.11.1 Preparation of cells for uptake assay 
The oocytes were prepared for uptake as described by Huang, et al., 1993. Briefly, stage 
VI oocytes were isolated from the ovarian tissue of Xenopus laevis and incubated 
overnight at 18°C in MBM buffer (88 mM NaCI, 1 rnM KCl, 0.33 rnM Ca(N03)2, 0.41 
rnM eaCh, 0.82 rnM MgS04, 2.4 mM NaHC03, 2.5 rnM sodium pyruvate, 0.05 mglrnl 
penicillin, 0.1 mglrnl gentarnycin sulphate, 10 mM HEPES, pH 7.S). RNA was prepared by 
transcribing linearised expression vector with T7 polymerase in the presence of m7GpppG 
cap using the mMESSAGE MACmNE (Arnbion) transcription system. The oocytes were 
injected with 10 ng of the capped, polyA-RNA and then incubated for five days in MBM at 
18°C. 
2.11.2 Transport assays in Xenopus I_vis oocvtes 
The injected oocytes were placed in transport buffer (loo rnM NaCl, 2 mM KCl, 1 rnM 
eaCh, 1 mM MgCh, 10 mM HEPES, pH 7.5). Uptake of 100 IlM eH] adenine, [3H] 
adenosine, eH] uracil or eH] uridine was assayed at 20°C over 30 minutes. Transport was 
stopped by six rapid washes in ice-cold washes in transport buffer. The oocytes were then 
solubilised in 5% SDS and the accumulated radioactivity was measured by liquid 
scintillation counting. 
2.12 Analysis of data from transport assays 
The small amount of radioactivity that was associated with the cell pellet in the presence of 
saturating concentrations of unlabelled perrneant (i.e. the component not accounted for by 
the active transport of the radiolabel) was subtracted from each data point. These corrected 
counts were converted to transport rates (Prnol (107 cellsrl S·I). The resuhs were plotted by 
non-linear regression using the FigP or PRISM software packages as appropriate. From the 
dose-inhibition curves, ICso values were calculated. Hill slopes were found to be near to-l 
supporting the assumption of single-site competitive inhibition. All assays were performed 
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in triplicate and ICso values were based on a minimum of 8 datapoints over the relevant 
range. In a few cases, complete inhibition curves could not be obtained due to limited 
solubility of the test compound. When >50% inhibition was achieved at the maximum test 
concentration, the ICso value was based on extrapolation, assuming a Hill coefficient of-1 
and eventual 100% inhibition, defined as equal to saturating concentrations of unlabelled 
permeant (or papaverine in case of erythrocytes). 
Conversion to Ki was then possible using the Cheng-Prusoff equation: 
I K1= ICso I [l+(L+Km)] 
where L is the permeant concentration and Km is the value obtained for this permeant 
(Cheng & Prusoff, 1973). It is important to note that this equation is only valid for 
competitive inhibition situations. 
Each final Ki value was the the mean Ki ± SE of at least three independent experiments. 
A derivation of the Nernst equation was then used to determine ~Go values for analogue 
binding to the transporter: 
I ~Go = -RT In(KI) I 
where R is the gas constant and T is the absolute temperature. The ~GO value gives a 
measure of the binding energies existing between the transporter and its substrate. 
2.13 Alamar Blue assays 
The active ingredient of the Alamar Blue reagent is a blue dye called resazurin which is 
non-fluorescent. In the presence of live cells the resazurin is reduced to resorufin which is 
pink in colour and is highly fluorescent. The extent of this change in fluorescence and 
colour is directly proportional to the number of viable cells. The Alamar Blue assay has 
been used in proliferation/cytotoxicity assays involving many different cells types 
(O'Brien, et aI., 2000). 
The in vitro trypanocidal activities of the purine analogues were evaluated using the 
Alamar Blue assay (Raz, et al., 1997). The stock concentration of the drug to be tested was 
prepared at two times the required highest final concentration in HMI-9 medium. Doubling 
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dilutions were prepared in 96 well plates in duplicate. A drug-free control was also 
included. Bloodstream trypanosomes of strain 427 (1 x 104 cells) from preadapted culture 
in HMI-9 medium, were added to each well and the plates were incubated at 37°C for 48 
hours. Alternatively, 1 x 104 procyclic cells in SDM-79 were added to drug dilutions in the 
same medium and incubated at 26°C for 48 hours. Twenty microlitres of Alamar Blue 
reagent was then added to each well (to give a concentration of 10%) and the plate was 
subsequently incubated for a further 24 hours. The plates were read for fluorescence using 
a LS55 Luminescence Spectrometer (perkin Elmer Instruments) at 530 run excitation and 
590 run emission wavelengths. Ahematively, the plates were subjected to colorimetric 
analysis by measuring the absorbance at 600 run. 
2.14 Molecular cloning techniques 
2.14.1 Pl!DllratJon and purification of genomic DNA from T. b. brucei 
T. b. brucei procyclics were grown in a 500 ml cuhure for 48 hours. After 48 hours, the 
cells were harvested by centrifugation at 1,500 x g for 15 minutes at 4°C. The pellet was 
resuspended in 450 ,.d of DNA extraction buffer (see Appendix A). 50 III of 10% SDS and 
25 III of proteinase K (10 mglml in dH20) was added. The lysis reaction was allowed to 
proceed at 37°C for 2 hours with gentle shaking of the sample on a rocking platform. Five 
hundred microlitres of liquid phenol (saturated with 10 mM Tris Hel, 1 mM ETDA, pH 8; 
phenol phase pH 6.7) was added and the sample was vortexed until opaque in appearance. 
The solution was microfuged at 13,000 x g for 5 minutes, and then the clear top layer was 
transferred to a fresh sterile tube. To this. 500 III ofphenol:chlorofonn (1:1) was added, 
and the sample was mixed thoroughly and microfuged as before. The upper aqueous layer 
was again removed into a fresh tube. and 500 III of chloroform was added, followed by 
vortexing and centrifugation. The upper layer was added to a final clean tube. The DNA 
was precipitated by adding a 1I10th volume of sodium acetate (3 M, pH 5.2) and 1 ml of 
ice-cold 100% ethanol. The solution was mixed gently and placed at -20°C for 30 
minutes. Centrifugation at 13,000 x g for 10 minutes to pellet the DNA was followed by a 
wash in 70% ethanol. The pellet was dried at 37°C before resuspension in sterile TE 
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buffer. RNA was removed from the preparation by incubation with 2 J..lI RNAse A (final 
concentration of 0.5 J..lg/J..lI) at 37°C for one hour. 
2.14.2 PI.mld VectolS 
Several vectors were employed for different aspects of the project. The vector pTSO-
HYG4 (Sommer, et aI., 1996) was utilised in the construction of a T. b. brucei genomic 
DNA library for expression in T. b. brucei. The plasmid vector pNS328 (supplied by Dr. 
G. Diallinas of University of Athens) was used to construct a T. b. brucei genomic DNA 
library for expression in Aspergillus nidulans. The pGEM-T Easy Vector system from 
Promega was used to clone PCR products before sub-cloning into other vectors. The 
plasmid vector pDRI95 (Rentsch, et al., 1995) was used to clone genes for expression in 
Saccharomyces cerevisiae. The plasmid vector pOEM-HE was used for production of 
RNA for expression in Xenopus laevis oocytes (Liman, et al., 1992). 
The pGEM-T Easy Vector was purchased "ready-to-use" and needed no further 
preparation before use in ligations. However, the other vectors required to be linearised by 
restriction enzyme digest and to be treated with calf intestinal alkaline phosphatase (ClAP) 
to prevent self-ligation. 
The choice of restriction enzyme to use for linearisation was dependent on the composition 
of the muhiple cloning site on each vector, and on the source of the insert DNA. The 
digests were carried out under the conditions described in section 2.14.3, below. 
ClAP dephosphorylates the 5' ends of the linearised vector, thus preventing it re-ligating to 
itself but still allowing it to be ligated with compatible inserts. The ClAP was provided at I 
U/J..lI but had to be diluted in Ix reaction buffer to 0.01 U/J.11 for use. Nineteen microlitres 
of digested vector was incubated for 1 hour with 5 J..lI of lOx reaction buffer, 5 J..lI of diluted 
ClAP and made up to 50 J..lI with sterile dH20. An extra 5 J.11 of diluted ClAP was added 
half way through the incubation. The enzyme was inactivated by incubation at 65°C for 10 
minutes. 
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2.14.3 Restriction enzvme digestion of DNA 
Restriction enzyme digests were used to prepare vector DNA for ligation, to excise insert 
DNA for subcloning, to prepare "random" fragments of DNA for library construction and 
to ensure correct size and orientation of insert DNA. 
A typical 20 J.11 digest mixture consisted of 1 J.1g of DNA, 2 J.11 of lOx reaction buffer 
(provided with enzyme) and 5 units of appropriate enzyme, made up to 20 J.11 with dH20. 
The usual incubation conditions were 37°C for 1 - 2 hours. 
Partial restriction digestion of genomic DNA was necessary for the production of 
"random" fragments of a defined size for the genomic DNA library. The digest protocol 
was ahered to maximise yield of appropriate fragments. A thirty minute digestion of 50 J.1g 
genomic DNA with 5 units of Sau3A with a total reaction volume of200 J.11 gave a good 
yield of DNA molecules in the 2-6 kb range. Following the digestion, the Sau3A enzyme 
was inactivated with 1I100th volume of 0.5 M EDT A to facilitate separation of the 
DNA/protein complexes. The digest was concentrated by precipitation with 1I25th volume 
of 5.0 M NaCI and 2 volumes of ethanol. The use of sodium chloride rather than sodium 
acetate prevented the co-precipitation of SDS. Following an incubation at -20°C, the 
DNA was pelleted by centrifugation for 20 minutes at 13,000 x g. 
The standardisation of the partial digestion protocol is outlined in Chapter 6. Figure 6.4 
shows agarose gel electrophoresis of the resuhant genomic DNA fragments. 
2.14.4 Mage electropho",/s of DNA 
DNA was separated by molecular size by electrophoresis through a 0.8% agarose gel 
containing 0.3 J.1g1ml ethidium bromide with TBE as the running buffer. The vohage used 
to run the gel was nonnally 60 V. The use of lower vohages aided separation of nucleic 
acid molecules and these were used for isolation of fragments for the genomic DNA 
library. Gel visualisation was by UV transilluminator (UVP Products). 
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2.14.5 Purification of DNA from agarose gel 
To purify DNA fragments of a defined size, the samples were run in a gel alongside an 
appropriate standard molecular size ladder. The relevant band was excised using a clean 
scalpel and transferred into a clean sterile microfuge tube. Exposure to UV was kept to the 
absolute minimum to prevent damage to the DNA. The agarose was removed using the 
QIAGEN Gel Extraction Kit following manufacturer's instructions. 
2.14.6 Ligation 
T4 DNA ligase was provided with the Promega pGEM-T Easy Vector System. The 
reaction mixture was as follows: 5 fll of2x reaction buffer, 1 fll (50 ng) ofpGEM-T Easy 
Vector, 3 fll of poly-A tailed PCR product, and 1 f.1l (3 units) ofT4 DNA ligase. 
For ligations not involving pGEM-T Easy Vector, the T4 DNA ligase was provided with 
lOx reaction buffer and the reaction mixture typically consisted of: 15 ng of vector DNA, 
45 ng of insert DNA, 2 fll of lOx reaction buffer, 1 fll (3 units) of DNA ligase and dH20 to 
final volume of 20 fll. The vector : insert ratio of 1:3 was usually sufficient for successful 
ligation reactions. 
The ligation mixture was incubated at 4 °C overnight and then the enzyme was heat-
inactivated at 65°C for 10 minutes. 
2.14.7 PreparatIon of chem/callv-competent Escherichia coli 
Initial stocks of 1MI09 E. coli were purchased from Promega. Further stocks were 
prepared in the laboratory using the rubidium chloride method. An LB agar plate was 
streaked with E. coli JMI09 and incubated overnight at 37°C. A single colony from the 
plate was inoculated into 2.5 ml of LB broth and this starter culture was incubated 
overnight at 37°C with shaking. This was added to 250 ml ofLB broth containing 20 mM 
MgS04, which was then incubated at 37°C with shaking until the OD600 reached 0.4-0.6 
(around 3 hours). The cells were harvested by centrifugation at 1,250 x g at 4 °C for 5 
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minutes and resuspended in 80 m1 of ice-cold TFBI solution (see Appendix A). The 
suspension was incubated on ice for 5 minutes. The cells were pelleted as before and 
resuspended in 8 m1 ofice-cold TFB2 (see Appendix A). The cells were left on ice for 15 -
60 minutes and then gently aliquoted into pre-chilled 1.5 m1 microfuge tubes. The tubes 
were flash-frozen in liquid nitrogen and stored at -70 °C until required. 
The efficiency of the competent cells was tested prior to use and was typically higher than 
1 x 107 colony forming units per J,lg of transformed plasmid DNA. 
2.14.8 Preparation of e/ecttpcompetent Escherichia coli 
Stocks of E. coli TOPIO electrocompetent cells were produced "in-house" by the following 
method. A single colony from a fresh LB plate was inoculated into 5 m1 of SLB medium, 
and this culture was then incubated overnight with shaking at 37 °C. The 5 ml "starter" 
was used to inoculate a 500 m1 flask ofSLB, which was shaken at 37 °C for approximately 
3 hours until the OD was 1.3. The culture was placed on ice for 30 minutes, before 
centrifugation at 1,500 x g for 15 minutes at 4 °C. The pellet was washed twice with 200 
ml of ice-cold sterile ultra-pure water and then resuspended in 30 ml of ice-cold 10% 
glycerol in ultra-pure water. The suspension was subject to a final centrifugation at 1,500 x 
g for 15 minutes at 4 °C. The pellet waS resuspended in 2.5 m1 of ice-cold 10% glycerol in 
ultrapure dH20 and aliquoted into Eppendorf tubes which had been chilled at -70 °C. The 
aliquots were then stored at -70 °C until required. 
The efficiency of the electrocompetent cells was tested prior to use. As shown in Chapter 
6, the efficiency was shown to be sufficiently high at 8.5 x 109 colony forming units per J,lg 
of transformed plasmid DNA. 
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2.14.9 Tranlfonnatlon otE. coli 
2. J 4.9. J Heat-shock method 
The JMlO9 cells were thawed in an ice-bath, and 50 ,.d were then added to 2 J.11 of the 
ligation mixture and gently mixed. The suspension was placed on ice for 20 minutes before 
a heat-shock at 42°C for 45 seconds. The suspension was returned to the ice-bath for 2 
minutes, after which 950 J.11 of room temperature SOC medium was added to the tube. A 
1.5 hour incubation at 37°C with shaking was followed by the spreading of250 J.11 of the 
suspension onto LB plates supplemented with 100 J.1g/ml of ampicillin. If pGEM-T Easy 
Vector was being used the plates also contained 0.5 mM isopropylthio-J}-D-ga1actoside 
(IPTG) and 80 J.1g/ml 5-bromo-4-chloro-3-indolyl-P-D-galactoside (X-Gal) to facilitate 
blue-white screening. The plates were incubated at 37°C overnight. 
2. J 4.9.2 Electroporation 
While the heat-shock method using chemically-competent cells was sufficient for 
obtaining a relatively small number of clones containing a known product, electroporation 
was used during construction of the libraries to maximise transformation yields. 
The TOPIO competent cells were thawed in an ice-bath, then 40 J.11 were dispensed into 
chilled microtubes containing 2-3 J.11 of the ligation mixture. The suspension was carefully 
transferred to pre-chilled electroporation cuvettes with a gap size of 0.1 cm. The 
suspension was then electroporated using the Bio-Rad Gene Pulser II with parameters of 
25 J.LF capacitance, 2000 resistance, and a voltage of 1.7 kV. After addition of 1 ml of 
SOC, the cells were transferred to a clean Eppendorf tube and incubated at 37°C with 
shaking for an hour. Two hundred and fifty microlitres of the cell suspension was spread 
onto LB plates supplemented with 100 J.1g1ml of ampicillin. The plates were incubated at 
37°C overnight. 
To harvest colonies for the production of the library, the bacterial colonies were simply 
washed from the plates using LB broth medium. 
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2.14.10 MinI-. midI-. and maxl-DreDS of plasmid DNA 
QIAGEN kits were used for the convenient small, mid and large scale purification of 
plasmid DNA from E. coli cultures. Manufacturer's instructions were followed. 
2.14.11 Polymerase chain reactions 
The proof-reading enzyme Pfu DNA polymerase was used for all polymerase chain 
reactions. PCR mixtures consisted of the following components: 2 J.11 Pfu lOx buffer; 200 
J.1M of each of dATP, dCTP, dTTP, dGTP; 2.5 J.1M of each primer; 10-20 ng of DNA 
template; 0.6 units of Pfu DNA polymerase; and sterile dH20 to final 20 J.11 volume. 
The PTC-200 Peltier Thermal Cycler from MJ Research was used to perform the PCRs. 
Choice of annealing temperature was dependent on the particular primers. The PCR cycle 
conditions were as follows: denaturation at 94°C for 2 minutes; and then a cycle of 
denaturation at 94 °c for 30 seconds, annealing temperature for 30 seconds, and extension 
at 72°C for 2 minutes. This three-step cycle was repeated 30 times, with a final extension 
step at 72 °c for 10 minutes. 
2.14.12 A-tailing of PCR products 
Since the pGEM-T Easy Vector is designed with 3'-thymidine overhangs, it was necessary 
for the peR product insert to have 5'-deoxyadenosine overhangs for successful ligation. 
However, PCR fragments produced with Pfu polymerase are blunt-ended. In order to 
facilitate addition of a single deoxyadenosine to each end of the product, it was incubated 
with Taq polymerase which adds deoxyadenosine residues to the end of the DNA in a 
template independent manner. Typically, 7 J.11 of gel-purified Pfu-amplified product was 
mixed with 1 f.ll of lOx Taq reaction buffer, 0.2 mM dA TP, 5 units of Taq polymerase and 
sterile dH20 to a final volume of 10 J.11. The mixture was then incubated at 72°C for 30 
minutes. 
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2.14.13 Transformation of chem/callv-competent Saccharomyces cerevisiae 
Transformation of Saccharomyces cerevisiae was by the method of Gietz & Woods 
(2002). A 5 ml Saccharomyces cerevisiae MG887.1 starter culture was grown in yP AD at 
30°C with shaking overnight and then used to inoculate 50 ml of pre-warmed yP AD. The 
culture was incubated at 30°C with shaking for 4-5 hours until the OD at 600 nm was 
between 1 and 1.5 (equivalent to 2 x 107 cells/mIl. The cells were harvested by 
centrifugation at 1,800 x g for 5 minutes, washed in 25 ml sterile dH20 and centrifuged as 
before. The pellet was resuspended in 1 ml of 100 mM lithium acetate and the suspension 
was then transferred to a 1.5 ml microfuge tube. The cells were pelleted by centrifugation 
at 13,000 x g for 15 seconds and the lithium acetate was removed. The cells were then 
resuspended in 100 mM lithium acetate to give a final volume of 500 J.11 with a cell density 
of approximately 2 x 109 cells/ml. The suspension was vortexed and SO J-ll were pipetted 
into fresh microfuge tubes for each transformation. The cells were pelleted and the lithium 
acetate removed with a micropipette. The following components were then added to the 
cells in the following order: 240 J.11 PEG (50% w/v in dH20), 36 J-li 1.0 M lithium acetate, 
SO J.11 SS-DNA (2.0 mglml, boiled for 5 minutes prior to use), 0.1-10 J.1g of plasmid DNA 
and sterile dH20 to final volume of 360 J-ll. Each tube was vortexed vigorously to ensure 
the complete mixing of the cell pellet. The suspension was incubated at 30°C for 30 
minutes, and then heat-shocked at 42 °C for 30 minutes. The cells were pelleted at 8,000 x 
g in the microfuge for 15 seconds and the transformation mix was removed. The cells were 
gently resuspended in 1.0 ml of sterile dH20 and then 200 J-li was plated on SC-URA 
plates. Sterile glass beads were used to distribute the fluid evenly on the plates. The plates 
were incubated at 30°C for 2-4 days to recover transformants. 
2.14.14 Growth of Saccharomyces cerevlsiae In se/ect/ve media 
To select for transformants that had gained the ability to transport purines, several colonies 
were spread on yeast selective medium plus adenine (1 mglml or 7.4 mM) or yeast 
selective medium plus hypoxanthine (4 mM). Growth of transporter gene transformants 
was compared with the growth of colonies transfonned with pDRl95 only. 
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2.14.15 Preparation and purification of total RNA from T. b. brucei 
Bloodstream form trypansomes or procyclic form trypanosomes were grown in cuhure as 
described in section 2.5. The cells were harvested by centrifugation at 1,050 x g for 3 
minutes at 4 °C. One millilitre of Tri Reagent was added to 107 cells and pipetted up and 
down to lyse the cells. The suspension was transferred to a sterile Eppendorf tube and 
incubated at room temperature for 5 minutes, after which 200 ,.d of chloroform was added. 
The tube was shaken vigorously for 15 seconds and then incubated at room temperature for 
two minutes. Cell debris was pelleted by centrifugation at 13,000 x g for 15 minutes at 4 
°C, and the supernatant was removed to a fresh sterile tube. An equal volume of 
isopropanol was mixed with the suspension, and the mixture was incubated at room 
temperature for 10 minutes. The RNA was pelleted by centrifugation at 13,000 x g for 15 
minutes at 4 °C. The pellet was washed in 75% ethanol and the pellet was resuspended by 
vortexing. A fmal centrifugation step of 7,500 x g for 5 minutes at 4 °C pelleted the RNA. 
The pellet was allowed to air-dry, and then resuspended in approximately 30 JlI of DE PC-
treated water. The RNA suspension was incubated at 55 °C for 10 minutes. RNA 
concentration was estimated using the GeneQuant II RNNDNA Calculator (pharmacia 
Biotech). The integrity of the RNA was assessed by running a small aliquot on an agarose 
gel to check for the presence of the three rRNAs (28S, 18S, and 5S) which make up 80% 
of the total RNA content of the cell. The RNA was stored at -70 °C until required. 
2.14.16 Radiolabeiling of probes 
The labelling of the probe was accomplished using the Stratagene Prime-It II Random 
Primer Labelling Kit, following manufacturer's instructions. 
2.14.17 Notthem hybrld/satlon 
The extraction of RNA from trypanosomes is outlined in section 2.14.15. A denatwing 
RNA gel was prepared by mixing 30 ml 2% molten agarose with 30 ml 12% formaldehyde 
in 2x Northern Gel Buffer (see Appendix A), pouring the reSUlting mixture into a gel cast 
and allowing to set. When the gel had cooled, the gel tank was filled with 1 x Northern Gel 
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Buffer/3% formaldehyde and the comb was carefully removed. A magnetic stirring bar 
was placed in the tank and the tank was set on top ofa stirring motor. 
The RNA samples were prepared in an RNAse-free microfuge tube as follows: 10-20 flg 
RNA, 1 fll 20x Northern Gel Buffer, 3.5 fll formaldehyde (37%), 10 fll formamide and 
DEPC-treated dH20 to a final volume of20 ,.tI. A tube of RNA markers (Sigma) was also 
prepared. The samples were heated to 55°C for 15 minutes and then chilled on ice. 2 fllof 
RNA loading buffer (Appendix A) was added to each tube and samples were loaded onto 
the gel. The electrophoresis was started and once the samples had migrated into the gel a 
little, the stirring motor was turned on to circulate the buffer. The gel was run at 15 V 
overnight. 
To transfer the RNA from the gel to a nylon support (Hybond N, Amersham), a standard 
capillary elution blotting apparatus was set up (Sambrook, et al., 1989). The flow of 20x 
SSC (see Appendix A) up through the gel carries the RNA to be deposited on the nylon 
membrane. The transfer was allowed to proceed overnight. 
The blotting apparatus was dismantled and the nylon membrane was cross-linked by 254 
nm uhraviolet irradiation using the Spectrolinker XL-l000 UV Linker (Spectronics 
Corporation). 
To assess RNA transfer, the blot was stained with Blot Stain Blue Reversible Northern 
Blot Staining Solution (Sigma) for 5 minutes and then washed in dH20. 
The filter was pre-hybridised for 2 hours at 42°C in hybridisation buffer consisting of 50% 
formamide, 5x SSC, lOx Dendhart's solution, 0.1% SDS, 20 mM NalhP04, 5 mM EDTA 
and 0.2 mg/ml of denatured herring sperm DNA. 
The probe was heated to 95°C for 5 minutes and then added directly to the hybridisation 
tube. Hybridisation was allowed to occur overnight at 42°C under constant mixing in a 
Hybaid Shake and Stack hybridisation oven. 
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The membrane was removed from the hybridisation mixture and washed twice in room 
temperature wash buffer (O.Ix sse, 0.1% SDS) for I minute. This was followed by three 
washes of 30 minutes each at 55°C. 
The filter was wrapped in Saran wrap and exposed to X-ray film at -70°C for an 
appropriate length of time. 
2.15 Software and web resources 
The Vector NTI Suite 7.0 (InforMax) was used to analyse DNA and protein sequences. 
Translations of nucleotide sequences were perfomed, and open reading frames and 
restriction enzyme sites were located using Vector NTI. AlignX was used to contruct 
alignments of related nucleotide and amino acid sequences. 
The following web resources were used: 
http://www.ncbi .nlm.nih.gov/ 
http://www.tigr.org/tdb/ 
http://www.sanger.ac.ukIProjectsiT bruceil 
http://www.ebi.ac.ukJparasites/parasite-genome.htm I 
http://www.ch.embnet.org/sofiware/TMPREDfoTm.html 
http://www . genedb. org/genedb/tryp/index.j sp 
http://parsunl .path.cam.ac.uk/ 
67 
Chapter Three 
Substrate recQqpition models for the H2 purine transporter of r. 
b. bruce; 
Chapter III Substrate recognition models for the H2 purine transporter ofT. b. brucei 
3.1 Introduction 
The aim of this stage of the project was to gain a greater understanding of how purine 
nucleobase substrates react with the H2 nucleobase transporter during the binding step of 
membrane transport. It is necessary for any permeants to reversibly interact with the 
transporter molecule in the form of non-covalent intermolecular interactions. Since 
recognition of the substrate by the transporter is central to its subsequent translocatio~ any 
potential drugs that would enter through the transporter would presumably have to share 
essential structural elements that would be able to participate in these intermolecular 
associations. The hypothesis was that if these constituents, essential for the first step in 
uptake, could be identified it would be a simpler process to design or select 
chemotherapeutic agents to be taken up by the H2 transporter. 
The administration of purine compounds forms part of the therapeutic intervention in many 
different disease conditions. Indeed, nucleoside and nucleobase anti-metabolites have a 
distinguished history as anti-viral and anti-neoplastic agents (Elio~ 1989). Among the 
more well-known examples are the antiviral drug acyclovir, the immunosuppressant 
azathioprine, the cancer chemotherapeutic 6-mercaptopurine and the anti-parasitic/gout 
treatment allopurinol. It is interesting to consider that the large bank of existing nucleobase 
compounds may constitute a possible source of future treatments for African 
trypanosomiasis. Nucleobase and nucleoside analogues were assayed for in vitro 
trypanocidal activity to establish if interaction of the drugs with the H2 transporter could 
be correlated to accumulation oftoxic concentrations of the analogues. 
3.1.1 Why study the 82 transporter? 
The concept of exploiting transport systems to deliver chemotherapeutic agents is not a 
new one. The specific action of many drugs can be attributed to the selective accumulation 
in target cells and the up- or down-reguJation of transporter genes can contribute to an 
increase or decrease in the target cell sensitivity to anti-metabolites (Lu, et al., 2002). 
Some of the existing trypanocides are known to enter the trypanosome via the P2 
nucleoside transporter (Carter & Fairlamb, 1993; Matovu, et al., 2003), and this filet lends 
support to the strategy of using the transporters as gateways. Although new drugs could 
possibly be engineered to enter via this transporter, given that loss of the P2 activity has 
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been implicated in the development of drug resistance (Carter & Fairlamb, 1993; Matovu, 
et 01., 2003), this may not be the best approach. Other transporters in T. b. brucei have 
merit as potential routes of access for trypanocides (Basne & Barrett, 2000a), including 
glucose transporters (Walmsley, et 01., 1998), amino acid transporters (Hasne & Barrett, 
2000b) and purine transporters other than the P2 activity (De Koning & Jarvis, 1997b; De 
Koning & Jarvis, 1999). It is widely recognised that uptake of melaminophenyl arsenicals 
via the P2 transporter is a consequence of the P2 recognition motifpresent in the melamine 
ring (De Koning & Jarvis, 1999; Barrett & Fairlamb, 1999). It has been suggested that 
replacing the melamine ring with an alternative structure designed to direct the arsenic-
containing toxophore through other trypanosomal transporters might provide at least a 
temporary respite from arsenical resistance due to reduced accumulation (De Koning, 
2001). 
Of the diverse range of transporters involved in purine nucleobase uptake in T. b. brucei 
(described in Chapter 1), the H2 transporter would seem to offer the best chance of 
providing a viable drug entry system. Obviously, the exploitation of any nucleobase 
transporters would require their expression in the clinically-relevant life cycle stage. 
Neither HI nor H4 activity has been detected in bloodstream forms by biochemical means 
(De Koning & Jarvis, 1997a), although TbNBTJ mRNA transcripts (TbNBTI is the gene 
responsible for H4 activity) are present in this life cycle stage (see Chapters 6 and 7; 
Burchmore, et 01., 2003). With the difficuhy of studying each individual activity in 
isolation in its natural environment, the absence of biochemical evidence does not rule out 
the expression of these transport components in the bloodstream forms. In any case, H2 has 
a much higher affinity for a wider range of penneants than does H3 (De Koning & Jarvis, 
1997b), HI or H4 (De Koning & Jarvis, 1997a; Burchmore, et 01., 2003) and so is 
preferable as a potential device for drug entry. 
3.1.2 MecbaDisms or molecular recogDitioD 
Various intermolecular forces can contribute to the recognition and binding of substrate to 
an enzyme or transporter. These forces include hydrogen bonds, electrostatic forces, weak 
van der Waal's forces, hydrophobic interactions or 1t bonding (Freitas Jr., 1999). The 
equilibrium constant for the association of an enzyme with its substrate is typically in the 
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range of 10.2 to 10-8 M, with this corresponding to Gibbs free energies of interaction of 
between 12 and 48 kJ/mol (Stryer, 1995). 
Electrostatic bonds form between charged particles, and so may form in protein secondary 
and tertiary structmes between positively-charged amino acids (e.g. lysine, and arginine) 
and negatively-charged amino acids (e.g. glutamate and aspartate). These interactions are 
unlikely to playa major role in recognition of nucleobase or nucleoside permeants, as these 
molecules are uncharged. However, partial charges may well contribute to interactions 
with charged groups in the transporter binding pocket. 
Vander Waals' forces are weak, transient dipoles which contribute to the attraction 
between molecules, but while these forces are numerous they are limited in strength and 
are only important at close distances. Consequently, they may playa role in stabilising 
transporter-penneant complexes but are not responsible for their formation. 
The contribution of hydrophobic forces to binding can be considerable but they are 
unlikely to be significantly involved given that nuc1eobase and nucleoside molecules do 
not possess significant hydrophobic domains. Furthermore these interactions tend not to be 
very specific and so probably don't play a large role in the recognition of specific 
molecules (Freitas Jr., 1999). 
Pi-pi stacking interactions occur between the delocalised electrons of aromatic ring 
systems and can contribute as much as an H-bond in terms of binding energy. In the case 
of purine binding to the H2 transporter, the interaction would occur between the purine 
ring and aromatic amino acid residues such as phenylalanine, tryptophan or tyrosine. The 
strength of the 7t-7t stacking interaction depends on the orientation of the rings relative to 
one another (Hunter, et al., 1991). 
The remaining intermolecular attraction is also likely to be the most vital- the hydrogen 
bond. This bond occurs between a highly electronegative acceptor atom (usually an oxygen 
or nitrogen atom) and a donor hydrogen atom which is covalently attached to another 
electronegative atom. The hydrogen bond is characterised by the greater proximity of the 
acceptor and donor atoms than that which would be anticipated from the van der Waals' 
radii for the atoms. Figure 3.1 shows the typical geometry of hydrogen bonds and shows 
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that the hydrogen bond is to some extent flexible in terms of the interatomic distances and 
angles encountered. There is some disagreement as to the restrictions on these factors. The 
most generous estimates given for inter-atomic distance in a hydrogen bond given by 
Kabsch & Sander stipulate that the acceptor-donor distance is no more than 5.2 A when the 
alignment is perfect (Kabsch & Sander, 1983). Similarly, Baker & Hubbard specify that 
the angle between the acceptor and the donor atoms (C=Q···H in Figure 3.1) must lie 
between 90 and 180° (Baker & Hubbard, 1984). Consequently, hydrogen bonds have quite 
a range of potential energies (between 2 and 20 kJ/mol) (Kubinyi, 2001). 
\ ~c-o~J--N~H7' .1_-0 
/ ".-~N.ft .. O 
Figure 3.1. The geometry of a hydrogen bond. The typical distance between the 
electronegative donor group member (N in the figure) and the acceptor ranges from 2.8 to 
3.2 A. The angle N-H···O is usually larger than 150°. Typical angles for C=Q···H are 
between 100 and 180°. (Diagram reproduced from Kubinyi, 2001.) 
Obviously, there has to be a degree of complementarity between the binding site of the 
transporter molecule and at least part of its permeant in terms of shape, however, the 
ability of the molecules to participate in hydrogen binding with each other would appear to 
be equally relevant. Certainly, it has been shown with the different modes of binding of 
dihydrofolate (DHF) and methotrexate (MTX) with the enzyme dihydrofolate reductase 
(DHFR), that two molecules with structures that at first glance seem very similar can be 
orientated differently for optimal participation of hydrogen bonds (Kubinyi, 2001) (Figure 
3.2). 
This dependence on the appropriate formation of hydrogen bonds for efficient 
transportltransformation may also help to explain why molecules as diverse as adenine, 
pentamidine and melarsoprol show such high affinities for the P2 transporter (De Koning 
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& Jarvis, 1999). The P2 substrate recognition unit, H2N-CH=N-R, present in these very 
different molecules represent residues with the potential to participate in hydrogen 
bonding. In addition, these molecules all contain aromatic rings capable of participating in 
1t-1t interactions. 
OHF 
Figure 3.2. Recognition of DHF and MTX by DHFR. This shows how superficially very 
similar molecules can differ in their recognition by biological molecules. The two 
alternative orientations for the DHF molecule are shown either side of the binding 
orientation for MTX. Hydrogen bond donors are indicated by arrows directed away from 
individual atoms and acceptors are indicated by arrows directed towards atoms. The grey 
arrows indicate that the acceptor/donor is able to participate in the same interactions as in 
the MTX molecule, while the white arrows mean that the interactions are no longer 
possible. In order to maintain the optimal number of H-bond connections the DHF 
molecule is actually bound by DHFR in a different orientation from that of MTX. 
(Diagram reproduced from Kubinyi, 2001.) 
3.1.3 Recognition models & use of analogues to characterise transporters or enzymes 
Analogues of enzyme substrates have been used for a long time in attempts to dissect 
structure-function relationships. Usually, it is simply the ability of a given analogue to 
inhibit normal function of the enzyme or transporter that is noted and related to the 
structural differences (Naguib, et ai., 1995). Use of the Cheng-Prusoff equation to calculate 
Kt values for competitive inhibitors (Cheng & Prusoff, 1973), which can then be 
compared, is perfectly acceptable but it is useful to be able take the analysis further and 
actually quantify these differences, and by using changes in .1Go this can be accomplished. 
73 
Chapter III Substrate recognition models for the H2 purine transporter ofT. b. brucei 
Gibbs free energy, AG, is derived from the combination of the first and second laws of 
thermodynamics and is essentially the change in energy within a system undergoing a 
transformation. The standard free energy, AGO, is the energy change observed under 
standard conditions. 
The standard free energy of binding of a substrate to a transporter or enzyme can be related 
to the ~ for the molecule using a derivation of the Nernst equation: I AGo=-RTlnKj I 
where R is the gas constant and T is the absolute temperature in Kelvin. 
Of course, these data analyses are subject to certain limitations and assumptions. Firstly, 
since use of the Cheng-Prusoff equation to calculate ~ values from ICso's is valid only for 
competitive inhibition-type situations, so too is the reliability of the AGO values derived 
from these results. Also, it is largely assumed that differences in translocation rates of the 
various ligands bound to the transporter molecule will not significantly affect ICso values. 
The value of AGO can also be affected by necessary conformational changes in the protein 
molecule during the process of ligand-binding. When portions of the ligand molecule are 
changed or removed ahogetber, the normal conformational changes can also be distorted 
due to the change in entropy, and hence the AGO can vary (Jencks, W.P., 1981). 
It is also very important to remember that just because a molecule can disrupt the uptake of 
the natural substrate it does not necessarily follow that said molecule is actually taken up 
by the transporter. 
Yet, when aware of the limitations, quantitative recognition models can identify which 
positions on the substrate molecules are important for recognition and can give an insight 
into the nature of the interactions between substrate and enzyme/transporter. This sort of 
functional characterisation can be particularly beneficial when the structure of the 
enzyme/transporter has not been elucidated. For integral membrane proteins such as 
transporters, with up to 14 transmembrane domains, it is still exceedingly difficult to 
obtain crystals suitable for X-ray diffiaction. 
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Studies into molecular recognition of ligands by protein molecules as diverse as antibodies, 
streptavidin and mv protease have taken advantage of the above derivation of the Nernst 
equation to quantify the strength of protein-ligand interactions (Freire, 1999; Lazaridis, et 
01.,2002; Akaho, et 01.,2001). 
This approach has been successfully employed in a study of the PI and P2 nucleoside 
transporters in T. b. brucei (De Koning & Jarvis, 1999). The H2N-CH=N-R motif for the 
recognition of substrates by the P2 transporter, as mentioned above, was identified by these 
means and also independently by other experimental means by the group of Alan Fairlamb 
(Barrett & Fairlamb, 1999). Similar methods have been used to derive substrate 
recognition models in other organisms and systems. Since this work was carried out 
associated researchers have developed substrate-activity models for the recognition of 
nucleobase compounds by the Leishmania major NBTI transporter (AI-Salab4 et 01., 
2003) and for the recognition of nucleobase/nucleosides by the Toxoplasma gondii AU 
transporter (De Koning, et 01., 2003). 
The models can effectively pinpoint areas of the substrate molecule that can be altered, or 
where toxic components can be coupled, so as not to disrupt initial recognition by the 
enzyme/transporters. This is of great importance if the analogue has a potential use in 
chemotherapeutic applications. In T. b. brucei, much research has been carried out on the 
grafting of the P2 recognition motif onto toxic molecules as a way to ''piggy-back ligand-
bound drugs" into the parasite (Borst & Fairlamb, 1998). Amongst the molecules that have 
been investigated as potential passengers on such a system have been polyamine analogues 
and nitric oxide-releasing agents (rye, et 01., 1998; Klenke, et 01., 2001; SouIere, et 01., 
1999). 
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Figure 3.3. Analowes used to characterise substrate recognition by the H2 transj)Orter. 
(a) Purines. 
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Figure 3.3. Analogues used to characterise substrate recognition by the H2 tranmorter. 
(a) Purines (ctd). 
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Figure 3.3. Analogues used to characterise substrate recognition by the H2 transporter. 
(b) Pyrimidines. 
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FiKW'e 3.3. Analogues used to characterise substrate recognition by the H2 transporter. 
(c) N ucleosides. 
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Figure 3.3. Analogues used to characterise substrate recognition by the H2 transporter. 
(d) Others. 
Many of the compounds used to characterise recognition of permeants by the H2 
transporter normally occur as a mixture of two or more different tautomeric forms. In most 
cases, the structures shown in Figure 3.3 have been experimentally shown to be the major 
components present under physiological conditions. 
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3.2 Results 
3.2.1 Structure-activity relationships 
Natural purines, a variety of purine analogues and other related compounds (Figure 3.3) 
were assayed for their ability to inhibit the T. b. bruce; 427 H2 hypoxanthine transport 
activity. At a eH] hypoxanthine concentration of 0.1 J,JM, H2 is responsible for over 95% 
of the hypoxanthine flux (De Koning & Jarvis, 1997b). The Ki values were determined 
from dose-response curves subject to the assumptions outlined in Chapter 2. 
Representative examples of the dose-response curves are shown in Figure 3.4. By 
calculating the binding energies, as Gibbs free energy (AGO), involved in the interaction 
between the transporters and the different molecules, structure-activity relationships were 
devised. The Ki and the AGO values for the different analogues are listed in Table 3.1. 
The most obvious observation about substrate recognition by the H2 transporter is that 
despite being selective for neither oxopurines (hypoxanthine, guanine) or aminopurines 
(adenine) it does have some preference for 6-oxopurines (see Figure 3.4, panels (a) and 
(b». The total AGO for the interaction of hypoxanthine with the transporter is greater by 8.1 
kJ/mol than that for adenine. This difference is substantial enough to account for the loss of 
a hydrogen bond. Taken on its own, this could lead to the notion that the keto group at 
position 6 in oxopurines is involved in a hydrogen bond contributing to substrate 
recognition. However, the AGO values for guanine and 6-thioguanine are virtually identical 
even though the thio group makes a far less effective acceptor than the keto group 
(papageorgiou, et al., unpublished). Therefore, this indicates that the keto group does not 
significantly contribute to the binding of the substrate by the transporter binding site. 
Furthermore, the difference in AGO between purine and adenine (the only difference being 
the amino group at position 6), of 4.4 kJ/mol would suggest that this amine is involved in 
binding interactions, and that an H-bond donor, rather than an H-bond acceptor (such as a 
keto group) is favoured at position 6 (Figure 3.4, panel (a». In further support of the idea 
that 6(NH2) participates in the binding of adenine, a similar difference in AGO value is seen 
when adenine is compared with 6-chloropurine (4.2 kJ/mol). It is also of note that bulkier 
substitutions at position 6 of the adenine molecule are detrimental to binding by the 
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transporter: AGO for 6-dirnethylaminopurine and 6-benzyloxypurine are approximately 10 
kJ/molless than for adenine. 
To explain why hypoxanthine is a much better permeant than adenine, despite having a 
keto group instead of an amino group at position 6, the situation at position 1 of the purine 
ring system has to be considered. At this position is the only other difference in structure 
between adenine and hypoxanthine: the Nt is protonated in hypoxanthine but IS 
unprotonated in adenine. The discrepancy in AGO values for adenine compared to 1-
deazapurine is 4.8 kJ/mol (inhibition trace shown in Figure 3.4, panel (c» but as already 
discussed above this can be attnbuted to interactions with 6(NH2), and so it can be stated 
that the unprotonated NI does not contribute to recognition by the transporter. It follows 
that the protonation of N1, being the only difference between hypoxanthine and purine 
other than the keto group, is responsible for the observed 12.5 kJ/mol difference in AGO. 
The same change in binding energy was observed upon methylation of the 6-keto group of 
hypoxanthine, which similarly changes the protonation status ofNI and the apparent loss 
of a strong hydrogen bond in that position (inhibition response curve for 6-methoxypurine 
shown in Figure 3.4, panel (c». The observed ~(AGO) of8.l kJ/mol between hypoxanthine 
and adenine is thus explained by a gain of 12.5 kJ/mol from NI(H) minus 4.3 kJ/mol from 
the loss of the interaction with 6(NH2). The absence of a contribution from the 
unprotonated Nt can also be clearly seen when the AGO values for purine and 1-
deazapurine are compared, i.e. less than 0.4 kJ/mol of a difference between the two 
molecules (Figure 3.4, panel (a) and (c». 
The only difference between hypoxanthine and guanine is the amine group at position 2 in 
guanine. This addition has made the molecule a less efficient substrate. This drop in uptake 
efficiency (2.72 kJ/mol) however is not equivalent to the loss of a full hydrogen bond, 
suggesting that this substitution leads to a weakening but not complete loss of any existing 
bonds. The data pertaining to 2,6-diaminopurine (Figure 3.4, panel (c» and 2,6-
dichloropurine, with differences in AGO of 5.1 kJ/mol and 6.1 kJ/mol from adenine and 6-
chloropurine, respectively, support this hypothesis. 
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Compound ~()J.M) AGO (kJ morl 
hypoxanthine 0.12 ±0.02 -39.5 
guanine 0.36 ±0.18 -36.8 
adenine 3.2 ± 1.1 -31.4 
xanthine 8.8 ±3.9 -28.9 
allopwiool 4.0 ±2.2 -30.8 
oxypurinol 16 ±3.S -27.4 
aminopurinol 240±SO -20.7 
purine 18 ±3.7 -27.0 
I-methyladenine 84 ± 14 -23.3 
l-deazaplUine 22 ±8.2 -26.6 
1,3 .. rine NE,I000 
theophylline (l,3-dimethylxanthine) 450 ±98 -19.1 
7-azaindole (l,7-dideazapmine) NE,I000 
2,6-diaminopurine 25 ±S.7 -26.3 
2,6-dicllloroplUine 200 ±38 -21.1 
3-methyladenine NE,2S0 
3-deazaguanine 10 ±2.0 -28.5 
6-methoxyguanine 3.4 ±0.6 -31.2 
6-thioguanine 0.43 ±0.03 -36.3 
6-thiopwine 1.3 ±0.4 -33.5 
6-methoxypwioe 6.9 ± 1.9 -29.5 
6-benzyloxypwine 150 ±33 -21.8 
6-ch1<ropurine 17 ±3.3 -27.2 
6-dimethylaminopurine 190 ±36 -21.2 
7-deazaguanine 55 ± 12 -24.3 
8-azaguanine 7.2±0.9 -29.4 
8-azaadenine 110 ± 14 -22.7 
8-azahypoxanthine 27±6 -26.0 
uric acid (8-bydroxyxanthine) NE,2S0 
9-methylguanine 70± 16 -23.7 
9-deazaadenine 70± 13 -23.7 
9-deazaguanine 8.0 ± 1.3 -29.1 
NS2063S 4100 ± 1800 -13.6 
4-(3H}pyrimidone 900±290 -17.4 
thymine 82±25 -23.3 
cytosine >500 
uracil 60± 14 -24.1 
guanosine II ± 1.8 -28.3 
inosine 70.2 ±9.2 -23.7 
adenosine 590± 180 -18.4 
acycloguanosine 62±5 -24.0 
ara-bypoxanthine 300 ±47 -20.1 
thymidine >1000 
cytidine NE,IOOO 
uridine 500 
lumazine 370±28 -19.6 
IlSaX'bate NE,2500 
Table 3.1. ~ and AGO values for the inhibition of hypoxanthine uptake by the T. b. bruce; 
H2 nucleobase transporter. Resuhs are shown ± standard error. All values are the average 
of three to five independent experiments. NE, no effect at stated concentration. 
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The loss in binding energy caused by these substitutions at position 2 could be explained to 
some extent by an associated reduction of the partial negative charge on N3, making this 
residue a less effective hydrogen bond acceptor. This mechanism was also noted in work 
relating to the PI and P2 nucleoside transporters of T. b. bruce; (De Koning & Jarvis, 
1999) and transporters in Leishmania major and in Toxoplasma gondii (AI-Salabi, et 01., 
2003, and De Koning, et al., 2003, respectively). Evidence that N3 does act as an H-bond 
acceptor is provided by the 8.3 kJ/mol energy difference between guanine and 3-
deazaguanine (Figure 3.4, panel (b)). Furthermore, methylation ofN3 leads to a dramatic 
loss in affmity, as 250 J.1M 3-methyladenine completely failed to inhibit H2-mediated eH] 
hypoxanthine uptake. 
Ahernatively, these substitutions at position 2 and 3 may physically prevent optimal 
positioning of the substrate in the binding pocket. It is interesting to note that N3 is 
unprotonated in all natural purines with the exception of xanthine and uric acid. 
The pyrimidine ring thus contributes -20.8 kJ/mol to the total of -39.4 kJ/mol Gibbs free 
energy for the interactions between the hypoxanthine molecule and the transporter, 
indicating a similar contribution from the imidazole half of this purine. Consistent with this 
prediction, 4(3-H)-pyrimidone (Figure 3.4, panel (d)), consisting only of the pyrimidine 
half of hypoxanthine, displayed a O(AGO) of -22.1 kJ/mol compared to hypoxanthine. 
Similarly, the O(AGO) ofNS20635 (Figure 3.4, panel (d», which is equivalent to adenine 
but with a saturated 5-membered hydrocarbon ring instead of imidazole, compared with 
adenine was 17 .8 kJ/mol. 
The involvement of N7 in binding, most probably as a hydrogen bond acceptor, follows 
most directly from the 8(AGO) between 7-deazaguanine and guanine of 12.5 kJ/mol (Figure 
3.4, panel (b». In addition, the affinity for allopurinol is significantly reduced compared to 
hypoxanthine, though its O(AGO) of 8.7 kI/mol suggests that a minor interaction is still 
possible with the nitrogen residue that has shifted from position 7 to 8. Uric acid had no 
effect on eH] hypoxanthine uptake at 250 J.1M, probably due to the protonation of N7 in 
the dominant tautomeric form of uric acid. An experimental ~ could not be determined for 
uric acid due to limitations of solubility. The comparatively low affinity of xanthine 
(O(AGO) of 10.7 kJ/mol relative to hypoxanthine) can be explained in part by the 
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energetically unfavourable substitution at position 2 (see above) and protonation ofN3, but 
mostly because its preferred tautomeric form is N(7)H!N9. 
12.6 
8.3 
HYPOXANTlllNE 
~Go = -39.5 kJ/mol 
4.3 
H 
7.7 
ADENINE 
~Go = -31.3 kJ/mol 
Figure 3.5. Model of the interactions between purines and the T b. bruce; H2 transporter. 
Estimations of the Gibbs free energy of these interactions are given in kJ/mol. 
The preference of the H2 transporter for nucleobases over nucleosides suggests that N(9)H 
may be involved in interactions with the transporter binding pocket. It is possible, 
however, that rather than preventing a hydrogen bond with N(9)H the bulky ribose moiety 
interferes with the proper positioning of the purine ring. It is very probable that, for most 
nucleosides, both factors contribute to the low affinity for the H2 transporter. The 8(~GO) 
of both 9-deazaguanine and 9-deazaadenine was 7.7 kJ/mol compared to their respective 
parent molecules, indicating that N(9)H most likely acts as a hydrogen bond donor. Given 
the higher difference in ~Go between most nucleobases and their respective nucleosides 
(adenine-adenosine 12.9 kJ/mol; hypoxanthine-inosine 15.8 kJ/mol), it is likely that steric 
factors equally contribute to the low affinity for nucleosides. 
The model shown in Figure 3.5 thus describes 4 interactions, probably hydrogen bonds, to 
bind either oxopurines or aminopurines. The ~Go values of hypoxanthine (-39.5 kJ/mol) 
and adenine (-31.3 kJ/mol) are within 5% of the total of the 4 predicted interactions (-41.1 
and -32.8 kJ/mol respectively). 
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3.2.2 TnpanotoIicity of purine analogues 
With the substrate recognition models in place, the purine analogues were next tested for in 
vitro trypanotoxicity, to assess the existence of a relationship between efficient uptake and 
toxicity. 
Many of the purine analogues that were tested have been used as chemotherapeutic agents 
in other diseases or disorders, e.g. allopurinol in the treatment of leishmaniasis and 6-
mercaptopurine against leukemia. The analogues were investigated for any toxic effects 
they might have on T. b. brucei. These tests were carried out on bloodstream parasites as it 
is these that the drugs would be required to act against in vivo. The Alamar Blue reaction is 
a more efficient way of testing toxicity than observation of the parasites for 
viability/motility following exposure to the test compound which is time-consuming and 
subjective. Exposure of the parasites to the test compound followed by incubation with 
Alamar Blue resuked in a measurable colour-change, due to the action of an unspecified 
parasite dehydrogenase. By using a range of drug concentrations dose-response curves 
could be generated (Figure 3.6). In order to have as sensitive an assay as possible, the 
bloodstream parasites were resuspended in a nucleobase-free version of HMI-9 medium 
(with adenosine supplement as purine source). This meant any analogue taken up by the 
H2 transporter did not have to compete with hypoxanthine when binding to the transporter. 
Figure 3.6 shows Alamar Blue assay dose-response curves for the three compounds to 
consistently show trypanocidal activity in vitro, namely aminopurinol, 2,6-dichloropurine 
and adenine 9-~-D-arabinoside. 
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Figure 3.6. Trypanocidal activity of purine analogues. Examples of Alamar Blue assay 
graphs. These were produced using colorimetric readings. 
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3.3 Discussion 
Most knowledge of the purine transport activities in T. b. brucei has been gained through 
biochemical studies as information on the encoding genes, as well as the structure of the 
proteins, has been largely absent. The current study has added a further layer to the 
biochemical characterisation of the H2 nucleobase transporter found in bloodstream form 
T. b. bruce; 427. 
By assaying the ability of a range of purine analogues to inhibit the uptake of eH] 
hypoxanthine and converting this inhibition activity to AGO values, a substrate recognition 
model has been constructed to describe quantitatively which positions of the purine ring 
are essential for transport by the trypanosome transporter. The AGO values calculated from 
the observed Ki have allowed prediction of how strongly a drug can bind to the transporter 
binding pocket. The recognition models are the key to the rational design oftrypanocides 
that are efficiently accumulated by the parasite. Comparisons with equivalent host 
transporters should be able to introduce a level of selectivity. It has been shown here that 
uptake of subversive nucleobase analogues, such as aminopurinol, is mediated by the H2 
transporter. 
There are of course some limitations to the methods used here. It is the ability of the 
analogues to inhibit a known penneant of the transporter and not actual uptake of the 
analogues themselves that has been studied. From these results it is unclear if an analogue 
is being fully chaperoned across the membrane by the transporter or if it is simply 
interacting with it in its external orientation. In order to study actual transport of the 
analogues by these methods they would have to be radio labelled individually, which is not 
practicable. Despite the limitations, these types of studies are in wide useage, and although 
the current methods to establish a model for substrate-transporter interactions do not 
depend on transport, they certainly have predictive value for the substrate recognition 
phase of membrane transport. 
Still, it is conceivable that such factors could distort individual estimates of~, and hence, 
AGO. The speed at which the transporter-permeant complex transverses the membrane and 
the speed of release of the permeant into the interior of the cell can vary for different 
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molecules, and may increase or decrease the observed Ki , as this value is ultimately 
derived from the amount of radio label taken up by the cell. A prolonged occupancy of the 
transporter by an inhibitor could theoretically reduce this significantly, in addition to its 
effects as competitive inhibitor. During the construction of the substrate recognition model, 
it was ensured that more than one analogue contributed to the final designated value for 
each interaction, and that the individual estimates were generally in good agreement. The 
model was also supported by the fact that the total sum of the AGO values [1:( AGO).] for 
the separate "-bonds, calculated from the apparent ~ values, is within 5% of the total AGO 
calculated from the actual K.n of the natural substrate. 
The H2 transporter appears to recognise several residues on both the pyrimidine part and 
the imidazole half of the purine ring system. This appears to leave relatively little room for 
the modifications and substitutions for binding antimetabolites. Certainly, the recognition 
motif for the P2 transporter is mostly confined to the pyrimidine part of the purine ring, 
allowing for coupling of toxic moieties to or in place of the imidazole ring. However, the 
H2 model may still be useful as a starting point for designing or deploying new 
trypanocides. Substitutions are possible at positions 2, 6, and 8, and the "allopurinol shift" 
in position N7 could be combined with other changes. Chapter 5 describes the recognition 
of some novel purine-like compounds by the H2 transporter. 
Of course, a high-affinity interaction with transporter does not necessarily mean good 
trypanocidal activity. An analogue may not actually be taken up by the transporter. In 
many cases, selective uptake alone may be insufficient for trypanocidal action. It will be 
necessary to investigate the structure-activity relationships of enzymes invoved in purine 
metabolism as a next step in the rational design of purine antimetabolites. 
The Alamar Blue assay was used to assess the potential therapeutic value of selectively 
transported reagents in an in vitro situation. Alamar Blue assay works very well for known 
trypanocides giving results comparable to those obtained by other means (RAz, et al., 
1997). In this wor~ a range of nucleobases and related compounds were assayed for 
trypanocidal activity. Alamar Blue assays and other toxicity assays filiI to address which 
transporter(s) are actually involved in the uptake of any drugs - the constitution of media 
can be changed to favour certain transporters but uptake by other transporters can only be 
effectively prevented by utilising transporter gene knock-outs or RNA knock-downs. 
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Although some compounds did show some activity, it is prudent to note that this research 
was preliminary - introducing the approach and validating it as a way of identifying 
possible lead compounds for the development of new trypanocidal regimes. The list of 
compounds assayed for trypanocidal activity was by no means comprehensive. Existing 
purine-related compounds are in use in other disease conditions and given that researchers 
in these other areas also strive to improve existing chemotherapy it is inevitable that new 
compounds will continue to be developed by chemists and drug companies. It is to be 
anticipated that compounds may have to be optimised for appropriate recognition by 
trypanosome transporters and also for active toxic side groups. Nevertheless, the Alamar 
Blue results obtained raised some interesting points. 
Allopurinol is the only purine compound currently in use against a species of 
Trypanasomatidae (Leishmania spp.) but is usually only used in conjunction with other 
drugs (Das, et al., 2001). The selective action of allopurinol is due to the different 
metabolic pathways in trypanosomatids as opposed to mammalian tissues. In Leishmania 
the allopurinol is metabolised to the toxic 4-aminopyrazolopyrimidine-5' -monophosphate 
(APPR-MP) which is further phosphorylated to APPR-DP and APPR-TP which is then 
incorporated into the cellular RNA (Marr, 1983). In mammalian cells the same molecule is 
metabolised to oxipurinol and other by-products and harmlessly excreted from the cell. As 
seen in this study, allopurinol is taken up by the H2 transporter with a relatively high 
apparent ~ of 4.0 J,.LM. However, in the Alamar Blue assay, allopurinol is not very 
effective in vitro against bloodstream form T. b. brucei 427 at the concentrations assayed. 
The adenine analogue, aminopurinol, conversely shows little affmity for the H2 transporter 
(~ of 240 J..LM) but in the Alamar Blue assay displays an in vitro ICso of 2.8 J,.LM. An 
adenosine analogue, adenine-9-p-D-arabinoside, also performed relatively well in the 
Alamar Blue (lC50 of 44.6 J..LM) while poorly inhibiting H2 activity in the transport assays. 
This apparent paradox can almost certainly be explained by the uptake of these compounds 
by the P2 transport activity - both molecules possess the P2 recognition motif. It is 
uncertain how theses analogues would affect the mammalian cell - they may be rapidly 
metabolised and excreted as happens for allopurinol but it may be that these amino 
analogues are more palatable to the metabolic enzymes of man. 
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Chapter IV. Substrate recognition models/or the FNTI o/human erythrocytes 
4.1 Introduction 
In the previous chapter, it was established that the H2 nucleobase transporter of the 
protozoan parasite T. b. bruce; has the potential to act as a conduit for the delivery of novel 
trypanocides to the interior of the organism where such molecules could interfere with 
trypanosomal metabolic pathways. However, it is also of paramount importance to 
examine how any new drugs would affect the mammalian tissues that they would 
inevitably come into contact with. With regards to the exploitation of transporters to 
conduct drugs across membranes, the ideal drug molecule would be efficiently conveyed 
across the parasite membrane while being excluded by the mammalian transport systems. 
Uptake of nucleobases by human erythrocytes was characterised in terms of substrate 
recognition motifs in the same way as for the trypanosome H2 transporter. 
Understanding the substrate recognition pattern for the facilitative nucleobase transporter 
(bFNTl) can add a further dimension to the design of new trypanocides, optimising for 
selectivity alongside efficacy, to at least one major host nucleobase transporter. 
4.1.1 Tbe buman erytbrocyte as experimental model 
There are several reasons why the human erythrocyte has been chosen as the model in this 
study. The plasma membrane of the red blood cell has long been a paradigm for studies of 
membrane structure and function (Stryer, 1995). This is partly due to the ease with which 
material can be obtained - although blood is a bonafide tissue in its own right, its fluid 
natme allows easy extraction and separation of the different components. The simplicity of 
the cell structure is also advantageous - with a lack of membrane-bound organelles the 
only erythrocyte membrane system is the plasmalemma. Glycophorin A, a major 
constituent of the erythrocyte membrane, was the first integral membrane protein to have 
its amino acid sequence elucidated, and membrane-associated systems such as the 
cytoskeleton were initially studied in the erythrocyte (Marchesi. 1985). 
The main function of the circulatory system is of course the transport of various chemicals 
around the body. The bloodstream provides oxygen and nutrients to all the tissues and is 
responsible for the removal of waste materials from these same tissues. It is also the 
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primary vehicle for hormone delivery and immune system components. Many drugs are 
adminstered via the bloodstream, allowing dissemination to many distant sites, and 
essentially co-opting this transport network, much as researchers want to exploit the 
transport activities of individual cells. 
It is therefore relevant to study nucleobase uptake by erythrocytes as a model human 
tissue. Moreover, effective salvage of anti-parasitic drugs by the erythrocytes would 
probably not only poison these vital cells, but also quickly deplete the free drug 
concentration in the bloodstream. 
4.1.2 The facilitative Ducleobase traDsporter 
As discussed in Chapter One, humans possess several different nucleobase and nucleoside 
transport activities. These range from concentrative transporters that usually reside in 
highly specialised tissues, such as placenta and kidney, to the more ubiquitous equilibrative 
transporter found in many different cell types (plagemann, et 01., 1988; Griffith & Jarvis, 
1996). 
The human facilitative nucleobase transporter (hFNT1) is the only nucleobase transporter 
present in human erythrocytes (Domin, et 01., 1988) but it, or transport proteins closely-
related in function, have also been described in various other tissues and have been shown 
to be involved in the uptake of several chemotherapeutic purine analogues including 
allopurinol (Razavi, et 01., 1993), acyclovir (Mahony, et 01., 1988), and 2',3'-
dideoxyguanosine (Gat~ et 01., 1992). In the range of different cell-types it has been 
described in, the Km or Ki values obtained have been similar to those derived in 
experiments using the erythrocyte. 
It was determined that adenine, guanine, and hypoxanthine are taken up by the erythrocyte 
facilitative nucleobase transporter with Km's of 13, 37 and 180 J.1M, respectively (Domin, 
et 01., 1988). Carrier mobility studies by Kraupp and colleagues (1991) confirmed that the 
three penneants were each carried by the same transporter. 
Even though mammalian cells are generally considered to be able to manufacture the 
purine ring, in fact not all cell types, including erythrocytes, are capable of this synthesis. 
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These cells. like the bloodstream trypanosome, must salvage free purines from the blood. 
Some purines will be obtained through the diet, but other tissues must synthesise and 
release sufficient quantities of nucleobase/nucleosides into the bloodstream. This follows 
most directly from the observation that man and other mammals can be maintained 
indeflnitely on purine-free diets (Murray, 1971). 
4.2 Results 
4.2.1 Confirmation of basic kinetics of hFNTl in human erythrocytes 
Transport of tritiated permeants by the hFNTl was determined using the rapid-stop oil-spin 
technique very similar to that used to study uptake by the parasite transporter. Transport 
was effectively terminated using ice-cold papaverine (a non-competitive inhibitor of 
hFNTl - KrauPP. et 01., 1994) rather than unlabelled permeant, and it was necessary to 
extract the accumulated radioactivity in the acid-soluble fraction of the cell pellets as 
haemoglobin would cause severe quenching during liquid scintillation counting. Transport 
of t J.1M eH] adenine by human erythrocytes was rapid, and linear over 20 s with a rate of 
0.056 ± 0.004 pmol (10' cellsrl S·I (Figure 4.1). The transport activity was saturable as 
shown by the 92% reduction in uptake rate in the presence of t mM unlabelled permeant. 
In the subsequent inhibition studies eH] adenine uptake was apparently monophasic. with 
a Hill slope close to -I, consistent with a single transport system for the transport of 
adenine (data shown in next section). This was in keeping with previous studies of 
nucleobase uptake by human erythrocytes (Domin, et 01., 1988). Figure 4.2 shows a 
Michaelis-Menten plot for adenine uptake. 
The apparent Km was 16.2 ± 4.5 J.1M and the Vmax was 1.92 ± 0.89 pmol (10' cellsrl S·I 
(0=3). Subsequent inhibition experiments were conducted using a [3H] adenine 
concentration of 1 J.1M and an incubation time of 3-5 S, which produced highly 
reproducible results. 
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Figure 4.1. Uptake of [3m adenine by human erythrocytes as a function of time. Uptake of 
1 J.lM eH] adenine in the absence (_ ) or presence (- ) of 1 mM unlabelled adenine. 
(a) Uptake over 120 s. (b) Linear phase of uptake over 20 s (r2 = 0.97 by linear regression) 
with a rate of 0.056 ± 0.004 pmol (107 ceUsyl S-I. Uptake in the presence of 1 mM 
unlabelled permeant was taken as the rate of diffusion: 0.0044 ± 0.0005 pmol (107 cellsrl 
-lover 120 s. 
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Figure 4.2. Michaelis-Menten plot for transport of 1 blM eH] adenine by human 
erythrocytes. Michaelis-Menten plot showing a Km of 16.7 ± 2.1 J..lM and a Vmax of 0.84 ± 
0.07 pmol (107 ceIJsrl S- I for this experiment. 
95 
Chapter IV. Substrate recognition models/or the FNTI o/human erythrocytes 
4.2.2 Structure-activity relationships 
Natural purines and selected purine analogues were assayed for their ability to inhibit the 
uptake of adenine by the human erythrocyte hFNTl transport activity. The ~ values were 
determined from dose-response curves subject to the assumptions outlined in Chapter 2. 
Even though the mechanism of transport is different from the T. b. brucei transporters (i.e. 
a facilitative-type transport rather than active-transport coupled to a proton-gradient) these 
data analyses are still subject to the same limitations, such as the necessity for a single 
transporter and competitive-inhibition. The single-site competitive-inhibition curve 
generally exhibits a standard sigmoidal shape - the slope of the curve is called the Hill 
slope and in this scenario is expected to be close to -1. Experimental Hill slopes 
approximating -I were routinely observed, consistent with competitive inhibition of a 
single transporter and the literature as discussed above. Representative examples of the 
dose-response curves are shown in Figure 4.3. By calculating the binding energies, as 
Gibbs free energy (~GO), involved in the interaction between the transporter and the 
different molecules, structure-activity relationships were devised. The ~ and the ~Go 
values for the different analogues are listed in Table 4.1. 
The hFNTl transporter has a clear preference for aminopurines over oxopurines, with the 
~ for hypoxanthine (288 ± 21 J.LM) over 10-fold higher than the Km for adenine (16 ± 4.5 
J.LM). This specificity for aminopurines is opposite to that of the H2 which has a preference 
for oxopurines. The difference of 1.1 kJ/mol in AGO between hypoxanthine and adenine 
could indicate that the 6-amino group and/or the unprotonated NI of adenine is involved in 
the recognition process by the erythrocyte transporter, and would appear to limit the 
potential contribution of the 6-keto group and/or NI(H). The deletion of the NI residue in 
l-deazapurine leads to a 5.1 kJ/mol reduction in AGO compared to purine, confirming that 
the unprotonated Nt is important for interaction with the transporter. Adenine and purine 
differ only in the presence or absence of the 6-amino group and the B(AGO) of 4.1 kJ/mol 
implies that this component is also necessary for the optimal interaction of adenine and the 
transporter recognition site. The combined AGO for interactions at position I and 6 of the 
adenine molecule is therefore 9.2 kJ/mol, but the B(AGO) between adenine and 
hypoxanthine is only 1.1 kJ/mol, suggesting that hypoxanthine is perhaps capable of 
making alternative, albeit weaker. arrangements. If the 6-keto group is involved, it would 
96 
Chapter IV. Substrate recognition models/or the FNTI o/human erythrocytes 
be predicted that 6-thioguanine would make a less effective substrate than guanine due to 
the 6-thione group being less capable of participating in H-bonds. Indeed, this is exactly 
what is observed with a AGO discrepancy of 3.1 kl/mol. The difference of 3 kJ/mol in 
binding energy between purine and hypoxanthine confirms that the H-bond with NI is 
stronger than with 6-keto. It also reinforces the assertion that the NI(H) does not 
participate in recognition. The AGO for molecules such as 6-chloropurine, in which NI is 
unprotonated, do not differ significantly from that for purine (p> 0.05 in Student t test) 
(Figure 4.3, panel (a». 
Elsewhere in the pyrimidine half of the purine ring system, the participation of 
substitutions at position 2 and the unprotonated N3 is indicated. The participation of 
substitutions at position 2 during substrate recogition can be deduced from the S(AGO) of 
5.8 kJ/mol between guanine and hypoxanthine. The involvement ofN3 is inferred from the 
8(AGO) of 7.3 kJ/mol between guanine and 3-deazaguanine, and the 8.6 kJ/mol difference 
between adenine and 3-methyladenine (Figure 4.3, panel (a) and (b». The inability of 
xanthine and uric acid to inhibit eH] adenine uptake at the limit of their solubility is 
consistent with the requirement for an H-bond donor at position 2 and an H-bond acceptor 
at position 3. 
The pyrimidine ring of adenine thus contributes -16.5 kJ/mol to the total of -27.3 kJ/mol 
Gibbs free energy for the interactions between the adenine molecule and the hFNTI 
transporter, indicating a contribution of -10 kl/mol from the imidazole half of the purine 
ring system. 
Consistent with this assertion, the total sum of the binding energy values calculated for the 
interactions of the pyrimidine halves of hypoxanthine and guanine are -8.9 kJ/mol and 
-16.2 kJ/mot, respectively; again these apparent AGO values are -10 kJ/molless than the 
observed AGO for the entire molecules. 
The imidazole half of the purine ring system somehow contributes -10 kJ/mol in binding 
energy to recognition by the transporter binding pocket. The participation of the imidazole 
ring, however, is not mediated by hydrogen-bonding at position N7(H) or N9 since the 
transporter actually exhibits slightly higher aff"mity for 7-deazaguanine, 9-deazaguanine 
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Figure 4.3. Inhibition of FNTI-mediated em adenine transport in human erythrocytes by 
purine analogues. Rates of uptake are expressed as a percentage of contro~ i.e. uptake in 
the ab ence of inhibitor. Ca) I-deazapurine CO), purine (_ ), and 6-chloropurine ( A). (b) 
adenine C. ) 3-methyladenine ( ), and NS20635 (0). (c) 9-methylguanine (0 ), 3-
deazaguanine ( .. ) and 7-deazaguanine (- ). Label concentration in these experiments was 
1 J.!M. 
98 
Chapter IV. Substrate recognition models/or the FNTI o/human erythrocytes 
Compound ~()lM) AGo (kJ mort) 
hypoxanthine 290 ± 21 -20.2 
guanine 28 ±2.0 -26.0 
adenine 16 ± 4.5 -27.3 
xanthine >150 
allopurinol 150±9 -21.8 
aminopurinol 120 ± 30 -22.4 
2-thioaminopurinol 20 ±6.2 -26.8 
purine 86±20 -23.2 
1-deazapurine 680 ± 17 -18.1 
7 -azaindole (1,7 -dideazapurine) -10,000 -11.4 
2,6-diaminopurine 43 ± 10 -24.9 
2,6-dichloropurine 59 ±3.9 -24.1 
3-methyladenine 520 ±52 -18.7 
3-deazaguanine 520±24 -18.7 
6-thioguanine 95±8 -23.0 
6-methoxypurine 240 ±66 -20.6 
6-chloropurine 45 ± 5.8 -24.8 
7-deazaguanine 15 ±4.8 -27.6 
Uric acid (8-hydroxyxanthine) NE,250 
9-methylguanine 7.4 ±2.0 -29.3 
9-deazaguanine 8.0 ±2.5 -29.1 
NS20635 1100 ±47 -16.9 
4-(3 H)-pyrimidone 7740 ± 1900 -12.1 
thymine >1000 
cytosine NE,I000 
uracil NE,I000 
pyrimidine >10,000 
guanosine NE,250 
inosine NE,I000 
adenosine NE,1000 
uridine NE,I000 
Table 4.1. Ki and AGO values for inhibition of adenine uptake by the human facilitative 
nucleobase transj>Orter. Resuhs are shown ± standard error. All values are the average of 
three to five independent experiments. NE, no effect at stated concentration. 
and 9-methylguanine than for guanine itself (Figure 4.3, panel (c». The O(AGO) of 8.6 
kJ/mol between 4-(3H)-pyrimidone and hypoxanthine emphasises that the presence of the 
imidazole ring is required for proper recognition by the transporter even though the 
interaction cannot be correlated to a particular position or group. The compound NS20635 
possesses a double ring system consisting of a 6-member ring corresponding to the 
pyrimidine ring of adenine, and a 5-member ring lacking nitrogen atoms and n-orbitals. 
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This compound was also recognised with very low affinity by the transporter molecule 
(Figure 4.3, panel (b)). 
The above data are all consistent with attributing the surplus binding energy to interactions 
between 7t-orbitals of the imidazole member of the purine ring with the 7t-orbitals of 
aromatic residues in the hFNTI binding pocket, rather than H-bonds to N7 or N9. 
5.1 
GUANINE 
~Go = -26.0 kJ/mol 
H 
3.1 
ADENINE 
~Go = -27.3 kJ/mol 
H 
Figure 4.4. Model of the interactions between purines and the hFNTl transporter. 
Estimations of the Gibbs free energy of these interactions are given in kJ/mol. 
The model h wn in Figure 4.4 thus describes 3 interactions, probably hydrogen bonds, to 
recogni e the pyrimidine subunit of the purine ring system and a further interaction 
through the 7t-orbitals of the imidazole ring atoms. The ~Go values of adenine (-27.3 
kJ/mo\) and guanine (-26.0 kJ/mol) are in close agreement of the total of the 4 predicted 
interacti ns (-26.5 and -26.2 kJ/mol respectively). 
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4.3 Discussion 
The Michaelis-Menten constants and limited substrate specificity details for hFNTl of 
human erythrocytes have been published previously (Plagemann, et al., 1987; Domin, et 
ai, 1988; Kraupp, et ai, 1991), and the current findings are in close agreement with these 
earlier studies. The Km and Ki values for adenine, guanine, and hypoxanthine, reported 
here for the hFNTI are very similar to those previously reported. In addition, the Ki value 
for allopurinol of 121 ± 29 J.1M is comparable to the reported Km value of268 J.1M (Razavi, 
et al., 1993). 
The interactions between the blood cell transporter and its substrates are quite different to 
those made by the trypanosome H2 transporter. The erythrocyte transporter has a lower 
affinity for all the nucleobases than the T. b. bruce; transporter and this is reflected in the 
consistently lower energies observed for individual binding interactions. By looking at the 
different efficiencies of uptake for the natural substrates hypoxanthine, guanine and 
adenine, some divergences are already apparent. The trypanosome transporter has a 
preference for oxopurines, such as hypoxanthine and guanine, as permeants, with the 
affinity for adenine lO-fold lower than for guanine. The situation for the erythrocyte 
transporter is the opposite of this - its favoured permeant is adenine followed by guanine 
and hypoxanthine. In fact, hypoxanthine uptake by the human erythrocytes is very poor -
hFNTl bound hypoxanthine with >2000-fold lower affinity than the H2 transporter. 
The ability of H2 to display very high affinity for both aminopurines and oxopurines 
appears to be linked to its potential to form H-bonds with either the 6-amine group or the 
NI proton of the predominant lactam tautomeric form of oxopurines. In contrast, optimal 
binding by hFNTl requires an unprotonated ''pyrimidine type" NI as present in 
aminopurines. Yet, hFNTl displays relatively high affinity for guanine due to a weak 
hydrogen bond to the 6-keto group and a stronger one to the amine at position two. These 
interactions appear to be absent in the H2 binding pocket, and this transporter displays 3-
fold lower affinity for guanine than for hypoxanthine, presumably for sterlc reasons. 
The one feature shared by the two base transporters is a strong interaction, presumably by 
H-bonding, with N3, which is unprotonated in all natural purines except xanthine and uric 
acid. This is consistent with the O(AGO) value of 10.6 kllmol for xanthine compared with 
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hypoxanthine binding by H2, which consists of the loss of the N3 H-bond (8.3 kJ/mol) and 
the steric effect of the substitution at position 2. For hFNTl the affmity of xanthine would 
also be expected to be lower than for hypoxanthine, particularly because an H-bond donor 
such as an amine appears to be favored in position 2, but it was not possible to establish a 
Ki value due to limitations of solubility. Similarly, the hFNTI transporter was not inhibited 
by up to 250 J.1M uric acid, but H2 also failed to bind this purine, in which N7 is 
protonated. The total lack of affmity of these transporters for uric acid, which exists at up 
to 400 J.1M in human plasma (Wung & Howell, 1980), is an essential adaptation to the 
bloodstream environment, because the high urate levels would compete with low levels of 
other purine bases, and urate cannot be utilised for the synthesis ofnucleotides. 
Both transporters derive roughly half of their binding energy from interactions with the 
imidazole part of the purine ring, explaining their preference of purines over pyrimidines. 
However, whereas H2 forms strong H-bonds with N7 and N(9)H, neither residue was 
directly involved in interactions with hFNTl. The conclusion that 1t-1t stacking of the 
aromatic purine ring and one or more aromatic residues in the transporter binding pocket 
plays an important role in stabilizing the binding of the penneant is not without precedent. 
Structural studies have shown that 1t-orbital stacking plays a major role in the active site of 
many purine-metabolizing enzymes (Somoza, et al., 1996) and in the stability of nucleic 
acids (Koo~ 2001). The PIIP2 recognition motif study by De Koning & Jarvis (1999) also 
showed that this mechanism is in large part responsible for the very high affinity with 
which the T. b. brucei P2 transporter binds its substrates. The combined electrostatic and 
Van der Waals interactions between the 1t-orbitals of aromatic amino acids can exceed 10 
kJ/mol at optimal orientation (Hunter, et al., 1991). 
The models for the substrate recognition motif for H2 described in Chapter Three and 
presented here for hFNTl show that there is ample scope for selective uptake of purine 
analogues by either transporter. Table 4.2 shows specificity ratios for interaction of various 
compounds with the different transporter molecules. Higher levels of selectivity could be 
achieved with rationally designed hypoxanthine analogues, because these display the 
greatest differential affmity between the two carriers. 
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Compound K j (H2){J1M) KI (hRBC) (uM) K j (hRBC) I Ki (H2) 
hypoxanthine 0.12 288 2404 
6-thioguanine 0.43 95.3 222 
2-aminopurine 3.5 686 195 
3-de mine 10 519 52 
6-methoxypurine 6.9 242 35 
I-deazapurine 22.1 676 31 
guanine 0.36 28 10 
adenine 3.2 16 5.1 
purine 18 86 4.7 
6-chloropurine 17 45 2.7 
2,6-diaminopurine 25 43 1.7 
7-d .......... e 55.2 14.8 0.27 
9-methyhmanine 70 7.4 0.11 
Table 4.2. Specificity ratio table. 
Although the hFNTI transporter, or closely related members of the same transporter 
family, appears to be the most ubiquitous human nucleobase transporter and the only one 
characterised in blood cells, other nucleobase transporters have been characterised in 
specialised cells of the kidney, intestine, choroid plexus, and placenta (De Koning & 
Diallinas, 2000). These sodium-dependent nucleobase transporters usually display high 
affinity for their substrates and seem to be expressed at the interface of the bloodstream 
with other environments. The importance of this class of transporters for the distribution, 
side effects, and pharmacokinetics of therapeutic nucleobase analogues would argue for 
intensified efforts for their cloning and characterisation. 
It is interesting to note that while hFNT1 and the H2 recognise and transport hypoxanthine 
with very different affinities, thus suggesting that hypoxanthine analogues might be worthy 
of pursuit, a note of caution is necessary, since many of the sodium-dependent active 
transporters in the mammalian system are capable of transporting hypoxanthine with very 
high affmity (De Koning & Diallinas, 2000). 
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5.1 Introduction 
The elucidation of the substrate recognition motifs for the trypanosome H2 transporter and 
the hFNTI were described in Chapter 3 and 4, respectively. Substrate recognition models 
for the trypanosome PI and P2 nucleoside transporters were described previously by De 
Koning & Jarvis (1999). In this chapter, the substrate recognition of a range of unusual 
purine analogues was assessed for both trypanosome and human purine transporters. Since 
preliminary studies suggested that these molecules may have trypanocidal activity, the 
compounds were also assayed for in vitro trypanotoxicity using the Alamar Blue assay. 
5.1.1 Tricyclic purine compounds - origins 
Tricyclic purine analogues were pioneered by Leonard and colleagues in the 1970's with 
the production of extended adenine analogues containing a benzene spacer ring between 
the imidazole and pyrimidine components. These new molecules could assume different 
configurations (lin-, dist-, prox-) depending on where the purine components linked to the 
benzene bridge (Leonard, et al., 1975). Figure 5.1 shows these original tricyclic molecules. 
II,,-beuoadeaiae dlst-beazoadeaine 
Figure 5.1. Original benzoadenine compounds. 
N 
~ 
N 
H 
prox-benzoadeaiae 
The rationale behind the design of these molecules was to enable their usage as 
"bioprobes" to investigate the recognition of substrates by enzyme active sites and to 
explore the physical limitations of these binding sites (Leonard & Hirernath, 1986). The 
numerous other nucleobase and nucleoside derivatives that were subsequently designed 
and synthesised often displayed significant biological effects both in enzyme activation 
and inhibition. Many of the analogues were fluorescent and this aided in the localisation 
and elucidation of intermolecular interactions (Seley, et 01., 2002). 
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Although the analogues differ from the parent molecule in size and shape, they still contain 
all the necessary purine ring components for molecular recognition - i.e. all the residues 
present on the purine scaffold that are able to participate in hydrogen-bonding are still 
intact. The original benzoadenine molecules were also flat, conjugated 1t-systems, hence 
they were still able to participate in 1t-1t stacking. 
5.1.2 Thieno-separated tricyclic and Oeximer purine analogues 
Katherine L. Seley and colleagues at the Georgia Institute of Technology have designed 
and synthesised a range of extended purines descended from the original benzo-analogues 
as investigational tools and as potential chemotherapeutic agents (Seley, et al., 2000; 
Seley, et al., 2001; Seley, et al., 2002). 
In collaboration with Seley and colleagues the ability of various analogues to inhibit 
trypanosome and human transporters was investigated and their trypanotoxicity was 
evaluated. Thieno-separated tricyclic purines have a sulphur containing 5-membered ring 
in place of the original benzene spacer (Seley, et 01.,2000). The inclusion of the third ring 
separates the purine subunits by a distance of 1.5 and 2.9 A (see Fig 5.2). In addition, the 
properties of a small number of fleximer purine nucleosides in which the spacer was a 
single 1.5 A C-C bond between the two subunits of the purine framework were examined 
(Seley, et al., 2001; Seley, et 01., 2002). The thieno-separated tricyclic molecules still 
maintain the rigidity of a joined-ring geometry while the fleximer connection allows the 
planes of the rings to rotate relative to each other. 
The thieno-separated nucleosides that were made available were the adenosine (TRI-001), 
inosine (TRI-002), guanosine (TRI-003), 6-thiomethylpurine nucleoside (TRI-004) and the 
purine nucleoside (TRI-005) analogues (as shown in Figure 5.2). The nucleobase 
counterparts of these thieno-separated molecules were also provided (Figure 5.3). The 
fleximer nucleosides that were supplied were the adenosine (FLX-OOI), inosine (FLX-002) 
and guanosine (FLX-003) analogues (Figure 5.4). 
It is important to note that with the addition of the thieno-spacer ring, the tricyclic purine 
derivatives are no longer conjugated 1t-systems. Although the pyrimidine component is 
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linear and continues to possess dislocated electrons, the separate rings are non-planar 
relative to each other and the imidazole ring is no longer able to participate in x-x stacking. 
The 3D molecular structure of the tricyclic derivative compared to the purine parent is 
shown in Figure 5.5. 
2.9 NH 
...--- 2 ~~S~N 8'~9.~3j/ N ..... N-;:::::.J 
~' 0 1.5 HO 8' l' .. 3' 2' HO OH 
TRI-OOI 
S 
N !( ~ 
Ho-sJOH 
TRI-004 
SMe 
Figure 5.2. Tricyclic analogues of purine nucleosides. The normal system of numbering the 
atoms of the purine ring is employed and the numbering of the tricyclic and fleximer 
compounds is equivalent to that for the corresponding purine ring. The distanceS between 
the pyrimidine and imidazole ring of the tricyclic purine system are shown for TRJ-OOI. 
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N=Q-i0 ~ I 
N If NH 
TRI-B-OOI TRI-B-002 
H N~ 
NH2 
TRI-B-003 
TRI-B-004 TRI-B-005 
Figure 5.3. Tricyclic analogues of purine nucleobases. 
N7J£JNH
2 
1/7 ~ ~ 1 N 8,9 3..J/ N ~ N:::::=.t 
~. 0 1.5 HO 6' l' " 3' HO OH 
FLX-OOI 
fN) ~o 
-yN~ ~H HO N~ NH2 
HO OH 
FLX-003 
Figure S.4. Fleximer analogues of purine nucleosides. The distances between the 
pyrimidine and imidazole ring of the fleximer purine system are shown for FLX-OOI. 
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6-metbylthiopurine 
TRI-B-004 
Figure 5.5. he 3-dirnensional structure ofTRI-B-004 compared to the parent molecule 6-
meth Ithi urin. With the addition of interspacing thieno-ring the molecule is no longer 
planar. (Yell wi ulphur, light blue is hydrogen, dark blue is nitrogen, grey is carbon.) 
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5.2 Results 
5.2.1 Analogues 
All the purine analogues were synthesised by Seley and colleagues as previously described 
(Seley, et al. 2000; Seley, et al., 2001; Seley, et al., 2002). All data analysis was as for 
original construction of substrate recognition models (Chapter 3; Chapter 4; Wallace, et 
ai., 2002; De Koning & Jarvis, 1999). 
5.2.2 Inhibition of H2 activity by thieno-separated purine nucleobases 
0 .5-r---------------~ 
0.4 
0.3 
0.2 
0.1 
O . O~-.....,._-.....,._-_,_-..:;:==:t=~~ 
-9 -8 -7 -6 -5 -4 -3 
Log [Inhibitor] (M) 
Figure 5.6. Inhibition of transport of 0.1 IlM em hypoxanthine by T b. bruce; s427 
bloodstream forms by the adenine analolWe TRI-B-OOI ( - ). the hypoxanthine analo~ue 
TRI-B-002 ( ) or the ~uanine analo2ue TRI-B-003 (0 ). 
Representative examples of the dose-response curves for the inhibition of H2 activity by 
the purine analogues are shown in Figure 5.6. The Ki and .1Go values obtained for the 
thieno-separated nucleobase compounds are shown in Table 5.1. The table also shows the 
8(.10°) for the analogue compared with the relevant parent molecule. 
AlJ the truen -separated nucleobase analogues showed reasonable inhibitory effects on the 
uptake of 0.1 J..lM hypoxanthine by the H2 transporter. Surprisingly, the substrate specifity 
spectrum 6 r the thieno- eparated analogues is the opposite of the normal spectrum 
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(hypoxanthine> guanine> adenine) for the parent molecules (De Koning & Jarvis, 
1997b). The adenine analogue displayed the best inhibition ofH2 activity with a ~ of 0.38 
± 0.04 JIM, followed by the guanine analogue with a Ki of 0.7 ± 0.24 JIM, and fmally the 
hypoxanthine analogue with a ~ of 1.87 ± 0.45 fJM. If the pyrimidine ring is bound as 
norma~ the energy associated with shifting the imidazole ring to a new position in the H2 
binding pocket would be expected to be similar for all the analogues, relative to their 
bicyclic natural parent bases, because all interactions to the imidazole unit are essentially 
the same for the parent molecules. This is not the case, suggesting that instead the shared 
imidazo Ie ring mostly maintains its normal position. The adenine analogue is a better 
inhibitor of H2 than adenine itself; the guanine analogue is slightly worse than guanine 
itself; and the hypoxanthine analogue is a much worse substrate than hypoxanthine itself. 
Thus, even though the imidazole ring has shifted relative to the pyrimidine moiety (Figure 
5.5), the internal structure of the five-membered ring is maintained and is able to 
participate in interactions with the transporter in a similar manner as the parent purine. 
From the resuhs it can be hypothesised that the rearrangement of rings is unfavourable for 
the usual binding to the protonated Nl (H). This would account for the much less efficient 
inhibition of hypoxanthine transport by TRI-B-002, and this assertion is supported by the 
equivalent ~Go obtained for TRI-B-005. This analogue of purine lacks the protonated 
Nl(H) residue and displays the same binding energy as TRI-B-002. When the O(~GO) 
values for the hypoxanthine and purine analogues compared to the parent molecules are 
considered it is apparent that the absence of an interaction to the Nl (H) is not the only 
discrepancy in analogue recognition. Despite a lack of participatory groups at position Nt 
and C6, the TRI-B-005 pmine analogue is still a significantly better inhibitor than purine 
itself (by -5.6 kJ/mol). If our assumption that the imidazole ring maintains its normal 
positioning is correct, this would implicate a strengthening of the bond to N3. This change 
at N3 would also explain why the interaction of the hypoxanthine analogue differs from 
hypoxanthine by only 6.8 kJ/mol despite involving the loss of a bond with an energy of 
12.6 kJ/mol. The ~Go values for each analogue suggests that the normal -7.3 kJ/mol 
interaction at N3 has increased to 12.9 kJ/mol for the analogue. This increase in bond 
strength is likely to have resuhed from the participating amino acid residues of the binding 
site being brought into a more favourable orientation and/or proximity to the substrate. 
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Given that the guanine analogue is a better inhibitor than the hypoxanthine analogue it 
seems that the 2-amino group of guanine is not disadvantageous in the analogue as it is in 
the parent molecule. Based on the ~GO value obtained for the TRI-B-003 molecule it 
seems that the 2-amino group contributes around 2.0 kJ/mol to the interaction of the 
analogue with the transporter. It is unclear whether this is the result of a very weak H-bond 
to 2-NH2 however, as the energy gain is perhaps a little low. Alternatively, an indirect 
contribution through the further strengthening of the N3 bond could be envisaged. 
These results confirm that the analogues are, at the very least, capable of preventing 
binding by the radiolabelled substrate to the H2 transporter binding site showing that the 
binding pocket will allow interactions with substantially larger molecules than its original 
substrate and this does not necessarily involve a concurrent loss of binding energy. A 
preliminary model for recognition of the tricyclic compounds by the H2 transporter is 
shown in Figure 5.7. More analogues including l-deaza- and 3-deaza- tricyclics are 
currently being synthesised by our collaborators and assay of these will help to support or 
refute these postulations. 
Analogue Ki n ~Go ~~GO) Parent molecule 
(JiM) (kJ/mol) (kJ/mol) 
KLS-TRI-B-OOI 0.38 ±0.04 3 -36.6 -5.3 Adenine 
KLS-TRI-B-002 1.87 ± 0.45 4 -32.7 6.8 Hypoxanthine 
KLS-TRI -B-003 0.70 ±0.24 3 -35.1 1.6 Guanine 
KLS-TRI-B-004 18.5 ± 1.6 3 -27.0 0.2 6-thiomethylpurine 
KLS-TRI -B-005 1.93 ± 0.27 2 -32.6 -5.6 Purine 
Table 5.1. Inhibition of T. b. brucei nucleobase uptake by thieno-separated tricyclic purine 
nucleobases. Ki and ~Go values for the T. b. bruce; H2 nucleobase transporter. Results are 
shown ± standard error. 
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KL -TRI-B-OOI 
~GO = -36.6 kJ/mol 
7.7 H 
2.0 
12.5 
KLS-TRI -B-003 
~Go = -35.1 kJ/mol 
7.7 
Figure 5.7. Model of the interactions between tricyclic purines and the T. b. bruce; H2 
transporter. Estimations of the Gibbs free energy of these interactions are given in kJ/mol. 
Hypothetical groups from the H2 binding pockets (blue/yellow) were retained in their 
positions from the original model as depicted in Wallace, et al. (2002) and Chapter 3. 
5.2.3 Inbibition of PI activity by tbieno-separated and fleximer purine analogues 
Only the nucleoside analogues were assayed for their ability to inhibit uptake of adenosine 
by the PI transporter since this transporter is specific for nucleosides and has little affinity 
for nucleobas . The Ki and AGO values obtained for inhibition of adenosine uptake by the 
PI transporter are hown in Table 5.2. The table also shows the 8(~GO) for the analogue 
compared with th relevant parent molecule. 
All the analogues tested howed a worse inhibitory effect on PI activity than their purine 
parent m lecule. Overall, the fleximer compounds were poorer inhibitors than the 
tricyclic compounds. This was not totally unexpected since the fleximer molecule is 
capable of as uming a variety of conformations due to the flexible nature of the link 
between the ring c nstituent of the purine system. The entropy of the analogue differs from 
that of th parent m lecule and a certain amount of energy may be required for the 
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conformational change to make binding possible and this will consequently reduce binding 
interaction energies. 
H-bonds 
PI 
Figure 5.8. The normal PI substrate recognition motif (De Koning & Jarvis, 1999). Typical 
bond strengths are between 13-15 kJ/mol. 
It is difficult to adequately explain the ~GO values obtained for the tricyclic analogues in 
terms of the current recognition model for the PI transporter (Figure 5.8). All the 
analogues still possess the residues necessary for recognitio~ and it would be expected that 
these residues have shifted by the same degree for all the analogues. The introduction of 
the thieno-separator seems to have given the 6-arninopurine tricyclic TRI-OOI a distinct 
advantage over tricyclic purines with other groups at position 6 (TRI-002, TRI-003, TRI-
004 and TRI -005). It is impossible to construct a viable model for recognition of these 
purine analogues by the PI transporter based on these preliminary studies. 
Ki AGO o(AGO) Parent 
Analogue (~M) n (kJ/mol) (kJ/mol) Molecule 
KLS-TRI -001 0.98 ± 0.19 3 -34.3 2.5 Adenosine 
KLS-TRI -002 26.4 ± 5.0 3 -26.1 10.2 Inosine 
KLS-TRI -003 21.1 ± 3.2 3 -26.7 6.1 Guanosine 
KLS-TRI -004 748 ± 262 3 -17.8 18.9 6-methylthiopurine nucleoside 
KLS-TRI -005 3.9 ± 1.4 3 -27.2 9.6 Purine nucleoside 
KLS-FLX-OOI 95.3 ± 44.5 3 -22.9 13.8 Adenosine 
KLS-FLX-002 461 ± 72 3 -19.0 17.2 Inosine 
KLS-FLX-003 244 ± 73 3 -20.6 12.1 Guanosine 
Table 5.2. Inhibition of T. b. bruce; Pl- transport activity by fleximer and tricyclic 
nueleo ide anal ue. Ki and AGO values for the inhibition of adenine-insensitive 
aden ine uptake. Re ult are shown ± standard error. 
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5.2.4 Inhibition of P2 activity by thieno-separated and fleximer purine analogues 
Only the adenine and adenosine analogues were tested for ability to inhibit the P2 
transporter since the transporter is highly selective for aminopurines and molecules 
containing the P2 recogntion motif - H2N-CH=N-R. The Ki and ~Go values obtained for 
inhibition of adenosine uptake by the P2 transporter are shown in Table 5.3. The table also 
shows the o(~GO) for the analogue compared with the relevant parent molecule. 
x-stacking 
HO 
OH OH 
P2 
Figure 5.9. The normal P2 substrate recognition motif (De Koning & Jarvis, 1999). 
Analogue Ki n L\Go 3(~GO) Parent 
(J.LM) (kJ/mol) (kJ/mol) Molecule 
KLS-TRI -001 16.2 ± 6.8 3 -27.3 7.1 Adenosine 
KLS-FLX-OOI 37.7 ± 3.0 2 -25.2 9.2 Adenosine 
KLS-TRI -B-OO 1 9.7 ±2.3 3 -28.6 8.7 Adenine 
Table 5.3. Inhibition of T. b. brucei P2- transport activity by fleximer and tricyclic purine 
analo es. Ki and ~Go values for the inhibition of inosine-insensitive adenosine uptake. 
Results are hown ± standard error. 
The three relevant molecules were poorer ligands than their parent molecules, despite all 
the analogue po ing an intact P2 motif When it is considered that the P2 transporter is 
involved in the uptake of comparatively large melamine-linked drug molecules it seems 
less likely that th analogues higher Ki values are due to steric interference. Interestingly, 
the L\ ° value obtained for the analogues were comparable to the L\GO obtained for 2-
amin pyridine (De Koning & Jarvis, 1999) which consists of the pyrimidine subunit of 
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adenine. This suggests the difference in ~Go values are due to some change occurring in 
the interaction of the imidazole subunit of the purine ring system and the transporter 
binding site. 1Ht stacking involving the imidazole subunit has been previously implicated 
in the recognition of purine molecules by the P2 transporter (De Koning & Jarvis, 1999). 
The introduction of the third ring in the tricyclic analogues can indeed cause a disruption 
of 1t-1t stacking as discussed earlier (Seley, et al., 2000), and so this seems a likely 
explanation for the observed results for the purine analogues. 
5.2.5 Inbibition of bFNTl activity by tbieno-separated purine nucleobases 
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Fiiure 5.10. Inhibition of tranSport of 1 LtM ell] adenine by human erythrocytes by the 
adenine analoiue TRl-B-OOI C- ). the hypoxanthine analoiWe TRI-B-002 C. ) or the 
iuanine analo~ue TRI-B-003 CO). 
Representative examples of the dose-response curves for the inhibition of hFNTl activity 
by the purine analogues are shown in Figure 5.10. The Ki and ~Go values obtained for the 
thieno-separated nucleobase compounds are shown in Table 5.4. The table also shows the 
o(~GO) for the analogue compared with the relevant parent molecule. 
The sub trate preference for interaction with the hFNTl is the same for the analogues as 
for the parent m lecules, i.e. adenine> guanine» hypoxanthine. Uptake of 1 ~M adenine 
was strongly inhibited by the tricyclic adenine analogue with a Ki of 0.47 ~M. Intriguingly, 
this K. i the highest affinity yet reported for the hFNTl and is almost 35 times the usual 
Km of 16.2 ~M for the adenine parent. Meanwhile, the guanine analogue, TRI-B-003, is 
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slightly less active than guanine itself, with a 6(AGO) of2.1 kJ/mol. With a ~ of290 J.1M 
hypoxanthine itself is a poor inhibitor of hFNTl activity but its tricyclic analogue is even 
poorer with a Ki of2440 JJM. 
It has proven difficuh to reconcile these resuhs with the recognition model constructed in 
Chapter 4. The most significant discrepancy is the very high affmity for the TRI-B-OOI 
adenine analogue. According to the 3-D model of the tricyclic compounds the imidazole 
ring is no longer able to participate in x-x stacking and so it would have been expected that 
all analogues would exhibit concordantly worse inhibition of hFNTl. Even though the 
inhibition ofhFNTl by the guanine and the hypoxanthine analogues is worse than for the 
parent purines the magnitude of these differences is not significant enough to be due to the 
absence of x-x interactions with the imidazole ring. Instead, the differences in AGO value 
between the guanine and hypoxanthine analogues suggests that the 2-amino group 
interaction has been maintained but that the interaction at the 6-keto group has been 
eliminated or weakened. According to the 3-D model (Figure 5.2) the pyrimidine ring still 
possesses a delocalised electron ring system. It is possible that this is significant for 
recognition of the analogues by the transporter but it was not possible to determine if this 
interaction exists based on the available evidence. Experiments with additional tricyclic 
analogues currently being synthesised will hopefully help to elucidate this issue. 
If it is assumed that sterlc effects allow equal access to N3 for all the analogues, it follows 
that the much improved affinity for the TRI-B-OOI compared to adenine must be at least 
partly due to a strengthening of the interactions with the unprotonated Nl and/or 6-amino 
groups. 
Analogue KI n AGO ()(AGO) Parent 
(11M) (lw/mol) (kJ/mol) Molecule 
KLS-TRI-B-OOI 0.47 ± 0.21 3 -36.1 -8.8 Adenine 
KLS-TRI-B-002 2440 ± 1200 3 -14.9 5.3 Hypoxanthine 
KLS-TRI-B-003 64±1l 3 -23.9 2.1 Guanine 
KLS-TRI-B-004 >1000 3 6-methyhhiopurine 
Table 5.4. Inhibition ofhFNT1- transport activity by tricyclic purine nucleobase analogues. 
~ and AGO values for the human eythrocyte nucleobase transporter. Resuhs are shown ± 
standard error. 
117 
Ch V Recognition of unusual potential trypanocides by purine transporters ofT. b. brucei 
5.2.6 Trypanotoxicity oftbieno-separated and fleximer purine analogues 
The thieno-separated purine analogues and the fleximer purine nucleosides were tested for 
trypanocidal activity against T b. brucei bloodstream forms in vitro in the same way as 
described in Chapter 3. The Alamar Blue assays were performed with T b. brucei s427 
bloodstream forms and T b. brucei TbATl knockout bloodstream forms. 
Figure 5.11 shows Alamar Blue assay dose-response curves for TRI-B-004 as compared to 
trypanocidal activity of allopurinol and aminopurinol. Table 5.5 show the ECso values 
obtained in Alamar Blue assays for the two parasite lines. 
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Figure 5.11. xample of Alamar Blue assay graph. Trypanotoxicity of TRI-B-004 
compared with aminopurinol and allopurinol. T b. brucei TbAT! KO. The fluorescence 
was measured using 530 run excitation, 590 run emission parameters. This graph was 
constructed using the data produced from one of two identical experiments which gave 
comparable results. 
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Analogue T. b. brucei 1427 n T. b. brucei TbATl KO n 
ECse (JiM) ECse (1.1M) 
KLS-TRI-oo 1 >100 2 >100 1 
KLS-TRI-002 595 ± 35 2 >100 1 
KLS-TRI-003 652 ± 19 2 >100 1 
KLS-TRI-004 >100 2 >100 2 
KLS-TRI -005 69.2 ± 14.8 2 66± 16 3 
KLS-FLX-oo 1 1660 ± 71 2 ND 
KLS-FLX-002 1205 ± 60 2 ND 
KLS-FLX-003 868 ± 0.35 2 ND 
KLS-TRI-B-OO 1 155 ± 1 2 71 ± 12 3 
KLS-TRI-B-002 450±7 2 >100 3 
KLS-TRI-B-003 243 ± 1 2 >100 3 
KLS-TRI -B-004 69.1 ± 6 3 29±4 3 
KLS-TRI -B-005 >100 2 >100 3 
Table 5.5. Anti-tr,manosomal activity of purine analogues. ECso values determined using 
the Alamar Blue assay (JiM). ND, not determined. 
As can been seen in these tables, the tricyclic compounds show more potential as lead 
trypanocides than do the fleximers. TRI-005, TRI-B-OOI and TRI-B-004 seem to offer the 
best starting points for design of new trypanocides, with ICso values of -70 J.tM for TRI-
005 and TRI-B-OOI and of29 J.1M for TRI-B-004 against the T. b. brucei ThATI knock out 
line. It is most interesting to note that TRI-B-004 offers significantly higher trypanocidal 
activity than does allopurinol. Aminopurinol still has a better in vitro trypanocidal activity 
but these results would suggest that tricyclic purine analogues may have potential for 
development as novel trypanocides, subject to further optimisation and their therapeutic 
index. 
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5.3 Discussion 
The study detailed in this chapter has demonstrated how specially-constructed purine 
analogues can be used both as investigational tools and as potential trypanocides. A 
number of the purine analogues showed encouraging trypanocidal activity which can 
hopefully be optimised with further molecular engineering. The use of the analogues have 
also contributed to om knowledge of how purines are recognised by the various purine 
transporters, and have also given insight into the physical dimensions of the transporter 
binding pocket. 
The resuhs detailed here are preliminary and have been limited by the small number and 
quantities of compounds available. More compounds are currently being synthesised and 
I-deaza- and 3-deaza-tricyclics in particular should augment the prelimary understandings 
detailed here. The availability of a larger range of compounds will enable some of the 
fmdings here to be verified. 
Despite these recognised limitations some initial inferences can be made. The affmity with 
which the analogues are recognised by the H2 transporter are certainly lower than for the 
parent molecules but the ~ values derived for the compounds are still in the low or sub-
micromolar range. This study has shown that even tricyclic pmines are efficiently and 
selectively recognised by the transporter. We have not proven that the analogues are 
actually internalised by the parasites but the fact that at least some of them do have a 
degree of in vitro efficacy is highly suggestive that they are able to be taken up by one or 
more of the transport systems present in the trypanosomal plasma membrane. 
As noted earlier, any speculation about the interaction of the analogues with the H2 
transporter are dependent on the assumption that the position and binding interactions of 
the imidazole ring really is unchanged. Ahhough the hypoxanthine analogue shows less 
affinity for the H2 transporter than the adenine analogue the selectivity index for the 
recognition ofTRI-B-002 by the H2 transporter as compared to the recognition by hFNTl 
is around 1300. This would appear to reinforce the suggestion from earlier chapters that 
hypoxanthine analogues are likely to be the most interesting lead compounds from the 
selective targetting perspective. Table 5.6 shows the selectivity indices for the recognition 
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of the thieno-separated tricyclic nucleobases for the parasite H2 transporter as compared to 
hFNTI. 
R1 
\-iSliN 
t( YN~ FN H 
R2 
Compound Rl Rz S.I 
FNTIIH2 
TRI-B-OOI NH2 H 1.24 
TRI-B-002 0 H 1304 
TRI-B-003 0 NH2 91.5 
TRI-B-004 SCH3 H >50 
TRI-B-005 H H N.D 
Table 5.6. The selectivity indices of thieno-separated tricyclic purine nucleobases for 
uptake by the H2 traIlSj>Orter and hFNT 1. 
Matters are somewhat complicated by the fact that although the adenine analogue shows 
very high affinity for both H2 and hFNTl, and so relatively low selectivity for the parasite, 
this analogue seems to offer a higher trypanocidal potential, based on the evaluation of the 
in vitro effects. 
Ahhough the trypanocidal activity of the analogues clearly needs optimisation, most of the 
analogues tested (with the notable exception of the fleximers) have comparable or better 
trypanocidal activity than allopurinol. Indeed, the action of TRI-B-004 is already 10-fold 
better against bloodstream form trypanosomes in vitro than allopurinol. 
Purine nucleobase analogues may be more amenable to use as trypanocides smce 
nucleosides are rapidly hydrolysed following acquisition by the parasite. The nucleobase 
on the other hand is just one enzyme step from the nucleotide pool through 
phosphoribosylation. One obvious mode of action for purine antimetabolites is their 
incorporation into RNA and DNA and so nucleobase analogues are that much closer to the 
end "target". In addition, as noted in previous chapters, nucleobase-specific transporters 
have the attraction of not having been implicated in the development of resistance and so 
121 
Ch V. Recognition of unusual potential trypanocides by purine transporters ofT. b. brucei 
drugs entering through these transporters are less likely to show cross-resistance to existing 
drugs such as the arsenicals. The complicating issue in this argument is that the transporter 
that has been definitively shown to playa role in the development of drug resistance (but 
that is not the only contributory factor) is the P2 transporter which has a very high affinity 
for adenine (Carter & Fairlamb, 1993). With the compounds that have been tested in this 
study the absence of a conjugated 1t-system has meant that the affinity of the analogues for 
the P2 is much reduced. The analogue which showed the most promising in vitro activity, 
in spite of showing only moderate interaction with the H2 transporter, was TRI-B-004. 
Based on its structure, this compound is unlikely to be an efficient substrate for the PI or 
P2 transporter. 
In the case of the fleximers there was a correlation in that poor recognition by the 
transporters was paired with concurrent poor trypanocidal effects. The correlation was not 
straightforward however. While the affmity of the PI and P2 transporter for FLX-OOI was 
the highest of all the fleximers, the in vitro effect of this analogue showed the worst ICso. 
Another intriguing aspect thrown up by the study was that several of the analogues were 
more toxic to the ThATl KO cells than the WT cells. In a paired Student's T-test these 
groups are not significantly different, partly because of the limited amount of data 
available. However, it raises the possibility that there is an upregulation of other 
transporter(s) in the absence ofa functional P2 system. This could mean that drug-resistant 
strains could actually be more vulnerable to the effects of purine nucleobase drugs. While 
this possibility is highly intriguing, it is at the moment also highly speculative and will 
require further investigation. 
It should be interesting to test what effect these unique compounds have on the parasite 
phosphoribosyhransferases and the other enzymes of purine metabolism and to study any 
incorporation into nucleotides. If the compounds strongly or even irreversibly inhibit the 
action of the parasite PRTases another chemotherapeutic option could be to administer a 
combination of the tricyclic purines so as to impede incorporation of natural purines by the 
PRTases with different substrate specificities (adenine PRTase, hypoxanthine/guanine 
PRTase and xanthine PRTase). Any effects on the parasite would have to be very potent 
since the trypanosome is able to survive if even low amounts of purine are able to be 
salvaged. Also this would again very much depend on any effect on the mammalian 
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systems. The thieno-separated tricyclic adenine and guanine analogues used in this study 
have previously been shown to have biological activity against colorectal tumour cells 
(Seley, et al., 2000), with the adenine analogue inhibiting growth of these cells by up to 
SOOIO over 72 hours. Ideally, molecular recognition models should be worked out for 
concentrative transporters of mammalian systems and also for the various purine-
metabo lising enzymes. 
Many other tricyclic purine analogues have been constructed and it may be interesting to 
test some of these other compounds on trypanosomes. As well as utilising different spacer 
rings, additional rings can also be added to the periphery of the natural ring system to give 
alternative tricyclic structures (Seley, 2002). 
As discussed in Chapter 3 it is the ability of substrates to form interactions with the 
enzyme that leads to "recognition". It therefore makes sense that analogues which possess 
the abilities necessary to maintain these elements but have an extended ring system and so 
are shaped differently can tell us a lot about the nature of enzyme-substrate recognition. In 
terms of chemotherapy, hopefully, these shape-modifed molecules will be sufficiently well 
recognised by the parasite transporters and enzymes but will be disruptive when 
incorporated into nucleotide systems such as RNA, DNA, and ATP, or possibly disrupt 
metabolic. signalling or other pathways dependent on purines as substrates or co-factors. 
With further work, the selectivity for the trypanosomal transporters and the anti-
trypanosomal action of these compounds could be increased by modifications to the 
tricyclic purine structure. 
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Ch. VI. Functional complementation strategy for cloning of nucleobase transporter genes 
6.1 Introduction 
The availability of gene clones is an invaluable tool in the characterisation of transporters 
and other proteins. The identification of a gene can allow further characterisation of the 
function and kinetic parameters of the resulting protein in a suitable heterologous system. 
The amino acid sequence will allow first predictions about protein secondary structure. 
Residues important for the function of the protein can be identified using site-directed 
mutagenesis leading to models for the structure of the activelbinding sites. Furthermore, 
elucidation of the gene sequence allows comparisons with homologues in other organisms 
and the mapping of evolutionary relationships as well as in-depth studies of regulation of 
gene expression and localisation studies using antibodies or fusion proteins. 
Until relatively recently studies of nucleoside and nucleobase transport in trypanosomatids 
relied almost exclusively on biochemical methodologies with little or no input from 
molecular approaches. This was largely due to the absence of gene information. When the 
work detailed in this chapter was undertaken, this situation was beginning to change with 
the cloning of nucleoside transporter genes from T. b. bruce; (Sanchez, et al., 1999; Maser, 
et ai., 1999; Sanchez, et al., 2002) and Leishmania donovan; (Vasudevan, et al., 1998; 
Carter, el al., 2(00). Some of the nucleoside transporters cloned by these groups were 
shown to mediate transport of nucleobase molecules in addition to nucleosides but usually 
with lower affmity than for the corresponding nucleoside and none of these genes were 
responsible for the high-affinity dedicated nucleobase transport activities seen in T. h. 
brucei. The aim of the work described in the next chapters was to clone and characterise 
nucleobase transporter genes from T. b. brucei. 
Several approaches were taken towards the identification of the nucleobase transporter 
genes. The initial strategy was to construct genomic DNA libraries for functional 
complementation studies in T. b. brucei itself and also in the ascomycete Aspergillus 
nidulans. It was anticipated that the cloning of one transporter gene sequence would 
facilitate the identification of other related transporter genes from the trypanosome genome 
database. 
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6.1.1 Functional complementation in T. be b,ucei 
Functional complementation is a reliable method for cloning of genes in Leishmania spp 
(Clayton, 1999). The first trypanosomatid purine transporter genes to be cloned were the 
Leishmania donovani nucleoside transporters LdNTI.I and LdNTI.2 (Vasudevan, et al., 
1998). These were isolated following functional complementation of a parasite line 
resistant to the nucleoside analogue drug tubercidin. The LdNT2 nucleoside transporter 
gene was also identified by functional complementation of a parasite line resistant to the 
nucleoside analogue formycin B (Carter, et al., 2000). 
Sommer, et al. (1996) showed that functional complementation was a valid method of gene 
cloning in T. b. brucei. In this study, transfection of a T. b. brucei genomic library into the 
ornithine decarboxylase (ODC) double-knockout cell line complemented the deficiency 
and allowed the isolation ofplasmids containing the ODC gene. In order to accomplish the 
cloning of a nucleobase transporter gene by functional complementation in T. b. brucei, a 
genomic DNA library in a suitable vector had to be constructed and a nucleobase transport-
deficient background had to be established. 
Introduction of exogenous genes into T. b. brucei is possible usmg homologous 
recombinatory events (Lee & Van der Ploeg, 1990) but the transformation frequencies 
obtained are relatively low and unlikely to be suitable for use in functional 
complementation studies. In the method pioneered by Sommer and colleagues (1996) an 
episomal self-replicating plasmid was constructed and it was this vector that was used for 
construction of the genomic DNA library. The pTSO-HYG4 vector contains an origin of 
replication (ori) isolated from a mitochondrial kinetoplastid minicircle (Metzenberg & 
Agabiao, 1994) which allows autonomous replication of the plasmid. To ensure expression 
of inserted gene sequences the vector also possesses the P ARP (procyclic acidic repetitive 
protein) promoter. This promoter is routinely used in T. b. bruce; vectors and nonnally 
controls the expression of procyclin which is constitutively expressed in procyclic 
parasites. To ensure the proper post-transcriptional processing of mRNA from introduced 
genes the vector also contains splice sites in the multi-cloning site to allow for the addition 
of the splice leader sequence typically appended to all T. b. brucei mRNA molecules. 
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The use of procyclics rather than bloodstream forms for the selection model was preferred 
due to several important practical considerations. Firstly, procyclics had the advantage of 
being simple to handle, easy to grow up in bulk and transformation protocols for procyclics 
were also more straightforward and featured higher transformation efficiencies than for 
bloodstream form parasites. In addition, at the time this strategy was devised the only 
purine nucleobase transport component known to exist in procyclics was the HI activity 
(De Koning & Jarvis 1997a). By exposing cell cuhures of procyclic T. b. bruce; S427 
parasites to increasing concentrations of the toxic purine nucleobase analogue allopurinol it 
was hoped that a nucleobase transport-deficient cell line would be generated through an 
induced loss of the transporter responsible for the HI activity. 
H i-deficient cells 
~ 
I 
Hypoxanthine 
as purine source 
Cell death 
Transformation with T. b. 
brucei genomic library -+ 
Functional 
complementation 
in T. b. bruce; 
Figure 6.1. Functional complementation strategy in T. b. brucei. 
Hypoxanthine as 
purine source 
1 
Selection of clones 
containing gene 
The complementation strategy is represented diagrammatically in Figure 6.1. A procyclic 
T. b. brucei 427 line deficient in HI activity due to drug pressure should be unable to 
grow on medium containing hypoxanthine as the sole purine source. Transformation of this 
newly tran porter-deficient line with the T. b. bruce; DNA library would allow the 
isolation of clone able to grow in the selective medium. The plasmid responsible for the 
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restoration of transport could then be extracted from the T. b. brucei cells and the gene 
sequenced. 
6.1.2 Functional complementation in AsDe1'fillus lIidHlqns 
Purine metabolism and uptake in Aspergillus nidulans has been extensively researched and 
the genes for the nucleobase transporters have been cloned and characterised. The uapA 
gene encodes a 595 amino acid protein predicted to have 12-14 membrane-spanning 
regions (Diallinas & Scazzocchio, 1989; Gorfinkiel, et al., 1993) and is responsible for 
uptake of uric acid and xanthine (Darlington & Scazzocchio, 1967). A hypoxanthine-
adenine-guanine uptake activity designated azgA (Darlington & Scazzocchio, 1967) is the 
result of the expression of a 580 amino acid protein predicted to have 10-12 
transmembrane domains (Cecchetto, et al., 2004). A 580 amino acid protein with 58% 
identity to the uapA protein is designated uapC (Diallinas, et aI., 1995) and has a broad 
substrate specificity mediating uptake of most natural purine nucleobases (Scazzocchio & 
Gorton, 1971). 
By characterising the function of the maize purine transporter LPEI in a uapA' uapC azgA-
mutant strain of A. nidulans, Argyrou and colleagues (2001) have validated the use of this 
fungus as a model heterologous system for the cloning and characterisation of transporters. 
The basic strategy for functional complementation in Aspergillus was very similar to that 
devised for T. b. brucei. In this case, however, the selection background in the form of the 
nucleobase transport-deficient Aspergillus nidulans ACZ strain was already available. This 
strain contains loss-of-function mutations in the uapA, uapC and azgA genes and therefore 
lacks endogenous purine transport systems. Functional complementation in A. nidulans 
was carried out in collaboration with Dr. G. Diallinas and colleagues at the University of 
Athens. A second DNA library had to be constructed in an Aspergillus expression vector. 
The pNS328 vector used for construction of the DNA library for transformation of 
Aspergillus was derived from pAN519. Regulatory sequences which usually control 
expression of the uapA gene surround the BamIll cloning site and should drive the 
transcription of introduced sequences. The vector integrates into the A. nidulans genome 
by heterologous recombination. 
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6.2 Results 
6.2.1 T. b. bruce; genomic DNA libraries 
Both libraries were constructed: one for expression in T. b. brucei and the other for 
expression in Aspergillus nidulans. The appropriate plasmids, pTSO-HYG4 (Figure 6.2) 
and pNS328 (Figure 6.3), were amplified in E. coli, then linearised by Bamlll digestion 
and the ends were de-phosphorylated with calf intestinal alkaline phosphatase (ClAP) as 
described in Chapter 2. After this treatment, the pJasmids were gel-purified to minimise 
contamination with any uncut plasmid. Genomic DNA extracted from T. b. bruce; S427 
procyclics was partially-digested with the enzyme Sau3A to generate a "random" 
collection of fragments. This enzyme is commonly used to generate DNA library 
fragments. It has the four base recognition site .j,GATC and in a complete digest cuts 
roughly every 256 bp. It also has the advantage of generating 5' overhangs compatible for 
cloning into Bamlll, Bcn or Bgm sites. This reaction was run out on an agarose gel and 
fragments of the required size (2-6 kb) were excised (Figure 6.4). 
The purified fragments were ligated into BamIll site of the multi-cloning site of the 
appropriate linearised. de-phosphorylated vector (Figure 6.5). The resulting products were 
used to transform electrocompetent E. coli TOP} 0 cells. Selection of transformed colonies 
was by the ampicillin-resistance encoded by the vector. Random screening of the resuhing 
colonies was carried out to check for the presence of integrated genomic fragments (Figure 
6.6). The basis of the screening was the HindIII restriction digest of miniprepped colony 
plasmids to evaluate insert presence and size. 
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Figure 6.2. Plasmid vector pTSO-HYG4 (Sommer, et al., 1996). 
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Figure 6.3. The UapA transcriptional cassette of plasmid vector pNS328. 
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Figure 6.4. Gel electrophoresis of T. b. brucei genomic DNA partially-digested using 
Sau3A. The same molecular weight markers have been used for all the gels documented in 
this chapter. 
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Figure 6.5. Ligation of Sau3A fragments and plasmid vector. 
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Figure 6.6. Nine random library colony minipreps digested with HindIII. The clones show 
a good range of different insert lengths and compositions (2 to 5 kb). 
Each stage of the above library construction route was optimised for best results, as 
described below. 
6.2.1.1 Optimisation of technique 
The main technical challenge was improving the genomic DNA 2-6 kb fragment yield to 
obtain suitable quantities for ligations. Several steps were taken towards this end. First of 
all, digest volumes were scaled up from 20 fll to 200 fll for 50 flg DNA which seemed to 
improve the quality of the digest, possibly by allowing the enzyme better access to the 
DNA. Following the partial digest the Sau3A restriction enzyme was inactivated using a 
11100 volume of 0.5 M EDT A rather than an incubation at 65°C. This chemical method of 
enzyme inactivation helps to separate the DNA from the enzyme molecules. Because of the 
larger volumes of the digest mixtures the reactions were precipitated prior to running out 
on an agarose gel. Instead of using the standard sodium acetate/ethanol method, a 1125 
volume 5.0 M sodium chloride and 2 volumes of ethanol were used to prevent any co-
precipitation ofSDS which may have remained from the DNA extraction process. 
A large amount of the digested genomic DNA always seemed to be lost following 
fractionation through and purification from an agarose gel. To minimise this loss the 
partial1y-dige ted DNA was run slowly (20V for up to 6 hours) to aid separation in a 
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"trench" rather than in individual lanes - this limited the time taken to excise the 
appropriate gel portion under damaging UV and reduced the amount of agarose associated 
with the DNA When using the QIAGEN Gel Extraction Kit to purify the DNA from the 
agarose the maximum weight of agarose used in separation columns was 50-100 mg. 
According to the manufacturer's instructions each column can handle up to 400 mg of 
agarose but using more than 100 mg drastically reduced the DNA yield. 
The resuhs of several transformation procedures were not satisfactory because 
contamination by small quantities of circular plasmid due to either incomplete linearisation 
or incomplete dephosphorylation by ClAP resulted in large numbers ofcolonies containing 
empty vector. This problem was corrected by adjusting the quantities of DNA and enzyme 
used in the linearisation and ClAP treatment, to allow complete reactions. 
It was verified that the E. coli TOP 1 0 cells used for electroporation were of suitably high 
transfonnation efficiency by setting up a control transformation with 0.01 ng of the control 
plasmid pUC18. Plating 10 JlI from 1 ml of the transformed cells resuhed in the formation 
of 852 separate colonies on LB solid medium. The following equation was used to 
calculate transfonnation efficiency: 
Transformation efficiency (colony forming units per J.lg of DNA) = 
(cfu on control plate/ng of control DNA) x (1 x 103 ng/Jlg) x dilution plated 
The transformation efficiency was thus 8.5 x 109 cfulJ.lg, which is more than adequate for 
these types of cells (E. coli TOPIO purchased ready to use usually boast a transformation 
efficiency of approximately 1 x 109 cfulJ.lg). 
6.2.1.2 Validation of DNA libraries 
It was necessary to establish if the libraries constructed were representative of the T. b. 
brucei genome. The total number of bacterial transformants making up the T. b. brucei 
library was approximately 92,000. The total number of bacterial transformants making up 
the Aspergillus nidulans library was approximately 50,000. The equation of Clarke and 
Carbon (1976) allows the calculation of the minimum number of transformation events 
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required in a screening for a particular DNA sequence to be present within a randomly 
produced library with ggoA, probability (i.e. P = 0.99). 
I N=ln(I-P)/ln[I-(lIn)] 
where N = number of events to be screened (i.e. number of colonies required) 
P = probability of obtaining a particular fragment 
n = size of haploid genome (kb) / size of fragment used (kb) 
In T. b. brucei the haploid genome size is 3.7 x 10" kb. The libraries were produced using 
DNA fragments in the range 2-6 kb. If it is assumed the average insert size is 4 kb, the 
minimum number of transformants for 99% coverage is --43,000. Both libraries meet this 
minimum criterion. The number of transformants obtained for the pTSO-HYG4 library 
was more than double this so the coverage of the library is more than satisfactory. This 
level of coverage represents almost ten haploid genome equivalents. 
The pTSO-HYG4library was also validated by the amplification of known gene sequences 
by polymerase chain reaction. The sequences chosen for this validation were all well-
studied genes, and included known or putative purine transporter genes and the enzyme 
phosphogluconate dehydrogenase (pGND). The PCR primers for PGND and ATI did not 
span the entire reading frames and so only fragments were produced. It is especially 
relevant that the ThATI gene was successfully amplified from the library since this gene is 
known to be a single copy gene. The PCR using the primers for NTX produced at least two 
products and this fits the profile of this putative transporter belonging to a family of 
closely-related genes. 
Primer Sequence Annealing temp. 
PGND-F 5'-GACTGGATCCATGTCAATGGATGTCGGTGTT-3' 60°C 
PGND-R 5'-GACTAAGCTTCCAATCTTCAAGAACGGCAGC-3' .. 
NTX-R 5'-AAAGTGGTGTTAGTGAGAGGC-3' 55°C 
NTX-F 5'-TTAACTGAATTGCATCGCTGG-3' " 
ATI-F 5'-GACTGGATCCATGCTCGGGTTTGACTCAGCC-3' 55°C 
ATI-R 5'-GACTAAGCTTTCATCGCCTCCGTGGGGGTCA-3' " 
Table 6.1. Primers used for polymerase chain reactions using DNA library as template. 
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Figure 6.7 shows gel electrophoresis of the PCR products resulting from use of the library 
DNA as reaction template. 
ladder L + ladder L + ladder L + 
--~---. 
PGND ThNTX ThAT 1 
Figure 6.7. PCR reactions using library as template. The template for the positive controls 
was 20 ng gen mic DNA. The negative controls contained no DNA template at all. 
The range of sequences amplified was obviously limited but the presence of known DNA 
sequence in th library was encouraging. These results are by no means proof that the 
library represents the whole genome but it gives an indication that the quality of the library 
could be ufficiently representative. 
6.2.2 Growth of T. brucei procyclics in allopurinol in attempt to obtain HI-deficient 
line 
A T. b. bruce; 427 line lacking purine nucleobase transporters was to be developed 
through expo ure to increasing levels of allopurinol as described in the introduction to this 
chapter. It was an experimental concern that resistance to allopurinol could also be induced 
by changes in purine metabolism rather than loss of the HI transporter. Loss of the 
adenyl uccinate synthetase enzyme responsible for conversion of the allopurinol 
ribonucle tide to the active adenosine ribonucleotide analogue would also render 
all purin I ineffective. To prevent this alternative metabolic change taking place and to 
minimi e all purinol having to compete for access to the HI transporter with hypoxanthine 
in the medium, th T. b. bruce; S427 procyc1ics were grown in purine-free trypanosome 
medium (P e Koning, et al., 2000) supplemented with inosine. Inosine is taken up 
by th PI nucleo ide transporter expressed in the procyclic life-cycle stage and is 
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converted into inosine nucleotides by the action of purine nucleoside hydrolase and 
hypoxanthine-guanine phosphoribosyltransferase. Growth on inosine as the sole purine 
source should not be affected by the loss of the hypoxanthine transporter. However, 
providing inosine as the only purine source requires that all the enzymes of purine 
metabolism including adenylosuccinate synthetase (see Figure 1.12 in the general 
introduction) are functional in order to supply all the different nucleosides required by the 
cell. This strategy ensured that selection of resistant clones would be based on a transport-
deficienct phenotype only. 
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Figure 6.8. ffect of allopurinol on growth of T. b. bruce; S427 procyclics. Trypanosomes 
were seeded at 106 cellslml in PFTM with 200 J.1M of inosine as sole purine source and 
grown at 25 0 in the presence of 2 mM (0), 1 mM C- ), 15 J.lM (0) or no allopurinol 
(e ). 
The pre ence of allopurinol in the culture medium affected pro cyclic growth in a dose-
dependent manner (Figure 6.8) but some growth continued to occur even in the highest 
concentration of allopurinol tested (2 mM). T. b. bruce; S427 procyclic cells were 
continually maintained in PFTM [+inosine] with 2 mM allopurinol for an extended period 
of time (>12 m nths). Growth rates were consistently lower then those observed for T. b. 
bru ei 427 pr cyclic grown under the same media conditions minus the allopurinol. No 
resistance to all purinoloccurred. When the effect of various experimental compounds on 
urvivalofth all purinol exposed cells was compared to their effect on T. b. bruce; S427 
WT cell it was ob erved that the results were not significantly different for the two types 
of ceU abl 6.2). 
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Compound Control Allopurinol exposed 
EDseblM) n EDse(1lM) n 
Adenine-9-p-D-arabinofuranoside 90±22 4 127 ±46 3 
Allopurinol 380 ± 101 5 315 ± 72 3 
Aminopurinol 12 ±2 3 11 ±5 3 
6-chloropurine 850± 260 3 680 ±20 3 
Thiopurinol 300±68 5 280 ±60 3 
2,6-dichloropurine 290 ± 56 5 310 ±76 3 
Pentamidine 0.35 ±0.04 4 0.41 ± 0.11 3 
Melarsen oxide 0.46 ±0.12 4 0.58 ± 0.23 3 
Table 6.2. Effect of various pwine analogues and trypanocides on T. b. brucei S427 WI' 
and T. b. brucei 8427 exposed to allopurinol. EDso values were determined using the 
Alarnar Blue method as described in Chapter 2. 
6.2.3 Aspergillus screening 
The T. b. brucei genomic DNA library for expression in this organism was constructed as 
described above and was screened in Athens for fragments capable of restoring nucleobase 
transport to the A. nidulans ACZ strain and allowing survival on hypoxanthine as sole 
nitrogen source. The library was transformed into the transport-deficient 
(AuapAlAuapC/AazgA) mutant strain but there was no success in identifying rescued cells. 
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6.3 Discussion 
The functional complementation approach to cloning of transporter genes from T. b. bruce; 
undertaken relied on the availability of both the genomic libraries and the appropriate 
selection backgroWlds. 
Construction of the genomic DNA libraries was ostensibly a straight-forward process but 
in practice the optimisation of the individual steps proved to be quite challenging and 
required a great deal of perseverance. However, satisfactory libraries of good quality were 
eventually produced and validated using the Carbon-Clarke equation and a small series of 
PCRs. 
The attempt to produce a nucleobase transport-deficient parasite line relied on HI being 
the only purine nucleobase transporter present in procyclics. Previous research had 
intimated that this was the situation in T. b. brucei S427 (De Koning & Jarvis, 1997a). 
Following the failure to induce allopurinol resistance by exposing cultures to allopurinol, 
uptake of eH] allopurinol by procyclics was studied in the laboratory by M.Sc. student 
Mana1 Natto. This work showed that 1 J.1M eH] allopurinol was rapidly taken up T. brucei 
bruce; S427 procyclics with a rate of 0.48 ± 0.02 pmol (l07 cellsyl min-I, compared with a 
initial uptake rate of 1.6 ± 0.1 pmol (107 cells)"1 min-I in L. major promastigotes (AI-
Salab~ et al., 2003). It was also shown that uptake of allopurinol radio label by the 
procyclics trypanosome could be completely inhibited by high concentrations of either 
unlabelled hypoxanthine or allopurinol. However, the uptake activity was only partially 
inhibited by uracil. This suggested that, contrary to the earlier studies, there were possibly 
two nucleobase transport activities present in T. b. brucei procyclics. 
Further work in our lab by Mohammed AI-Salabi led to the characterisation of this second 
activity which was designated H4 (characterisation described in Burchmore, et al., 2003). 
When the hypoxanthine uptake activities by HI and H4 in the allopurinol exposed cells 
were compared with that in control cells (Table 6.3), no significant differences were 
observed, though V_values were somewhat lower in the exposed cells. The ~ values for 
the inhibition of uptake of eH] hypoxanthine by allopurinol for the two transpOrters were 
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found to be 5.0 ± 0.9 J.1M and 2.5 ± 0.4 JlM for HI and H4, respectively. The fhllure to 
induce the loss of the procyclic nucleobase transport activity must be attributed in large 
part to the presence of two separate transporters equally able to mediate allopurinol uptake. 
An additional factor may have been that allopurinol is not sufficiently toxic at low 
concentrations to apply strong selective pressure. Since uptake of allopurinol by T. b. 
bruce; procyclics was shown to be reasonably efficient, this insufficient in vitro toxicity 
compared to the leishmanicidal activity of allopurinol, is likely to be due to differences in 
the metabolism of allopurinol in the different trypanosomatids. 
HI H4 
Ken Vmax n Km Vmax n 
(J.LM) (pmoVIO' cell sis) (JlM) (pmoVI07 cellsls) 
Control 15.2 ± 2.3 2.4±0.7 7 0.55 ± 0.07 0.27 ± 0.08 7 
Exposed cells 19.5 ± 7.0 1.2 ± 0.6 8 0.49 ± 0.14 0.09 ± 0.02 8 
Table 6.3. Kinetic parameters of procyclic hypoxanthine transporters in control and long-
term allopurinol exposed cells. Experiments carried out by Mohammed AI-Salabi at the 
University of Glasgow. 
The failure of the functional complementation of Aspergillus mutants to identify 
nucleobase transporter sequences from the T. b. bruce; library was disappointing. It is 
possible that the Aspergillus cellular machinery is not compatible with the expression, 
processing and targeting of the T. b. brucei transporter gene product. There has also been 
the suggestion that multiple integration events into the Aspergillus genome can be toxic 
and that the resulting over-expression of genes (even those normally found in Aspergillus) 
can lead to significant decreases in cell growth (Argyrou, et al., 2(01). Yeast studies have 
suggested that over-expression of endogenous and/or introduced transporter gene may lead 
to over-crowding during formation of membrane proteins in the ER or Golgi (Loayza et 
al., 1998) and thus to degradation of the protein or the formation of inclusion bodies. Other 
attempts to express a known T. b. bruce; purine transporter gene in A. n;duIans were also 
unsuccessful (De Koning, unpublished). 
The functional complementation attempted in our laboratory did not lead to the 
identification of oovel transporter sequences but I believe the approach in T. b. bruce; is 
still a valid concern if the appropriate background could be established. With the advent of 
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novel molecular techniques, such as RNA interference (LaCount, et al., 2000), there are 
new options for the construction of deficient backgrounds for the cloning of genes. 
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Chapter VII Characterisation ofTbNBT 1 
7.1 Introduction 
Another approach to the cloning of the T. b. bruce; nucleobase transporter ge~ carried 
out in parallel to attempts at functional complementatio~ was the regular interrogation of 
the burgeoning T. b. bruce; genome database with the aim of identifying sequences with 
homology to known nucleobase transporter genes. 
7.1.1 Identification ofseg.ence in T. b. brucei genome database with homology to 
ThATI 
The fIrst steps towards the sequencing of the entire T. b. brucei 927 genome were taken in 
1994. The majority of the actual sequencing has been undertaken by researchers at The 
Sanger Institute in the UK and The Institute for Genomic Research (TIGR) in the USA. 
The expected completion date was in 2005 but as of writing the first release of the entire 
sequence of the eleven megabase chromosomes is now available. 
Based on comparison of sequence identities there are at least three families of nucleobase 
transporter genes - the nucleobase/ascorbate transporters (NAT), the purine-related 
transporters (PRT) and the plant purine-related transporters (pUP) (De Koning & Diallinas, 
2000). Known nucleobase transporter gene sequences were used as search tools to 
interrogate the genome database. Using the amino acid sequence of NAT, PRT and PUP 
family members as query sequences in TBLASTN searches produced no signifIcant hits to 
any sequences in the T. b. bruce; genome database. 
At the start of the project, substantial knowledge was available on the range of different 
transport activities that are present in T. b. brucei. For several nucleoside transport 
components in T. b. bruce; sequence information was also available. These sequences have 
identified ThATI and ThNT2-7 as members of the equilibrative nucleoside transporter 
family. Some of the ENT family members characterised to date, including some of the T. 
b. bruce; transporters, have been shown to also transport nucleobases but usually with 
much lower affinity than for the corresponding nucleoside, e.g. ThNT5 has affinity for 
hypoxanthine of 50 J1M and of <5 J.1M for adenosine/inosine (Sanchez, et al .• 2002). One 
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possible exception to this "nucleobase uptake as low-affinity secondary activity only" 
assertion is the ThAT} transporter. 
Although ThAT} is most often described as a nucleoside transporter its substrate profile 
suggests that nucleosidelnucleobase transporter is more accurate. ThAT} from T. bruce; 
actually displays higher affinity for adenine than for adenosine but the entire functional 
characterisation of ThAT} was conducted using adenosine as the substrate. It is for this 
reason that the T. b. brucei genome database was probed with ThAT} rather than any of the 
NT2-7 sequences. 
A TBLASlN search of the available T. b. bruce; sequence information using the predicted 
protein sequence of TbAT} conducted by Richard Burchmore identified a novel 1308 
nucleotide open reading frame coding for a protein with 33% identity (53% similarity) to 
the query sequence (Figure 7.1). The 435 amino acid protein was predicted to have 11 
transmembrane domains. This secondary structure and the fact that the protein has such 
high similarity to a known transporter is consistent with a protein that resides in the 
membrane and that has a transport function. The presence of II putative transmembrane 
regions was also significant since other members of the ENT family have been shown or 
predicted to possess II membrane-spanning domains (GriffIths, et 01., 1997; Hyde, et 01., 
2001). 
The novel putative transporter gene was amplified by PCR and cloned into pGEM-T Easy 
vector by Richard Burchmore. Sequencing verified the complete open reading frame 
composition (nucleotide sequence and amino acid translation shown in Figure 7.2). 
Due to the substrate preference ambiguity of ThATI it was hypothesised that this novel 
sequence might code for a nuc1eobase transporter. To investigate substrate preference, it 
was necessary to express the gene in an appropriate heterologous system, as T. b. bruce; 
expresses a multitude of purine transporters with overlapping substrate specificity (Carter 
& Fairlamb, 1993; De Koning & Jarvis,I997a; De Koning & Jarvis,l997b; De Koning, et 
01., 1998). 
The heterologous system chosen for the characterisation was expression in an fcy2-null 
Saccharomyces cerev;s;ae cell line. The lack of the FCY2 permease resulted in cells 
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deficient in purine nucleobase and cytosine uptake (see later). A limited senes of 
experiments involving the transient expression of introduced mRNA in Xenopus laevis 
oocytes was also conducted. 
TbAT1: 2 LGFDSANEFIVYVTFLFFGMSVVVVTNSIFSMPFFFIEYYKYAQGKPDAKPEDPKFWKHM 61 
?,G SA E +Y T + G+S+++ N++ 5 P F ++YYKY GK D++P P FWK++ 
AT-like: 3 LGFSSAGEVYMYATCILLGVSLLMPLNALVSAPRFMVDYYKYVSGKEDSEPNLPFFWKNI 62 
TbAT1: 62 FTYYSIAAFLVELVLASLMLTPIGRRISVTVRLGVGLVIPIVLVFSVMMVTIVTTTETGA 121 
F' ~Y + + ++ +LT RR+ ++VR + + + + VF V+M+ ++ +T A 
AT-like: 63 FTFYNVVSLASQVTAGPTVLTRAARRLPLSVRFALSITLMMSEVFVVLMMPVIKVPQTVA 122 
TbAT1: 122 KVTIMLIAIANGVAMTLCDAGNAALIAPFPTKFYSSVVWGIAVCGVVTSFFSIVIKASMG 181 
V L+ I G+ + +A L+A P+KF S+V++G+++CGV+TS +IKASM 
AT-like:123 IVLLCLVTIFAGIGKSYHEATCYVLVASMPSKFMSAVMFGVSLCGVITSTLQCIIKASME 182 
TbAT1: 182 GGYHNMLIQSRIYFGLVMFMQVISCALLVLLRKNPYAQKYAAEFRY--AARKGIDDKGAD 239 
i ~ L Q5 IYF L + + + A+ + LR N YAQ++ AE+R +G+D + + 
AT-like:l83 DTYESVLTQSYIYFSLGLLIMAGTLAMALCLRYNSYAQEHVAEYRMLKLQEQGVDAE-SQ 241 
TbAT1: 240 GDEGNGAAKGPADQDDDPHGGDDTDKGNVMTATVDPDTMKDMDQVENITTSQQMLMARVW 299 
DE ~+G + G+ +G + TA E +T + M +AR+ 
AT-like:242 NDENEPVAEGKGE-------GEGKSEGAMTTA------------ -EQLTATAVMPVARI- 280 
TbAT1: 300 NVFWRVWPMLFACFMVFFTTFLVYPAVYFAIKADTGDGWYLTIAAALFNLGDFLSRLCLQ 359 
+ ML F FF T ++P++ I D W+ TIA L+N GD + R 
AT-like:281 -----IRMMLVTVFCGFFLTLFIFPSLIIPI--DRDHNWFATIAILLYNCGDAIGRFSTS 333 
TbAT1: 360 FKALHVSPRWVLIGTFARMLLIIPLVLCVRSIITGPWLPYILVHAWGFTYGYYGGISQIY 419 
FK R +L TFAR + ++P +LC+ I G PYI G T G +5 +Y 
AT-like:334 FKCVWPPRRALLYATFARFIFVLPFMLCIYQYIPGHVGPYIFSFLLGLT-NCVGAMSMVY 392 
ThAT1: 420 APRTGSLTTAGERSLAANWTIISLLGGIFVGAMFALAVNEGLP 462 
l! L TAG++ +A I5LL GI ++ A+ v LP 
AT-like:393 GPITPGLETAGQKLMAGQLMGISLLSGlAAASVLAMIVVVFLP 435 
FiiMe 7,1. Alilmment comparin~ predicted amino acid seguences of ThAT1 and AT-like 
gene. The two sequences share 33% identity (53% similarity). 
7.1.2 Yeast expression systems 
The availability of appropriate plasmid vectors and the progress in transformation 
protocols for yeast cells at the end of the 1970's allowed the isolation of the yeast arginine 
permease gene in the first yeast complementation study (Broach, et al., 1979). Studies 
involving complementation of yeast mutants by expression of genes from a variety of other 
organi ms quickly followed on from the original experiments. Since then yeast 
complementation has presented a robust system for both identification of novel genes and 
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M A L G F S S A G E V Y M Y A T C 
1 ATGGCTCTTGGATTTTCCTCTGCGGGGGAAGTGTACATGTACGCAACATG 
-' G V S L L M P L N A L V S 
51 CATCCTTCTTGGAGTGTCCCTTCTAATGCCCCTTAACGCTCTCGTTTCCG 
p R F M V D Y Y K Y V S G K E D 
101 CACCGCGCTTTATGGTGGACTACTACAAGTACGTATCTGGTAAAGAGGAT 
s E P N L P F F W K N I F T F Y N 
151 TCCGAACCGAACCTTCCCTTTTTCTGGAAGAATATTTTCACGTTCTACAA 
1r 5 .., A S Q v T A G P T V L T 
201 TGTTGTATCGCTTGCGTCGCAGGTGACTGCTGGACCGACCGTTCTAACTC 
R A A R R L P L S V R F A L S I T 
251 GTGCAGCCCGTCGACTTCCATTATCTGTGCGCTTTGCCCTTTCCATCACG 
L M M S E V F V V L M M P V I K V 
301 TTGATGATGTCGGAGGTATTTGTAGTTCTCATGATGCCTGTGATCAAGGT 
P Q ~ V '!. I V L L C L V T I F A 
351 ACCTCAAACAGTTGCCATTGTTCTTCTCTGCCTTGTGACAATATTTGCAG 
G 
-
G K S Y H E A T C Y V L V A s 
401 GTATTGGGAAATCATACCATGAGGCGACGTGCTACGTTCTGGTGGCGTCG 
M P S K F M S A V M F G V S L C G 
451 ATGCCATCTAAGTTCATGTCTGCTGTTATGTTTGGAGTGTCACTATGCGG 
1r I '" S T L Q C I I K A S M E D 
501 TGTAATAACGTCCACATTACAGTGCATCATCAAGGCATCAATGGAAGATA 
T Y E S V L T Q s y I Y F S L G L 
551 CCTATGAGTCCGTGCTGACGCAGTCATACATTTATTTTTCACTTGGTCTA 
L ~ M A G T L A M A L C L R Y N s 
601 CTGATAATGGCGGGTACACTTGCGATGGCTCTCTGTCTACGATATAATTC 
Y A Q E H V A E Y R M L K L Q E 
651 CTACGCGCAGGAGCACGTTGCTGAGTACCGTATGCTCAAACTACAAGAAC 
Q G V D A E 5 Q N D E N E P V A E 
701 AAGGAGTAGATGCTGAGTCTCAAAATGATGAGAATGAACCCGTGGCTGAA 
G K G E G E G K S E G A M T T A E 
751 GGTAAAGGTGAAGGTGAAGGTAAGAGTGAGGGTGCCATGACGACAGCAGA 
Q L T A T A V M P V A R I I R M 
801 GCAACTGACGGCAACTGCTGTTATGCCCGTAGCGAGGATAATCCGTATGA 
]A V ~ V F C G F F L T L F I F p 
851 TGTTAGTGACAGTCTTCTGCGGCTTCTTCCTCACCTTATTTATCTTCCCC 
I P I D R D H N W F A T I A 
901 AGTCTTATTATTCCCATCGATCGTGACCACAATTGGTTTGCGACAATTGC 
I .., j: N C G D A I G R F S T s 
951 CATTCTGCTATACAACTGTGGGGATGCTATTGGACGTTTCTCCACCTCGT 
F K C V W P P R R A L L Y A T F A 
1001 TCAAGTGCGTTTGGCCGCCCCGCCGTGCTCTGCTGTACGCCACCTTCGCC 
R F V L P F M L C I Y Q Y I P 
1051 CGCTTCATTTTTGTTCTGCCCTTCATGTTATGCATTTACCAATACATCCC 
G H V G P Y I F S F L L G L T N 
1101 TGGCCATGTCGGTCCGTATATCTTCTCGTTTCTCCTTGGCCTGACCAACT 
C V G A M S M V Y G P I T P G L E 
1151 GTGTGGGTGCCATGTCGATGGTGTATGGCCCAATAACCCCTGGTCTTGAG 
T A G Q K L M A G Q L M G I S L L 
1201 ACTGCGGGTCAGAAATTGATGGCTGGACAGTTGATGGGGATTTCGCTGCT 
s C r '\ A A S V L A M I V V V F 
1251 TTCTGGAATTGCCGCTGCATCTGTGCTTGCGATGATTGTGGTTGTCTTCC 
L P • 
1301 TACCATGA 
Figure 7.2. Nucleotide and amino acid sequence of AT-like sequence. The highlighted 
the all restriction site. The predicted transmembrane domains are shown in 
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functional characterisation of genes discovered by other means (Frommer & Ninnemann, 
1995). 
Uptake of purines and pyrimidines in Saccharomyces cerevisiae is meditated by three main 
transport components. FUR4 represents a high-affinity, highly specific uracil uptake 
activity. The substrate preference for this transporter is very particular - the system has no 
affinity for any other pyrimidine substrates such as cytosine and thymine (Jund, et al., 
1911; Chevallier, 1982). The FUll permease exhibits high selectivity for its uridine 
substrate and does not seem to contribute significantly to the uptake of any other 
nucleosides or nucleobases (Grenson, 1969; Vickers, et al., 2000). The 533 amino acid 
purine-cytosine permease FCY2 is a broad specificity purine transporter which also has a 
significant cytosine uptake capacity. This transporter has no affinity for uracil or thymine 
(polak & Grenson, 1973; Schmidt, et al., 1984; Weber, et al., 1990). 
Saccharomyces cerevisiae M0881.1 is a fey2 mutant effectively deficient in purine 
nucleobase and cytosine uptake (Gillissen, et al., 2000). As Saccharomyces cerevisiae does 
not have a plasma membrane transporter for pmine nucleosides or nucleotides, this strain is 
completely deficient in mediated purine uptake. The strain has also been engineered to 
have a truncated copy of the ura3 gene making it auxotrophic for uracil. This uracil 
auxotrophy is a useful means of selecting cells transformed with plasmids containing the 
full-length ura3. Cells not in possession of the plasmid will not grow on media lacking in 
uracil while successful transformants will prosper. 
The pDR195 plasmid is one such plasmid and was used by Rentsch and colleagues (1995) 
to characterise the function of the NTRI oligopeptide transporter from Arabidopsis 
thaliana in Saccharomyces cerev;s;ae. Gillissen subsequently used this vector for 
functional expression of the A. thal;ana purine transporter AtPUPl in Saccharomyces 
cerevisiae M0881.1 (Gillissen, et al., 2000). 
The pDR195 vector is shown in Figure 1.4. It contains the ADH expression cassette and 
also contains the PMAI (yeast plasma membrane ATPase) promoter to increase expression 
levels of the introduced permease. As noted above, the vector also contains a functional 
full-length ura3 to allow for selection oftransformants on uracil drop-out medium. 
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7.1.3 Xenopus laevis oocyte expression systems 
Pioneered by Gurdon and colleagues (1971, 1983), the technique of transiently expressing 
foreign genes in Xenopus laevis oocytes has made an important contribution to functional 
characterisation of myriad gene products. In particular, expression of transport proteins in 
oocytes has become a dependable method for elucidating transporter properties (Frommer 
& Ninnemann, 1995). Parasite transporters characterised in Xenopus oocytes include 
several classes of Plasmodium falciparum transporters (penny, et al., 1998), other 
Trypanosoma brucei purine transporters (Sanchez, et aI., 1999; Sanchez, et al., 2002) and 
Leishmania major purine transporters (Sanchez, et al., 2004). 
Figure 7.3 shows a diagrammatic representation of the methodology used to establish the 
expression of exogenous permeases in the Xenopus oocyte system. 
The vector used for the production of mRNA for expression of the putative AT-like 
transporter in the oocytes was the pGEM-3Z-based pGEM-HE (Liman, et al., 1992). This 
plasmid is 3019 bp in size and the multi-cloning site is surrounded by the 5' and 3' UTRs 
of the Xenopus ~-globin gene (Figure 7.7). 
eDNA 
I 
in vitro 
transcription, 
1 
mRNA ----t---. mRNA (in cytoplasm) 
microinj 
1 transJation modifications 
functional protein 
Figure 7.3. ransient expression of exogenous permease genes in Xenopus laevis oocytes. 
Adapt d fr m Miller & Zhou, 2000. 
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7.2 Results 
7.2.1 Sub-cloning of AT-like putative transporter gene into pDR195 
The cloned AT-like gene was provided by Richard Burchmore as a pGEM-T Easy 
construct. The complete open reading frame was excised from the vector using the NotI 
restriction enzyme to give a 1.35 kb insert. The digestion was electrophoresed and the 
fragment was purified from the agarose. The AT-like fragment was ligated into the NotI 
site of the linearised, de-phosphorylated pDR195 vector (Figure 7.4). 
Ampicillin 
rooRV(3M4) 
pDR195 
6310bp 
J 
/ 
0"'(3153) 
HirdIll(233) 
PMA 1 promoter 
Xhd (1006) 
SAcll (1018) 
'----" B.mH( (1019) 
\ ~ ADH tenninato 
Sp.H( (1352) 
SnAB! (2454) 
Figure 7.4. Vector pDR195 for expression in Saccharomyces cerevisiae. 
This new construct was amplified in E. coli 1MI09 and restriction digests were used to 
verify that the insert had integrated in the correct orientation for expression. The restriction 
map for the integrated insert and surrounding vector sequence is shown in Figure 7.5. 
A restriction digest of the appropriately orientated construct with San and XhoI should 
produce a 280 bp fragment and a larger band of 7400 bp representing the vector (6.3 kb in 
size) and the remainder of the ORF (Figure 7.6). The generation of a 1070 bp product 
indicates that the insert has integrated in an inverted position. 
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HindIII XhoI SalI (280) BamID 
I I i 
! 
i I 
Not! Not! 
1350 bp 
... • 
... . ... ~ 
280bp 1070 bp 
Figure 7.5. Orientation of AT-like sequence in pDR195 multicloning site. The SalI 
restriction site is situated at nt 280 of the AT-like sequence when it is ligated in the correct 
way. The total size of the pDRI95 vector is 6.3 kb. 
~8.0 kh 
~O.3 kh 
Figure 7.6. Orientation of the AT-like insert in pDRI9S. 
7.2.2 ub-cloning of AT-like putative transporter gene into pGEM-HE 
The AT-like insert was excised from the pGEM-T Easy construct using EcoRI to give a 
1.33 kb in crt. The insert was purified from the agarose gel as before and ligated into the 
EcoRI site of the prepared pGEM-HE vector (Figure 7.7). Following amplification in E. 
coli the new construct was subjected to restriction digest to determine which way the insert 
had integrated into the vector. For this construct the appropriate digest was a SalI-XbaI 
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double digest (restriction map shown in Figure 7.8) with the correct assembly generating a 
1060 bp fragment as well as a larger 3290 bp fragment consisting mostly of vector 
sequence (3019 bp) and the remainder of the AT-like ORF (270 bp). Figure 7.9 shows the 
banding pattern for the desired construct and also shows the banding pattern produced 
from an incorrectly orientated construct (270 bp and 4080 bp bands). 
Flo" 1.l611 (3018) 
Sat'! (I) 
, Ie\::' 6S1 (3) 
~tp 718(3) 
"Pn 1(7) 
. r 1(2819) 
M. 1(2818) 
.Id.! 1 (TI6 7) 
Aat n (2518) 
.'" 1(2400) 
It'nt 1 ( 16(6) 
Globin 3'UTR 
pGEMHE 
3019 bp 
11:<" I (1657) 
Figure 7.7. Xenopys oocyte vector pGEM-HE. 
BamID Sall (270) 
I i 
! 
EcoRI 
1330 bp 
• 
• •• 
270bp 1060 bp 
\.on, 1(70) 
Sma 1m) 
BamHI(75) 
h ,RI(8J) 
00 1(87} 
Ifmd m '9<;) 
Pst I (302) 
Sph 1 (308) 
Nhe 1 (312) 
Sap 1(587) 
}{baI 
i I 
EcoRI 
• 
• 
Figure 7.8. Orientation of AT-like sequence in pGEM-HE. For this construct, the Sail 
restriction site is situated at nt 270 of the AT-like sequence when it is ligated in the correct 
way. The total size of the pGEM-HE vector is 3019 bp. 
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-4.0 kb 
-3 .0 kb 
-1.0 kh 
-0.27 kb 
Figure 7.9. Orientation of AT-like insert in pGEM-HE. The gel shows band pattern for 
correct and incorrect orientations. 
7 .2.3 :;:,:::::=~:...¥.::...u=st:..;c::.::o:.:.;lo~n:.:i.::es:..;e=..=p:.:.r.:.:es~s=in:..lga..:t=h:..::e~A..:.T=--...:oli=k:..::e~g.::e=ne 
Electrocompetent accharomyces cerevisiae M0887.1 was transformed with the correctly-
orientated AT-like:pDR195 constructs and plated onto solid SC-URA medium. 
Transformants were recovered by the acquired ability to grow on uracil-minus plates (due 
to the reintroduction of the full-length ura3 gene). The lithium acetate transformation 
protocol used appeared to give a good yield of trans formants (Gietz & Woods, 2002). 
Colonies from the S -URA plates were transferred onto yeast selective medium plus 
hypoxanthine (4 mM) plates. This medium contained very few nutrients and the 
hypoxanthine supplement constituted the only nitrogen source available to the growing 
yeast. veral colonies were selected for further investigation by their apparent ability to 
survive and grow on the minimal medium. 
7.2.4 Characterisation of uptake by AT-like permease expres ed in Saccharomyces 
887.1 
ptake of tritiated purines by the AT-like transformants was assayed by the same rapid-
top oil- pin technique used to study uptake in T. b. brocei. Throughout, there was no 
significant accumulation of any of the radiolabelled permeants by control transformants 
which r ceived only the empty pDR195 vector. 
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Accumulation of 0.1 ~ eH] adenine by Saccharomyces cerevisiae MG887.1 transformed 
with the AT-like gene was rapid, and linear for over a minute with a rate of 0.0216 ± 0.001 
pmol (107 cellsrl S·I (Figure 7.10). The transport activity was saturable and in the presence 
of 1 mM unlabelled adenine uptake was not significantly different from zero. 
The uptake of 0.1 ~ eH] hypoxanthine by the yeast transformants was even more 
voracious than that of adenine with a linear phase throughout the 5 minute timecourse and 
an uptake rate of 0.048 ± 0.006 pmol (107 cellsrl S·I (Figure 7.10). Again transport could 
be completely suppressed in the presence of unlabelled permeant. 
2.5....--------------, 
...... 
~:(/) 2.0 
~ 't' ~ (,) 1.5 
c ... 
'2 ~ Q) _ 1.0 
~~ S, 0.5J .... ~-'*--*-------... 1 
0.0~=~=~==~~==~==::!¥1 
o 2 3 4 5 
lime (rrin) 
7.5-r--------------.. 
o 2 3 4 5 
lime (min) 
Figure 7.10. Uptake of eH] purine permeants versus time for TbNBTl expressed in S. 
cere vi ioe strain MG887-1. (a) Transport of eH] nuc1eobases by TbNBT1:pDR195 
transformants was assayed in the presence (D ) or absence (_ ) of unlabelled permeant. 
Transport by control transformants with pDR195 was similarly measured in the presence 
(C ) or ab ence (. ) of unlabelled permeant. 
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Figure 7.10 (ctd). Uptake ofeH] purine permeants versus time for TbNBTl expressed in S. cerevisiae strain MG887-1. Cb) Transport of eH] 
nucleosides by TbNBTl:pDR195 transformants was assayed in the presence CO ) or absence C- ) of unlabelled permeant. Transport by control 
transformants with pDR195 was similarly measured in the presence CD ) or absence C- ) of unlabelled permeant. 
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The nucleosides of adenine and hypoxanthine (adenosine and inosine, respectively) were 
also assayed at this stage to determine if the transporter had any preference for nucleobases 
over nucleosides. The nucleosides were taken up by the yeast transformants (Figure 7.10) 
but at much lower rates than their nucleobase counterparts. In addition, it was not possible 
to completely suppress these [~ nucleoside uptake activities with 1 mM unlabelled 
nucleoside substrate, indicating very low affinity. Uptake in the presence of unlabelled 
substrate was shown not to be due to diffusion as no uptake was observed in the "empty 
vector" controls. 
0.100...---------------, 1.8 
I:: 1.5 
Q)~ 1.2 
c Q) ._ 0 
~""o 0.9 
.~ 0.6 8,0 ~~ 0.3 
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Figure 7.11. Transport of rm hypoxanthine by TbNBTJ in S. cerevisiae strain MG887-1. 
Inset shows Michaelis-Menten plot. Incubation of 30 s. ICso value - 0.37 ~; Km - 0.93 
~. 
Further experiments led to the determination of Km and V max values for uptake of adenine 
and hypoxanthine by the transformants. Figure 7.11 shows the Michaelis-Menten plot for 
hypoxanthine transport. The apparent Km for hypoxanthine uptake was 0.66 ± 0.22 ~ and 
the Vmax was 0.69 ± 0.24 pmol (107 cells)"l S·l (n=3). The apparent Km for adenine uptake 
was 2.1 ± 0.6 ~ and the Vrnax was 0.41 ± 0.14 pmol (107 cells)"1 S·I (n=4). 
Subsequent inhibition experiments with other potential permeants were conducted using a 
eH] adenine or hypoxanthine concentration of 0.1 ~ and an incubation time of 30 s, 
which produced highly reproducible results. Table 7.1 shows the Km and Ki values 
obtained for uptake by the AT-like transporter expressed in Saccharomyces cerevisiae 
MG887.1. The permease mediated uptake of all the purine nucleobases with high affinity. 
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Nucleosides were also able to inhibit uptake of radio labelled permeant but all of the 
nucleosides demonstrated considerably lower affinities than the nucleobases. Even the 
reasonably high-affinity interaction exhibited by guanosine of 5.3 J.LM was significantly 
less than for its nucleobase counterpart. 
At this stage, it was possible to conclude that, based on the functional characterisation, the 
AT-like sequence did indeed code for a nucleobase transporter and the gene was 
designated as the T. b. brucei nucleobase transporter 1 (TbNBT1). 
Compound K.aorKa n 
Hypoxanthine 0.66±0.22 4 
Adenine 2.1 ± 0.6 3 
Guanine 1.4 ± 0.3 3 
Xanthine 4.3 ± 1.1 3 
Allopurinol 5.4 ± 1.1 3 
Uracil 68 ±6.5 4 
Adenosine 1900 ± 980 3 
Inosine 47± 17 4 
Guanosine 5.3 ± 1.5 3 
Table 7.1. Km or Ki values obtained for TbNBTl expressed in Saccharomyces cerevisiae 
MG887.1. Values were determined using either 0.1 J.LM [~ hypoxanthine or eH] adenine 
as radio label for ~ determinations and 25 nM radiolabel to measure Km values. Km were 
derived from Michaelis-Menten or Eadie-Hofstee plots. Results are shown ± standard 
error. 
7 .2.~ Characterisation of uptake by TbNBTl expressed in Xenopus laevis OOcytes 
The Xenopus oocyte transport assays were conducted by the group of Prof. Stephen 
Baldwin at the University of Leeds. The TbNBTl :pGEM-HE constructs were used for the 
in vitro transcription of mRNA. The transcripts were capped and poly A-tailed to prevent 
degradation of the message and lOng of transcript was injected into the cytoplasm of 
isolated stage VI oocytes. The injected oocytes were incubated for 4-5 days with daily 
medium changes before transport assays were performed. The oocytes were assayed for 
uptake of 100 J.LM radiolabelled adenine, adenosine, uracil and uridine over a 30 minute 
timecourse. The level of transport activity was expressed as a percentage of the amount of 
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uptake seen over the same time-course in oocytes from the same batch of cells when 
injected with DEPC-treated dH:zO only. The transport values shown were the result of the 
simulataneous assay of 10-12 oocytes. Figure 7.12 shows the uptake recorded for oocytes 
injected with TbNBTJ and hENrI mRNAs. As the positive contro~ hENT1-injected 
oocytes accumulated uridine and adenosine, but not adenine or uraci~ in keeping with 
previous studies (Griffith, et al., 1997). 
o 
// / 
Fiaure 7.12. Purine and pyrimidine transport in Xe1lQJlUS oocytes injected with RNA 
transcripts encodina protozoan and mammalian members of the ENT family. TbNBTl -
open bars; bENTl - filled bars. Transport is expressed as a percentage of the rates of 
uptake in control oocytes injected with water alone. Uptake was measured at pH 7.S. 
These oocyte system results served to reiterate what had been determined with the yeast 
expression system. The newly-named TbNBTl transporter was specific for adenine and, to 
a lesser extent uracil, over adenosine and uridine. 
7.2.6 BccODcUiatiog or bctcroloaog. "Item results with tranlport actiyitinin sitH 
The fact that the substrate specificity and kinetic profile for TbNBTl expressed in yeast 
was very similar to that observed for the H4 uptake activity in procyclics (see Table 6.3) 
was strongly suggestive that the TbNBTI gene codes for the H4 transporter. A series of 
elegant experiments by Mohammed AI-Salabi using the RNAi approach further 
corroborated this assertion (Burchmore, et al., 2003). 
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7.3 DllCuHlon 
The TbNBTI (T. b. bruce; nucleobase transporter 1) gene described here is the first 
dedicated nucleobase transporter gene to be characterised not only from T. b. bruce; but 
from any protozoan. The level of sequence identity with members of the equilibrative 
nucleoside transporter family suggests that TbNBTl is a new relative. As noted earlier in 
the chapter, other ENTs have been shown to mediate uptake of nucleobases but only in 
addition to nucleosides. The most significant examples of this situation are hENT2 (Vao, et 
01.,2(02), TbATI (Miser, et aI., 1999) and TbNT5 (and to a much lesser extent TbNT6 and 
TbN17) (Sanchez, et aI., 2002). 
The 435 residue TbNBTl protein is predicted to form 11 membrane-spanning helices with 
a large cytosolic loop between TMS 6 and 7, and this is particularly significant since this 
topology is a feature of most ENT family members (Griffiths, et 01., 1997; Hyde, et 01., 
2001). It should be considered, however, that predictions ofTMDs are speculative at best 
and ideally topology should be determined experimentally (Sundaram, et 01., 2001). 
Several permeases that are clearly defined as ENT members in terms of sequence indentity 
and substrate specificity are predicted to possess a variable number of TMDs. LdNT2 is 
predicted to possess only 9 TMDs (Carter, et 01., 2000), and ThATl was initially predicted 
to possess only 10 helices (MIser, et 01., 1999). 
It was necessary to express the transporter in a heterologous system in order to study its 
function unimpeded by interference from other endogenous T. b. bruce; transport activities. 
The two systems used here are both long-established techniques for study of gene 
expression and both are also associated with the cloning and characterisation of many 
different transporters (Frommer & Ninnemann, 1995). 
Expression in the yeast system demonstrated that TbNBTl encoded a permease capable of 
uptake of adenine and hypoxanthine and that the transporter displayed high affinity for 
these substrates. Other nucleobases were also able to interact with the transporter with high 
affinity. Nucleosides were able to inhibit uptake of radio labelled adenine and hypoxanthine 
but to a much lesser degree. Even the relatively low ~ value for guanosine was almost five 
times higher than that obtained for guanine (5.3 JJ.M compared with 1.4 J.1M). Guanosine is 
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a special case with several of the 1. b. brucei and L major nucleobase transport activities 
showing surprisingly high affinity for this nucleoside only. An internal H-bond between 
the 5' -hydroxyl group and the 2-amino group stabilises the molecule in the advantageous 
.syn conformation, whereas all other natural nucleosides are in the anti conformation (AI-
Salabi, et al., 2003). 
The yeast system also offered robust controls in the form of empty vector transformants. 
The uptake of labelled nucleosides even in the presence of 1 mM unlabelled nucleosides 
could not be explained by endogenous uptake systems or diffusion as there was no 
apparent uptake by these control pDR195 transformants. 
The results in Saccharomyces cerevisiae were corroborated by the limited characterisation 
of TbNBTJ in Xenopus laevis oocytes. The same general trends were observed, namely that 
the TbNBT I transporter was specific for nucleobases and had much less preference for 
nucleoside permeants. It also showed that although the transporter was very much specific 
for purines it did have some ability to transport the pyrimidine nucleobase uracil (Ki of 68 
J.1M in yeast assays). 
Saccharomyces cerevisiae (or other yeast species) may be the expression system of choice 
for 1. b. brucei transporter genes since it also utilises the proton-motive force for 
energisation of the transport process, whereas energy-dependent transport in Xenopus 
oocytes is known to use the Na + -gradient (Shayeghi, et al., 1999). However, this does not 
necessarily mean that the Xenopus oocyte is an unsuitable system for proton symporters 
since it does maintain a substantial proton-motive force across its membrane. 
It is necessary to verify results obtained from expression in any heterologous system since 
proteins can behave differently in "alien" environments particularly if other cofactors or 
proteins necessary for proper function are absent. 
The kinetic profile of TbNBTI expressed in Saccharomyces cerev;s;ae was very similar to 
that elucidated for the H4 transport activity in 1. b. bruce; procyclics (Burchmore, et aI., 
2003; see Chapter 6). In fact, none of the Km or Ki values derived for TbNBTl in yeast and 
for H4 in situ were significantly different (p> 0.05). 
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In a series of elegant RNAi experiments by Mohammed AI-Salabi, expression of the 
TbNBT] gene in procyclic parasites was "knocked-down" to confirm the assertion that 
TbNBTl encodes the gene for H4. In the "knock-down" cells the TbNBT] mRNA 
transcript was reduced by -80010 and the H4 hypoxanthine transport activity was 
concurrently very much reduced (Vmax fell from 3.2 pmol (107 cellsrl S·l in normal cells to 
0.20 pmol (107 cellsrl S·l in RNAi cells). 
The fact that the results in the yeast system could be corroborated by the results obtained in 
T. b. bruce; was significant because it validated the use of this particular yeast expression 
system for the study of trypanosome transporter genes. 
It is somewhat ironic that the TbNBT] gene belongs to the equilibrative nucleoside 
transporter family considering that it is primarily a nucleobase transporter and is likely to 
be an active transporter reliant on the proton gradient for function (De Koning & Jarvis, 
1997a; De Koning, et al., 1998). The family name was based on the characterisation of the 
definitive member (hENT]), and many other family members do not quite conform to the 
profile inferred by the name either. It is possible that ENT family members are also 
responsible for the nucleobase-specific high-affinity transport activities characterised in a 
range of other organisms, including humans, though this remains to be proven. 
Many issues remain to be resolved regarding nucleobase uptake in T. b. brucei. Although 
TbNBT} belongs to the ENT family this does not preclude the presence of nucleobase 
transporter genes in T. b. brucei that are not connected to this family. Also there is the 
continuing uncertainty of whether each characterised activity is the result of only one gene 
product or the result of the expression of a combination of similar genes, leading to 
closely-related transporters that are not easily distinguished using kinetic profiles. 
There are at least 3 sequences in the T. b. bruce; genome databases that are very similar 
(>95%) to TbNBT]. One of these sequences which differs at only 3 amino acid positions 
has been cloned and characterised as TbNT8.} by other researchers (Henriques, et al., 
2003). Although both TbNBTI and TbNT8.1 both mediate high-affinity uptake of 
nucleobase compounds the substrate profiles do not completely concur. Initial 
characterisation of NT8.1 showed that it had little affinity for either guanosine or uracil 
even at concentrations as high as 400 JAM but NBTI activity is affected by guanosine with 
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a Ki of 5.3 J,LM and by uracil with a Ki of 68 J,LM. Of course, these kinetic parameters were 
obtained in different heterologous expression systems and may reflect either this or other 
variations in methodology. Recently, a nucleobase transporter of the ENT family that 
mediates uptake of hypoxanthine, guanine, adenine and xanthine has also been cloned and 
characterised for the related parasite Leishmania major (Sanchez, et aI., 2004). 
Until very recently, the only information about the nucleoside and nucleobase transporters 
in T. b. bruce; had been gleaned solely by biochemical means. With this work and the 
cloning of several nucleoside transporters from trypanosomes in the past few years, there is 
now an unprecedented opportunity to dissect the vital role the purine transporters play, 
both in terms of purine salvage and chemotherapy. One example of the latter is the 
construction of a genetic knock-out for ThAT} and the subsequent full elucidation of the 
role of the resulting P2 transport activity in drug transport (Matovu, et al., 2003). 
The initial discovery, cloning, functional characterisation of the gene/gene product and 
identification of H4 as the in situ transport activity corresponding to ThNBT 1 expression is 
described in our paper (Burchmore, et al., 2003). 
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Cloning and characterisation of AT-like transporter genes 
Chapter VIII. Cloning and characterisation of AT-like transporter gene family 
8.1 Introduction 
The previous chapter discussed how the TbNBTJ gene was cloned, characterised and 
detennined to be responsible for the H4 transport activity. This was a significant 
accomplishment since it marks the first time a gene has been identified for any protozoan 
nuc1eobase transporter. However, there are still at least three other purine nuc1eobase 
transport components in T. b. bruce; for which a genetic basis remains to be identified, in 
addition to at least two pyrimidine nucleobase transporters. As well as three sequences 
with very high sequence homology to TbNBTJ (>95% identity at amino acid level), which 
included the TbNT8.1 characterised by Henriques and colleagues (2003), several other 
AT -like sequences were recovered following interrogation of the T. b. bruce; genome 
database with the TbATI protein sequence. The predicted primary amino acid sequences 
for three of these putative purine transporters, designated AT-like A, AT-like Band AT-
like D, shared between 54% and 58% identity with the ThATl protein sequence. 
This chapter describes the cloning and preliminary characterisation of these AT-like 
permeases. It also provides a comprehensive overview of the known and other predicted 
ENT family members that appear in the T. h. bruce; genome, as of March 2004. 
8.2 Results 
8.2.1 Polymense chain reactions and cloning or AT-Uke sequences 
PCR primers were designed for the AT-like sequences A, B and D (Figure 8.1). The primer 
sequences lay outwith the predicted open-reading frame so as to amplify the entire putative 
gene. Products of the expected sizes were obtained for all three putative gene sequences 
following PCR using the proof-reading enzyme Pju, as described in Chapter 2 (see Figure 
8.2 for the resuhs of the AT-like D PCR). The annealing temperature for the amplification 
of AT-like A and AT-like B was 56°C while the annealing temperature for the 
amplification of AT-like D was 52°C. The positive control utilised primers which 
amplified a fragment ofNBTI. The gel-purified products were A-tailed by incubation with 
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Forward 
Sequence of interest 
5 ' 3' 
Reverse 
Forward : 5 ' A CTCAAAGGTGTGCTGGCTG3' 
AT - like A 
Reverse : 5 ' CGGCGGTGTCAAAATCCAAG3' 
Forward : 5 ' CTTCACCATCTAGCTGAGTC3' 
AT-like B 
Reverse : 5' TTACCTCCTCTTAGGGACAG3' 
Forward: 5 ' GATGCTCGGTTTTTATTCAG3' 
AT - like D 
Reverse : 5' ATGTCACACTGTTATTTCAGc3' 
Figure 8.1. Primers used for amplification of AT-like sequences from total T. b. brucei 
genomic D A. 
PCR + 
- 1.5 kb 
-0.7 kb 
Fi ure 8.2. Pol merase chain reaction. AT-like D amplified from T b. brucei using PCR 
primer d tail d a ve. A positive control was included and consisted of primers designed 
to amplify a fragm nt of TbNBTI. The molecular weight markers are the same as those 
u d in hapt r i and even. 
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-4.5 kb 
a 
~3.0 kb b) 
~1.5 kb 
Taq and cl n d int the pG M-T Easy vector. The resulting constructs were amplified in 
E. c Ii 1M] and a eries of restriction enzyme digests, as described below, confirmed 
that all in rt were of the correct predicted size and possessed the restriction enzyme sites 
predi ted fr m th gen me database sequences. 
oil di ti n of the AT-like A:pGEM-T Easy and AT-like B:pGEM-T Easy constructs 
gen rat d th ector as a 3.0 kb fragment and the AT-like A or AT-like B fragments of the 
appr priat ize igure 8.3 and Figure 8.4). 
M-T Easy construct with HindIIlled to linearisation of the 
wh I c nstruct a ingle 4465 bp band) since this enzyme is predicted to cut once in the 
u n e but not at all in the vector (Figure 8.3). 
-4.5 kh 
~3.0 kb b) 
~1.5 kb 
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There i a ingle XhoI restriction site in the AT-like B:pGEM-T Easy construct as part of 
the AT-like B equence. Digestion led to a linearisation of the construct and produced a 
single 4405 bp fragment on electrophoresis of the digest mixture (Figure 8.4). 
Dige ti n of the AT-like D:pGEM-T Easy construct with EcoRJ released the 1410 bp 
in ert fr m th vector (3000 bp) as shown in Figure 8.5. Another digest of the construct 
with P II released approximately half of the insert as a fragment of 680 bp. This was the 
result 0 fa P II site in the multicJoning site of the vector and a site in the insert sequence. 
Thi P II dig t also gives a fragment of90 bp as a consequence of a second PstI site in the 
RF but this i not resolved on the agarose gel. 
-4.0 kb 
a) - 3.0 kb b) 
- 1.5 kb 
-D.7 kb 
8.2.2 eguencing 
The cl n d pr duct of two independent polymerase chain reactions for each of the AT-
like uence were equenced by MWG. Four separate sequencing reactions (Figure 8.6) 
Ii reach cl ne led t a complete double-stranded read for each sample. The two clones for 
ea h f th AT -like products were found to possess identical sequences. In addition, the 
verified equ nc of AT-like B and AT-like D were identical to those found in the genome 
data . Th erified equence of AT-like A had several single base differences from the 
qu n e in the database ( 369T; G436T; A501G; T1332C) but only one of these changes 
led t a chan e in the amino acid sequence (G436T changed a glycine residue to a serine 
r idu . 
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T7 and P6 sequencing primers 
u tom sequencing primers 
~~~~--=e~u=e=n=i:.:..:n:o. Reactions required to elucidate nucleotide sequence of entire 
putative permea gene. The custom sequencing primers were internal primers which 
allowed full c verage of th quence. 
The verified sequence of all three AT-like sequences are shown in Figures 8.7-8.9 along 
with the predicted amino-acid sequences. 
8.2.3 Prediction of tran membrane domains 
The pre nee of putative membrane-spanning domains in a protein can be detected by 
subjecting the primary amino acid sequence to hydropathy analysis (Stryer, L., 1995). By 
inve tigating th likelihood of certain hydrophobic a-helical regions of the protein 
showing a preference for the non-polar environment of the membrane interior it is possible 
to make predicti n regarding the structural organisation of transmembrane proteins. The 
TMpred program (http://www.ch.embnet.org/sofiwarefTMPRED form.html) was used to 
determin th in iden e of putative transmembrane domains in the AT-like A, B and D 
secondary tructur . All three amino acid sequences exhibited an apparent secondary 
structure consi tent with a membrane location and a transport function. The 
tran membrane h lix length was set between 14 and 23 amino acids and with these 
parameter all thr e AT-like sequences were predicted to have 11 transmembrane regions 
with th N-t rminal n the cytosolic side of the membrane (Figure 8.10). Other ENT 
family m mbe ha been hown or predicted to have 11 transmembrane domains. The 
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M L G F G S V H E L A Y I T F M 
1 ATGCTTGGCTTCGGTTCTGTGCATGAACTCCTTGCCTATATCACCTTCAT 
C F G M S V v v S N T V L S F 
S1 GTGTTTTGGGATGTCGGTGATGGTGGTGTCGAACACGGTCTTGTCGTTCC 
L E F F L Q F '.I L F A A K D G E N 
101 TGGAGTTCTTCCTCCAGTTCTACCTTTTCGCGGCCAAGGATGGCGAGAAC 
I K L E T E F. Q K F F W K N V F T 
lS1 ATCAAGCTGGAGACGGAAGAGCAGAAATTTTTCTGGAAAAATGTCTTCAC 
l' Y L A T T V E C L V V S L 
201 GTACTATCTTGCGACGACGTTTATTGTGGAGTGTTTGGTAGTGTCACTGA 
M L T N F G K R I P I T L R L Y I 
2S1 TGCTCACAAACTTTGGAAAGCGGATTCCCATAACCCTTCGCCTCTATATT 
G L V r p I I V F S V M M V T I 
301 GGTCTTGTCTTTCCGATTATCTTAGTATTTTCTGTGATGATGGTTACCAT 
G K T T E T G A R V T I I L I G 
351 CGGAAAAACAACGGAAACTGGTGCCAGGGTAACCATTATACTGATTGGTT 
L I N G A S T "\ C S S S A V A L 
401 TGATAAACGGAGCTTCCACTGCACTTTGCAGCTCCTGTGCCGTTGCACTT 
A G P F P T K 
"' 
S A Y V W G V S 
451 GCCGGTCCCTTTCCAACGAAGTTTTTGAGTGCGTACGTGTGGGGTGTTTC 
V C G V I T F A I V I K A s 
S-1 GGTGTGTGGTGTTATCACGTCGACGTTTGCGATTGTTA' 
T E S N F K R T E D R V A S R L T 
551 CGGAGAGTAACTTCAAGCGTACAGAAGACCGCGTCGCGAGTAGGCTCACT 
0 S R I Y F , V M I M Q s I S C 
601 CAGTCACGCATATACTTTGGGTTGGTCATGATTATGCAGTCGATTTCTTG 
G L L L L L R K N P Y A M K Y T 
651 TGGTCTTCTGCTGCTGCTGAGGAAGAACCCTTACGCCATGAAGTATACAG 
A 0 F R Y A A R K G N A V E G D D 
7 1 CAGACTTTCGTTACGCGGCGAGGAAAGGGAATGCTGTTGAAGGTGATGAC 
A G D D N E P S S L G K G P A D Q 
751 GCTGGAGATGATAATGAACCGAGTAGCTTAGGAAAGGGTCCGGCCGACCA 
D D 0 L K A D C N A G K S N V M 
801 GGATGACGATTTGAAAGCGGATTGCAACGCGGGCAAGAGCAACGTGATGA 
T S T V D P D T M R D T D Q V E N 
851 CTTCCACTGTAGACCCTGACACGATGAGGGACACGGACCAGGTTGAGAAT 
I T N S Q Q M L K A S A L S V F R 
901 ATCACGAACTCGCAACAGATGTTGAAGGCGAGTGCGTTGTCTGTGTTCAG 
R v W P M A V '- F I A F F T A 
951 GCGTGTTTGGCCCATGTTAGCCGTGTGCTTTATTGCGTTCTTTACCGCCT 
F L I l' P G V F F A V K L G P D D 
1001 TCCTCATCTACCCTGGTGTATTCTTTGCTGTCAAACTGGGGCCGGATGAC 
N G W Y M V I I P M M F N L G D F 
1051 AACGGCTGGTATATGGTGATCATTCCGATGATGTTTAACTTGGGAGATTT 
v A R L F V Q F K T L H A S P L 
1101 TGTGGCGCGCCTTTTCGTTCAGTTCAAGACTCTGCACGCATCACCGCTCT 
F v V I G ~ F A R L L L V I P I V 
1151 TTGTGGTGATTGGGACGTTTGCGCGTTTGTTGCTCGTCATTCCAATTGTG 
L C A Y K G T T F P Y I L C 
.,01 CTTTGCGCATACAGTGTGATTAAGGGCACGACATTCCCTTATATTCTTTG 
F L W S L T 1 Y V G G L A G V 
1251 CTTCCTCTGGTCGCTCACGTATGGCTACGTGGGGGGTCTAGCGGGAGTCT 
Y A P R T G S L T T A G E R S L A 
1301 ACGCGCCGCGTACTGGTTCGCTGACGACCGCCGGCGAACGTTCTCTAGCA 
A N W A V S T F' G I F A G C M 
1 51 GCCAACTGGGCCGTTAGTTCACTGCTGTTTGGTATCTTTGCTGGATGTAT 
C A L G V N S A L P K D E S Q • 
1401 GTGTGCCCTGGGTGTCAATTCGGCTCTCCCGAAAGATGAGTCACAGTAA 
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1 M L G F E 5 F 5 E F V V Y V T F I 
ATGCTCGGGTTTGAGTCGTTTTCTGAGTTCGTCGTCTATGTCACCTTCAT 
F F G M S V M M V T N A I Y S I 
51 CTTTTTTGGGATGTCGGTGATGATGGTGACAAATGCCATTTACTCCATAC 
P A F F T E Y Y K Y A Q G S S D A 
101 CAGCCTTCTTTACGGAATACTACAAGTATGCACAAGGCAGCTCGGACGCT 
Q ~ ENE N F W N N IL T Y Y N A 
151 CAAACAGAGAATGAGAATTTCTGGAACAACATACTCACGTACTACAACGC 
V 1QVLLETFMLT N 
201 CGCAGTGTTTAGTGCTCAGGTGCTTCTGGAAACTTTTATGCTGACGAATG 
V G R RIP I R I R L I F G L T I 
251 TTGGAAGGCGAATCCCCATCCGGATCCGGCTTATCTTTGGCCTCACTATT 
P L V A L I LIT V C H T S 
301 CCTCTTGTAGAACTTATTGCGCTTATACTTATCACCGTGTGCCATACCAG 
E A G A K , T I I I I A L V G G 
351 TGAAGCAGGCGCCAAAGCAACTATTATAATTATTGCTTTGGTTGGTGGTG 
VSKTl C DSSNAALVGPF 
401 TTTCCAAAACACTTTGCG AATGCGGCACTGGTAGGACCGTTT 
P T R F G ~ I V W G L G V S G L 
451 CCAACGAGGTTTTATGGGGCTATTGTGTGGGGTCTTGGTGTTTCCGGGCT 
T S M 5 I I I K A 5 M DDS 
501 
Y 
551 TCGAGAGCATGTTAACTCAGTCGAGGATATACTTTGGTATTGTCATATTT 
V I C V L L ALL T K N P Y 
601 ATTCAGGTGATCGCCTGTGTTCTTTTGGCTCTGCTAACGAAGAATCCTTA 
A K Y A A E F R H A A A K E S 
651 TGCGATAAAATACGCCGCTGAGTTTAGGCATGCTGCAGCGAAAGAGAGCG 
A V E 5 N E P v Q E TIT D Q E A 
701 CAGTGGAAAGTAACGAACCTGTTCAAGAGACCATTACAGACCAAGAAGCT 
NAG E E G E R V E K S T S K M N 
751 AATGCCGGAGAGGAGGGCGAACGGGTGGAGAAGTCAACTTCCAAGATGAA 
V L N V 5 E D P D K M K D T D Q 
801 TGTCCTGAACGTCAGCGAAGATCCGGACAAGATGAAGGATACCGATCAGG 
V D G T T N A Q Q M L DAN L W F 
851 TTGATGGCACCACCAACGCACAACAAATGCTCGATGCTAATTTGTGGTTT 
v V K R I WP M L V S C F F V F F 
901 GTGGTGAAGCGCATTTGGCCCATGTTGGTCTCGTGTTTCTTCGTATTTTT 
A L V F P G V F F A V E V K 
951 TGCTACCCTCCTCGTCTTCCCCGGTGTATTTTTCGCCGTTGAAGTGAAAG 
D G W Y T A A M F N F G D F 
1001 ATGGATGGTACATAACTCTCACCGCCGCTATGTTTAACTTCGGTGACTTT 
L S R V Q F K Q L R P S P I V 
1051 CTCTCCCGCCTCGTACTTCAGTTCAAGCAGCTGCGCCCATCGCCCATCGT 
V L G T FAR L L I I P L L V 
1101 GGTCCTTATCGGAACGTTCGCTCGTTTGTTGATCATTCCACTGCTTGTGT 
L C ~ I I P GSA L P Y I L C 
1151 TGTGCGTGCGCGGCATCATTCCCGGTTCCGCACTCCCTTATATTCTTTGT 
L L W ~ I N G Y F G G M S M I Y 
1201 CTTCTTTGGGGTCTCACAAATGGTTATTTTGGTGGTATGTCTATGATTTA 
A PR T G 5 L T TAG Q R S L A 
1251 TGCGCCACGTACCGGCTCTTTAACAACTGCGGGTCAACGCTCCCTTGCCG 
A C G N [ ALL L G L FAG S M 
1301 CCATTTGTGGGAATTTGGCCCTTTTACTCGGCCTCTTTGCCGGCTCCATG 
L A L A V ~ TAL PES • 
1351 TTGGCTTTGGCGGTTATGACGGCTCTTCCAGAATCATAA 
Figure 8.8. he nucleotide and amino acid sequence of AT -like B. The sequence 
highlighted in blu i the HindIll restriction site and the sequence highlighted in pink is the 
XhoI r tri ti n ite. The predicted transmembrane domains are shown in red. 
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M L G F Y 5 V P E V V Y V T F I 17 
ATGCTCGGTTTTTATTCAGTACCTGAATTTGTCGTTTACGTCACCTTCAT 
F F G M S V M N V T N A I Y 5 I 33 
51 CTTTTTTGGGATGTCGGTGATGAATGTGACGAATGCCATCTATTCGATAC 
P F F F K E Y Y K F A Q G D A D V 50 
101 CATTTTTCTTTAAGGAGTACTACAAGTTTGCTCAGGGGGACGCTGATGTA 
Q P K D E G F W K H M F T Y Y N V 67 
51 CAGCCGAAGGACGAAGGCTTTTGGAAGCACATGTTCACGTACTACAATGT 
v V y T M L L E A F M L T P 83 
201 CGTTGTGTACACTATGCAGGTGCTTTTGGAGGCCTTCATGCTTACGCCAC 
L G R R F P I R W R L T F G L A V 100 
251 TGGGAAGAAGGTTTCCAATACGCTGGCGGCTCACCTTTGGTCTGGCGGTT 
P I V E L v I P V V R T 5117 
301 CCTATCGTGGAGATCATTGTGATTTTAGTGATCCCTGTGGTCCGCACAAG 
E D A A K , "\ 11 M M I A F I G G 133 
351 CGAGGACGCGGCAAAGGCGGCTATGATGATGATCGCCTTCATTGGTGGTG 
V S K ;) 5 G N A A L V G P F 150 
401 TTTCGAAGACATTGTGTGACTCTGGTAATGCCGCACTTGTAGGGCCGTTT 
p T K F 'I V V W G L G I S G L167 
451 CCCACCAAGTTCTACGGTGCCGTCGTTTGGGGTCTCGGTATATCCGGGCT 
L T S F M S I I I K V 5 M D D 5 183 
501 TCTCACCTCATTCATGTCTATTATCATCAAGGTATCTATGGACGATAGCT 
F S S L L T Q 5 R I Y F G L I M L 200 
551 TTTCCAGCTTGCTTACACAGTCGCGGATATACTTTGGACTAATTATGCTT 
L Q v r A L V L L R K N P Y217 
601 CTTCAGGTGATCGCGTGCATTCTTCTAGTTTTACTGAGGAAGAACCCCTA 
A M R Y A A E L R F D A K K S G 233 
651 CGCCATGAGGTATGCTGCAGAGTTAAGGTTTGACGCAAAGAAGAGTGGTA 
T K D S N G L V D V A D A R G T G 250 
701 CAAAGGACTCCAACGGTTTAGTCGACGTAGCCGATGCGAGAGGAACTGGT 
P A 0 E E C E R E A D E R 5 D I N267 
751 CCTGCAGACGAGGAATGCGAACGTGAGGCGGATGAAAGGTCTGACATAAA 
v M N A T T D P D T M R D T D Q 283 
801 TGTGATGAATGCCACGACAGATCCAGATACAATGAGAGATACCGACCAGT 
L E N M T N A K Q M L D A 5 V M V 300 
851 TGGAAAATATGACTAACGCAAAACAAATGTTGGACGCGAGTGTTATGGTT 
v A K R I W P M L V S C F F V F F3 17 
901 GTGGCAAAGCGTATTTGGCCCATGCTTGTTTCCTGTTTCTTTGTGTTCTT 
A T L L V V F F A V K T D 333 
951 TGCAACACTTCTCGTCTTCCCTGGTGTGTTCTTTGCTGTCAAGACGGATG 
v p 5 G W l' F '" I V A A M Y N L G 350 
1001 TTCCCAGTGGGTGGTATTTCACCATCGTCGCTGCGATGTACAACTTGGGT 
D F L S R V Q F K R L H P 5 P367 
1051 GACTTCCTATCTCGCCTTGTCCTTCAGTTCAAGCGGTTGCACCCTTCGCC 
R G V V I G T F 5 R L L V I P L 383 
1101 ACGTGGCGTTGTGATCGGAACCTTTTCGCGTTTGTTGGTTATTCCACTGC 
L A L C V Y n V I S G P W v p y V 400 
1151 TTGCACTTTGCGTGTACGATGTTATTAGTGGCCCGTGGGTCCCTTATGTT 
L C L I W G N G Y F G G M 5 M417 
1201 CTTTGCCTTATTTGGGGCCTTACGAATGGCTACTTTGGCGGCATGTCGAT 
I Y G P R T G S L T T A G Q R 5 433 
1251 GA'I! l".''''":ZI. .! Irn.n.rZl.r-r:c:;c:;c:;rrn.r,n.""""'l'C::I.-~ 
L A A I C I N L L L G L F G G 450 
1301 TTGCTGCCATTTGCATTAATTTGGCCCTTCTTCTTGGCCTCTTCGGTGGT 
A M S A M A \I K A L P H • 
1351 GCCATGTCTGCCATGGCGGTTATAAAAGCTCTTCCGCATTAA 
Figure 8.9. The nucleotide and amino acid sequence of AT-like D. The sequence 
highlighted in green i the Bamill restriction site and the sequences highlighted in yellow 
are the P II re triction ite. The predicted transmembrane domains are shown in red. 
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predicti ns for the AT-like sequences are also ENT-like in that they have a large 
intracelluJar 10 p between transmembrane domain 6 and 7. It is prudent to note that useful 
th ugh the predictions are, they are speculative only. The number of transmembrane 
domain may be over-estimated or under-estimated since soluble proteins can contain areas 
of hydr ph bicity and transmembrane segments can contain amphipathic regions that 
would n t be flagged as potential membrane spanning regions (Stryer, L., 1995). The 
resuJts from TMpred were accompanied by the disclaimer that caution must be exercised in 
the interpretati n of any predictions. 
8.2.4 ub-cloning of AT-like sequences into pDR195 
The three AT-like sequences were subcloned into the NotI site of the pDR195 yeast 
expres i n vector as described for TbNBTl in Chapter Seven. 
The orientation of the insert for each AT-like sequence:pDRl95 construct was verified 
using an appropriate series of restriction enzyme digests as described below. 
Figure 8.11 h ws the restriction map for the AT-like A:pDRI95. A HindIll-BamIll 
double dige of the construct generates three bands on an agarose gel. The correct 
orientation f th gene produces bands of 1400, 920 and 5460 bp, while the incorrect 
orientation give bands of 560, 1760, and 5460 bp. Figure 8.12 shows examples of both 
banding patterns. 
To verify the c rrect orientation of AT-like B in the pDR195 vector (Figure 8.13) the 
construct was dige ted with the XhoI enzyme. The correct orientation gave 2 bands of 440 
and 7280 bp while the incorrect orientation yielded fragments of 980 and 6740 bp. Figure 
8.14 h w th band variations but there were other banding patterns observed, also 
sh wn in th figure. These aJternative digest products were consistent with more than one 
in ert being inc rporated in tandem during ligation events. 
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HindUI XhoI HindfII (560) BamBI 
I If I i 
! 
i 
I 
~ 
otI NotI 
840 bp 1480 bp 
• ~~ ~ 
1400 bp 920bp 
• ~. ~ 
Figure 8.11. Orientation of AT-like A in pDR195. Vector size is 6.3 kb. 
2 
-5.5 kb 
~1.7 kb 
~.5kb 
Figure 8.12. T-like A:pDRI95 digested with BamHllHindfII showing 1) correct 
orientation and 2) incorrect orientation. 
XhoI XhoI(440) HindUI (550) I ! ! 
NOll 
• 
440 bl? 
1420 bp 
Figure 8.13. ri ntati n of AT-like Bin pDR195. Vector size is 6.3 kb. 
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1 2 3 4 
-7.0 kb 
-1.5 kb 
-LOkb 
-OAkb 
Figure 8.14. AT-like B:pDRI95 digested with }(hoI showing 1) correct orientation and 2-4) 
incorrect orientation. 
The BamHI site in the vector and the AT-like D insert were situated qwte close together if 
the orientation in the construct was correct. Digestion with BamHI produces a small 136 bp 
fragment and the remainder of the construct is essentially linearised and shows up on the 
gel as a large fragment of - 7590 bp. Incorrect orientation effectively leads to the excision 
of most of the insert (1290 bp) out of the vector (-6436 bp) on digestion. 
HindlII XhoI BamHI (1290) BamHI 
I # I i 
! 
i I 
oil NotI 
1426 bp 
... • 
• .... • 
1290 bp 136 bp 
Figure 8.15. rientation of AT-like D in pDR195. Vector size is 6.3 kb. 
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1 2 
~7.5 kb 
....{).s kb 
~1.3 kb 
Figure 8.16. AT-like D:pDR195 digested with Bamlll showing 1) correct orientation and 
2) wrong orientation. 
8.2.5 el ction of yeast colonies expressing the AT-like A, B or D gene 
The transformation of the pDRI95/AT-like constructs into the S. cerevisiae strain 
M 887.1 and the selection of transformants on fITst SC-URA and then minimal media 
supplemented with 1 mglml (7.4 mM) adenine plates was carried out as described for 
TbNB 1 in hapter even. 
8.2.6 reliminary characterisation of uptake by AT-like permeases expressed in 
Saccharomvc cerevisiae MG887.1 
a haromyce erevisiae MG887.1 cells transformed with AT-like A, AT-like Band 
A -lik 
nstruct were assayed for ability to internalise radio labelled adenine. When 
ys showed that the AT-like A and the AT-like B transformants had not 
fa ility t transport adenine, these cells were then presented with a range of 
lIed tentiaJ purine perrneants. As well as an absence of adenine uptake, there 
f uptake of hypoxanthine, adenosine, inosine, cytosine, or uracil by the 
transfi rmant compared to cells transformed with empty pDR195. Due to time 
c traint th nly additional radio label the AT-like B cells were assayed with was 
hyp xanth in - gain n transport activity was detected. 
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As h wn in Figure 8.17 the cells transformed with AT -like D construct were able to 
internal ise adenine. The uptake was linear over 2 minutes and was inhibited by the 
presence of unJabelled adenine. However, this inhibition was not total suggesting low 
affinity for this ub trate and that perhaps adenine was not the primary substrate for the 
introduced pennease. As noted above, the empty vector transforrnants did not seem to 
accumulate adenine and there was no significant difference in the presence or absence of 
unlabelled permeant. 
The AT-like D transformants were shown to take up 0.015 IlM adenosine rapidly and the 
uptake was linear over the entire 4 minute timecourse with a rate of 0.024 ± 0.002 prool 
(107 cellsrl min- I (see Figure 8.18). Transport was saturable as shown by the capacity for 
unlabelled aden sine to completely suppress uptake of the radio label. Adenine could also 
inhibit the transport of the adenosine radio label but this was only partial inhibition again 
indicating that adenine has a relatively low affinity for this transporter. 
-
020 (1) ' Vl 
~-S '- 0.15 n!1 
::> (1) 0 .~ ..... o 0.10 c ..-
(1) ; ~ g <{ 0.05 >~ n 0.00 
0 2 3 4 5 
lime (min) 
Figure 8.17. ptake of ad nine by Saccharomyces cerevisiae MG887.1 transformed with 
AT-like D: DR195 r em t DR195. AT-like D:pDRI95 - 0.1 IlM eH] adenine only 
(_ ) + 1 mM adenine ( ); pDR195 - O.IIlM eH] adenine only (. ), + 1 mM adenine ( '&'). 
Figure 8.19 h w th ubstrate saturation curve for inhibition of the transport of 15 oM 
tritiated aden in by various concentrations of unlabelled adenosine for a fixed time 
cour . Th I 0 f4 r inhibition of radio labelled adenosine by unlabelled adenosine is 0.042 
IlM. Th data fr m Figure 8.19 was used to contruct the Michaelis-Menten plot for 
aden in uptake by the AT-like D transporter expressed in Saccharomyces cerevisiae 
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.S ...... 
(I) a 0.04 0 ~ 
c 
CD g ~ 0.02 <{ 
a. 
0.00 
0 2 3 4 
lirre (min) 
Figure 8.18. Uptake of 15 nM em adenosine by Saccharomyces cerevisiae MG887.1 
transformed with AT-like D:pDR195. Label only (_ ), + I mM adenine (e ), or + 1 mM 
adenosine ~). 
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~ ' (I) 00025 
-5,"";"-
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O.OOO+--r---.--,.----,----,---.J 
0.0 0.2 0.4 0 .6 0 .8 1.0 
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Figure 8.19. CA) Inhibition of 15 nM em adenosine uptake by Saccharomyces cerevisiae 
MG887.1 transform d with AT-like D:pDR195. Ki value is 0.042 IlM. (B) Michaelis-
Menten pi t of adenosine uptake in Saccharomyces cerevisiae MG887.1 transformed with 
AT-like 0: DR195. Vma of 0.015 pmoI (107 cellsrl S-I. Km of 0.093 IlM. 
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M0887.1 (Figure 8.20). The apparent Km was 0.093 J.LM and the apparent Vmax was 0.015 
pmol (107 cellsrl S·I. 
The substrate specificity of the transporter was determined with a series of transport 
assays. The inhibition constants for various potential purine penneants are shown in Table 
8.1. 
CompouDd Ki(J,LM) D 
Adenosine' 0.058 ± 0.012 4 
Inosine 4.3 ± 1.5 4 
Ouanosine 5.7±0.6 3 
Uridine 219 ± 37 3 
Thymidine 471 ± 32 3 
Cytidine 86±30 3 
Cordycepin 5.5 ± 1.3 3 
AraA 1.3 ±0.3 3 
Tubercidin 2.2±0.1 2 
6-mercaptopurine riboside 102±42 3 
'2-deoxyadenosine 0.043 ± 0.005 3 
5' -deoxyadenosine 0.30± 0.07 3 
hypoxanthine 82± 1 2 
adenine 112 ± 51 3 
Table 8.1. Affinity constants for AT-like D exPressed in Saccharomyces cerevisiae 
M0887.l. I. Km value. 
These experiments showed that the AT-like D sequence encodes a high-affinity purine 
nucleoside-specific transporter which has extremely high affmity for the definitive 
substrate adenosine and only relatively low affinity for nucleobases. 
8.2.7 Northern hybridisatioD 
Northern blots were canied out to detect the presence or absence of AT-like A, B and D 
transcripts in both bloodstream and procyclic form T. b. brucei 927. Figure 8.21 shows the 
RNA markers and ribosomal RNAs successfully transferred to the membrane. The 
membrane was probed with DNA probes consisting of the entire gene sequences. The AT-
like B probe hybridised to the region between 3638 and 4981 kb in the bloodstream RNA 
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6583 
4981 
3638 
2604 
1908 
1383 
955 
623 
281 
Figure 8.21. Transfer of RNA to membrane for Northern analysis. Following overnight 
blotting the Hybond membrane was stained with Blot Stain Blue Reversible Northern Blot 
Staining lution ( igma). There are three size categories of ribosomal RNA in 
Trypano oma brucei accounting for up to 80% of the total RNA present in the cell. The 
pre ence of the three rRNAs on the membrane (2.3 kb, 1.9 kb and 1.5 kb) confirmed that 
transfer had been accomplished and also controlled for differences in RNA loading. 
6583 
4981 
3638 
2604 
1908 
1383 
955 
623 
281 
PC BSF 
rthem hybridisation using the full-length AT-like B ORF as probe. 
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lane but not in the procyclic sample. (Figure 8.22). There was no apparent hybridisation to 
the membrane for AT-like D or AT-like A with the hybridisation conditions used. 
S.l.S Overview of ENT fa.iI! .e.ben identified in the T. b. brucei genome 
database 
As well as the previously characterised ThAT1, ThNT2-7, ThNBTl and ThNT8.1 there 
appears to be several other putative ENT genes present in the T. b. bruce; genome. The 
identification and cloning of AT-like A, B and D have been described in this chapter. In 
addition 5 more ENT-like sequences were identified in silico which have sequence identity 
to the genes listed above. These sequences have been designated AT-like E-1. 
All the known sequences were used to construct a muhiple alignment (Figure 8.23). The 
sequence comparisons resolved three distinct groups. ThAT-like A, E and G aligned most 
closely with the ThATI sequence; ThAT-like F and H associated with TbNBTl and 
ThNT8.1; ~ finally, ThAT-like B, D and I aligned with the TbNT2-7 sequences. Figure 
8.24 shows the tree constructed as a resuh of the muhiple alignment. Table 8.2 shows how 
the sequence identity and similarity compare for each pair of sequences. ThAT-like F and 
H differ from TbNT8.1 at only one amino acid position (AT-like F has an alanine residue 
at position 51 while NT8.1 has a serine residue; AT-like H has an asparagine residue at 
position 245 and NTS.l has a lysine residue at the same position). Whether these 
differences reflect sequencing errors or perhaps the presence of different alleles is unclear. 
AT-like G only differs from AT-like A at three positions but also possesses a putative 12 
amino acid N-tenninaI extension. 
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TbAT1 
AT-E 
AT-A 
AT-G 
AT-F 
AT-H 
TbNT8.1 
TbNBTl 
AT-B 
AT-O 
TbNT4 
TbNT3 
TbNT2 
AT-1 
TbNT5 
TbNT7 
TbNT6 
1)------------ L 
(l)-----------H 
(1)------------
(l)MLLKGVLAE1GR 
(l)-----------HA 
(l)-----------HA 
(l)-----------HA 
(l)-----------HA~ 
(1)------------
(1)------------
(l)----------HA 
(l)----------HA 
(l)----------HA 
(l)----------HA 
(l)----------HA 
(1)----------
(l)----------HA 
Consensus (1) MLGFES AEFFVYLTF1FFGMSVMMVTNAIYS P FF EYYKFA G DA P N FWKHM FTY 
TbATl 
AT-E 
AT-A 
AT-G 
AT-F 
AT-H 
TbNT8 . 1 
TbNBT1 
AT- B 
AT-O 
TbNT4 
TbNT3 
TbNT2 
AT-1 
TbNTS 
TbNT7 
TbNT6 
(65) ~ 
(66) ..,. ,,"''1'1-' 
(69) 
(81) 
(66) 
(66) 
(66) 
(66) 
(65) 
(65) 
(67) 
(67) 
(67) 
(67) 
(67) 
(67) 
(67) 
Consensus (81) YNVVVFTHQVLLEAFMLTPLGRRIPISVRL FGLTIPMVEIIVILMIPVV S E GAI ATMMLVA1VGG1SKTLCDSSN 
TbAT1 (14 4 ) 
AT-E (145) 
AT-A (148) 
AT-G (160) 
AT-F (14S)y v"",u. "M< 
AT-H (145)Y 
TbNT8 . 1 (145) Y 
TbNBT1 (145) Y 
AT-B (14 4 ) 
AT-O (14 4 ) 
TbNT4 (147) 
TbNT 3 (147) 
TbNT2 (146) 
AT-1 (146) 
TbNT5 (146) 
TbNT7 (1 46) 
TbNT6 (1 46) 
Consensus(161) AAL GPFPT KFYSAVVWGLAVSGL1TSFLSIVlKASMEDSFES 
TbAT1 (217) 
AT-E (218) 
AT-A (228) 
AT-G (2 40) 
AT-F (218) 
AT-H (218) 
TbNT8.1 (218) 
TbNBT1 (218) 
AT-B (217) 
AT-O (217) 
TbNT4 (220) 
TbNTJ (220) 
TbNT2 (219) 
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AT-I (219) 
TbNT5 (219) 
TbNT7 (219) 
TbNT6 (219) 
consensus(241)YAIKYAAEFRYAARKO 0 
TbATl (293) 
AT-E (292) 
AT-A (307) 
AT-G (319) 
AT-F (269) 
AT-H (269) 
TbNTB.1 (269) 
TbNBTl (269) 
AT-B (293) 
AT-O (293) 
TbNT4 (2BB) 
TbNT3 (292) 
TbNT2 (291) 
AT-I (290) 
TbNT5 (291) 
TbNT7 (291) 
TbNT6 (292) 
DE OAKG G ADEO 
Consensus(321)MLOASVMVVVKRIWPMLVSCFFVFFATLLVFPGVFFAVK 10 
TbATI (371) 
AT-E (370) 
AT-A (386) 
AT-G (39B) 
AT-F (345) 
AT-H (345) 
TbNT8.1 (345) 
TbNBTl (345) 
AT-B (369) 
AT-O (371) 
TbNT4 (368) 
TbNT3 (372) 
TbNT2 (371) 
AT-I (370) 
TbNT5 (371) 
TbNT7 (371) 
TbNT6 (370) 
. --- --~- ~ --.- ! --~----
-- - -- ~ .----.----I. I~ 
- " - .---- - - .... ----
• • 
o NVLNA IOPO MKOTOQVE TTNAQQ 
WY TI IAMFNLGOFLSRLVLQFK LH SPR V 
Consensus(401)LIGTFAR LLIIPLVLCV G IPG LPYILSLLWGLTNGYFGGLSMIYGPRTGSLTTAGQRSLAAICINVSLL GLFAG 
TbATI (451) K----
AT-E (450) Q----
AT-A (466) KOESQ 
AT-G (478) r TC KNESQ 
AT-F (424) 
AT-H (424) 
TbNT8.1 (424) 
TbNBTl (424) 
AT-B (449) 
AT-O (451) H----
TbNT4 (448) KTE--
TbNT3 (452) E----
TbNT2 (451) E----
AT-I (450) K----
TbNT5 (451) E----
TbNT7 (451) KEKK-
TbNT6 (450) K----
Consensus(481)AH ALAV EGLP 
Figure 8.23. Multiple alignment of ENT gene family members in T. h. brucei. The 
tranSmembrane domain as they appear in TbATl are represet(ted as bold lines above the 
sequenc s. 
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r T bA T · Iike A (00022) 
~--------------~ T bA T ·Iike G (0.0061) 
_...-JI.....------------ TbAT · Iike E (0.1723) 
L--___________ T bA T 1 (0.1635) 
T bA T ·Iike F (0.0007) 
T bA T ·Iike H (0.0017 ) 
L-________________________________ ~I T b N T 8.1 (0 .0006) 
L-------------T bAT ·like 8 (0.1678) 
L--_________ TbAT · Iike D (0.1439) 
'-----T bNT 4 (0.1066) 
~-TbNT3 (0 .0575) 
--.r T bA T · like 1(0.0216) 
~ TbNT2 (0.0109) 
~TbNT5 (0 .0527) 
~ TbNT7 (0.0445) 
L----TbNT6 (0.0649) 
T b N 8T 1 (0.0037) 
Figure 8.24. Tree showing how T. b. brucei ENTs relate to each other. This tree was 
constructed in VectorNTI by the Neighbor-Joining method (Saitou & Nei, 1987). The 
figures in brackets represent the branch length. 
When all the T. b. brucei sequences were aligned it was observed that 74 amino acid 
residues dispersed throughout the proteins were conserved in all cases (15-17%). Many of 
these completely conserved residues were found in the predicted transmembrane helices 
suggesting role in structural integrity. Other groups of residues were conserved within the 
three separate protein groups outlined above, suggesting a possible role in substrate 
recognition or translocation. Sanchez and colleagues have previously identified differences 
in the primary amino acid sequence of nucleoside transporters capable of limited 
hypoxanthine uptake (TbNT5, 6 and 7) and those that are incapable of such a function 
(Sanchez, el al. 2002). Two of the sequence differences highlighted are also conserved in 
the TbNBTl and TbNT8.1 sequences (Va147 and Pross as in TbNT5). Pross is also found at 
the corre ponding position in the ThAT! and AT-like D sequences. It is difficult to 
correlate quence differences to function when the functions of most of these genes have 
yet to be characterised. It has not been possible to assign functions to the cloned TbNT3, 
TbNT4, AT-like A and AT-like B due to difficulty in detecting transport activitites in 
heter logou y terns. AT-like E, AT-like F, AT-like G, AT-like H and AT-like I have not 
yet been cl ned. It will be necessary to elucidate the functions of these genes in a 
heterol gous y tern, and the relative importance of distinct residues or groups of residues 
can be pr bed u ing ite-directed mutagenesis. 
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TbATI TbNn TbNn TbNT4 TbNT5 TbNT6 TbNT7 TbNU.I TbNBTI TbATA TbATB TbATD TbATE TbATF 
TbATI 100 
(100) 
TbNn 57.2 100 
(7U) (I00) 
TbNT3 57.9 BU 100 
(71.4) (92.S) (I00) 
TbNT4 54.0 SO.5 B2.0 100 
(66.B) (86.3) (86.1) (100) 
TbNT5 56.7 B7.3 86.9 77.0 100 
(71.5) (92.0) (91.4) (B3.7) (100) 
TbNT6 57.0 86.6 B7.1 79.7 86.9 100 
(71.01 _(90.3) (9O.8) (B5.21 ,(90.9) (IOO) 
TbNT7 56.4 B8.4 86.5 79.4 B9.7 B5.2 100 
(71.1) (92.3) (90. I} (B5.4) (94.4) (B9.9) (100) 
TbNT8.1 32.3 32.4 32.5 31.4 33.7 32.7 32.0 100 
(51.9) (52.3) (SJ.3) (50.4) (51.8) (51.9) (51.3) (IOO) 
TbNBTl 32.1 32.0 32.4 31.4 33.5 32.5 31.6 99.3 100 
(51.5) (52.7) (51.9) (50.2) (52.5) (51.5) (St.7) (99.3) (100) 
TbATA 57.9 47.8 49.2 47.9 4B.5 49.4 4B.S 29.6 30.0 100 
(71.0) 
.(62·91 163.Ql. 160·51 (61.6) (63.6} (62.9) (48.7) (48.9) (100) 
-()C) 
w 
TbATB 55.2 65.6 64.6 62.3 64.3 64.2 64.9 31.7 32.0 47.9 100 
(70.5) (76.7) (75.3) (73.8) (75.6) (75.3) (75.5) (51.6) (51.6) (63.9) (100) 
TbATD 56.5 70.4 69.9 66.0 67.9 70.5 68.7 33.0 33.2 48.1 67.7 100 
(74.1) (80.1) (79.5) (76.4) (78.4) (80.4) (79.4) (52.2) (52.2) {64.7J 179.1) (100} 
TbATE 65.8 55.3 56.0 52.6 54.6 54.4 54.9 31.8 32.0 57.0 57.4 55.6 100 
(77.0) (70.5) (69.7) (66.9) (68.8) (68.9) (69.2) _ (SO.9) (50.9) (69.2) (74.2) (72.4) {I 00) 
TbATF 32.5 32.8 33.2 31.6 34.3 32.9 32.2 99.8 99.1 29.6 32.0 33.0 32.0 100 
(51.9) (52.5) (51.7) (50.4) (52.3) (S1.9) (51.5) (100) (99.3) (48.7) (51.6) (52.2) (50.9..1 (100) 
TbATG 56.1 46.9 48.2 47.0 47.5 47.8 47.5 28.9 29.4 96.8 46.2 46.6 55.2 29.1 
(§9.01 (61.6) (61.7) (59.3) (60.4) (62.6) (61.4) (47.4) (47.61 . (96.8) (61.7) (63.0) (67.1) (47.8) 
TbATH 32.3 31.8 32.2 31.2 33.3 32.3 31.4 99.8 99.5 29.8 31.7 33.0 31.8 99.5 
(51.91 (52.7) (51.9) (50.2) (52.5) (51.5) (51.7) (99.8) (99.5) (4B.9) (51.6) (52.2) (50.9) (99.B) 
TbATI 57.2 96.5 86.2 80.4 84.9 86.2 86.3 32.3 32.3 47.S 66.5 70.7 54.8 32.7 
(7l.S) (97.0) _ .(90.3) (86.S) (90.1) (90.9) ~·ft L..~~.6) (52.4) (63.1) (77.1) (80.5) (69.7) (52.S) 
Table 8.2. Amino acid sequence similarities and identities (%) shared between T. b. bruce; ENT -fumily members. 
TbATG TbATH TbATI 
100 
(100) 
29.1 100 
(47.6) (100) 
46.7 32.3 100 
(61.6) £52.6) (lOOl 
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8.3 Discussion 
Evidently there are several putative ENT fBmily members in the T. b. bruce; genome 
database for which activities have yet to be assigned. In addition to the new AT-like 
sequences described here, these transporters of unknown function include several of the 
NT genes described by Sanchez and colleagues (2002). Conversely, there are nucleobase 
uptake components for which a genetic basis has yet to be detennined. This situation is 
compounded by the indefinite nature of biochemical elucidation of uptake components - it 
is difficult given the multitude and overlap of the different activities to conclude that they 
have all been accounted for. 
The AT-like A, B and D sequences were encountered in the same BLAST searches that 
uncovered the ThNBTI gene. They showed better sequence homology to ThATI than did 
the ThNBTI sequence and. in met, AT-like B and D were more akin to the TbNT2-7 than 
to any of the other genes. Although prediction of function based on such relationships are 
far from infallible it seemed reasonable to speculate that AT-like Band D might code for 
transpOrt proteins leaning more towards nucleosides as preferred permeants. ThAT-like A 
seemed quite unique in that it had a reasonably high amount of shared sequence identity 
with all of the known purine transporter genes sharing only slightly higher levels of 
homology with ThAT I than with the others. 
With the successful expression of ThNBTI in Saccharomyces cerevisiae M0877.1 this 
heterologous system was validated as a route for elucidation of T. b. bruce; purine 
transporters and so it seemed plausible that the same system would allow the 
characterisation of the other three AT-like sequences that had been cloned. Although 
colonies ofMG887.1 transformed with each of the sequences could be isolated on adenine-
selective plates only colonies possessing the AT-like D gene were shown to have acquired 
the ability to internalise purines. 
Given the identification of the AT-like D activity as a high affmity nucleoside uptake 
system with relatively low affinity for nucleobase molecules it may seem curious that its 
presence in yeast could allow selective growth on adenine as the sole source of nitrogen. 
This is an indication of the sensitivity of the yeast system for allowing selection even on 
secondary substrates of introduced penneases. The NTRI gene cloned and characterised by 
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Rentsch and colleagues (I99S) in Saccharomyces cerevisiae was originally selected for its 
ability to complement a histidine-uptake deficient strain but further characterisation 
showed that the encoded permease was actually an oligo-peptide transporter and has 
comparatively low affinity for histidine itself. Considering this sensitivity and the 
flexibility with which yeast strains can utilise purines and pyrimidines as nitrogen sources 
this approach has the potential to identify many transporters with widely varying substrate 
specificity (Gillissen. et aI., 2(00). 
The AT-like 0 transport component characterised in the yeast heterologous system 
exhibited a PI-like substrate specificity and the AT-like D gene also aligned most closely 
with the PI-type NT permeases previously characterised by Sanchez, et al. (2002). Despite 
this relationship there was a more significant degree of identity within the previously 
characterised NT sequences than there was between AT-like D and any individual NT 
sequence. It is noteworthy that AT-like D displays higher affmity for adenosine by at least 
an order of magnitude than any of the other T. b. brucei ENT fiunily members yet 
characterised. 
Northern analysis was undertaken to try to determine the lifecycle stage in which the AT-
like A. AT-like 8 and AT-like D genes are transcribed. Under the hybridisation conditions 
used only AT-like B mRNA was detected and this was only present in the bloodstream 
fonn parasites. Given that the AT-like D has been characterised as a transporter operating 
at very low adenosine concentrations (at least in the heterologous system which may not 
reflect the actual activity of AT-like D in situ) and given that AT-like D mRNA could not 
be detected in either procyclics or bloodstream forms it was speculated that AT-like D may 
be expressed in the Iifecycle stage exposed to the lowest endogenous purine levels (e.g. in 
the metacyclic stages). Due to time constraints it was not possible to investigate this 
hypothesis any further. 
Regulation of gene expression in T. b. brucei seems quite complex as the Northern analysis 
has shown previously that the ThAT} mRNA transcript is present in both bloodstream 
fonn and procyclic parasites although the P2 transport component is not biochemically 
detectable in insect-stage parasites (De Koning, et al., 1998). Conversely, the initial 
characterisation of the PI-type TbNT2 (Sanchez, et al., 1999) showed that mRNA was 
only foWld in bloodstream stage parasites in the strain used (EATRO IlO) although PI 
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activity is present in both life-cycle stages. Further studies in reference strain T. b. brucei 
927 showed that in this strain the TbNT2 gene (distinct from gene in EATRO 110) was 
expressed in both bloodstream forms and procyclics (Sanchez, et al., 2002). The TbNBTI 
gene is also transcribed in both bloodstream form and procyclic parasites as determined by 
Northern analysis but the biochemical activity has only been studied in procyclic forms 
and it is unclear if it is present in bsf. Many questions remain regarding the mechanisms 
present in trypanosomes for the regulation of gene expression. There is the possibility that 
T. b. bruce; genes and the subsequent proteins can be regulated at several different levels 
including post-transcriptionally or post-translationally. 
The current situation with AT-" AT-B, TbNT3 and TbNT4, i.e. not knowing exactly what 
role they fulfil. highlights major problems with identifying functions for the enormous 
number of genes that are being generated by genome projects. If a function can be 
putatively assigned either by resuhs in heterologous systems or by homology with proteins 
of known function techniques such as RNAi should prove very useful for reconciling 
genetic information with biochemical profiles in situ. 
Considering the phylogenetic distance and the clear functional differences between the 
protozoan and mammalian ENTs it is not so surprising that there is a great deal of diversity 
between the transporters at the amino acid level. Even so there are some residues and 
putative motifs that seem to bridge the gap. 
There is a good deal of sequence homology shared between the ENTs identified in T. b. 
bruce; to date ahhough it has been challenging to link structure and function given the gaps 
in our knowledge. Ahhough some residues have been conserved across the phylogenetic 
distance between trypanosomes and mammals there is a large amount of sequence 
divergence (Carter, et al., 2(01). Gtyl° (as appears in ThATl) is completely conserved in 
more than thirty ENTs from organism as diverse as C. elegans and A. thaliana analysed by 
Acimovic &: Cae (2002). Glycines are also completely conserved at positions 161 and 166 
of ThAT] (within TMS S). A conserved proline at position 151 fulls in the 
intracytoplasmic loop between TMS 4 and S. A NXXDXXGR motif or very similar is 
found in the TMS 8 of most of the ENTs analysed - there is some speculation that these 
residues are involved in recognition of substrates or inhibitors. A putative motif of 
unknown functional significance, S/fNGY has been observed in TMD 10. Interestingly, in 
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the nucleobase transporter sequences only the threonine and asparagine residues are 
conserved in this region. 
Found throughout the ENT family, the conserved residues most likely play some role in 
structural integrity, substrate recognition and/or translocation. Some of the sequence 
variations found for the various taxonomic groups will determine the functional differences 
observed for the different transporters such as sensitivity to inhibitors, the higher affinities 
with which the parasite transporters recognise their substrates, and the differences in 
energy-dependency. 
The relatively recent explosion in sequence data available has obviously provided a 
veritable gokimine for gene discovery. Certainly, nucleobase and nucleoside transport in 
protoman parasites has proved to be much more complicated at the molecular level than 
had been anticipated from biochemical investigations. Clearly, with a muhitude of 
potential transporters still to characterise functionally and transport activities still to 
characterise genetically there remains much to explore and clarify in the elucidation of 
nucleobase and nucleoside transport in T. h. brucei. 
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9. General DIscussion 
The main aim of project was to further our understanding of the purine transporters of the 
parasitic protozoan Trypanosoma brucei at the biochemical and molecular level, with an 
emphasis on advancing the current knowledge regarding purine nucleobase uptake. 
The study of selectivity and substrate recognition is particularly challenging for 
transporters. yet is of obvious pbannacological relevance given the importance of drug 
uptake by target cells. Particular difficulties include obtaining genetic information through 
functional cloning. considering the problems with (over)expressing membrane proteins, 
not to mention purifying them in an active configuration. Even when the gene encoding a 
particular transport activity is known, obtaining structural data through crystallisation is 
extremely difficult. We have therefore opted to study substrate-transporter interactions 
using kinetic approaches using intact cells to characterise transporters in situ. 
Using these techniques it bas been possible to identify and quantify the components 
necessary for the recognition of purine substrates by the H2 transporter of T. b. brucei and 
by the hFNTt transporter of human erythrocytes. As well as identifying differences in the 
host and parasite transporters these experiments have allowed the prediction of which 
analogues are most likely to be efficiently accumulated by the parasite. The relevance of 
the models and the implication for possible rational uptake of trypanocides becomes even 
more evident when it is considered that models constructed for the Leishmania major 
NBTt transporter (Figure 9.1) show that this transporter appears to recognise its substrates 
in a very similar manner to H2. This raises the possibility of a broad-spectrum 
trypanocidelleishmanicide, although caution is warranted since the LmNBTI model has 
been constructed using data obtained from experiments with promastigotes rather than 
from the amastigotes that cause human disease. In addition, even if the same activity is 
evident in the clinically relevant life-cycle stage, the situation is further complicated by the 
intracellular status of Leishmania amastigotes, which introduces further barriers between a 
drug in the bloodstream and the parasite. 
As an ahemative to using the free energy calculations used for a large portion of this 
thesis. a recent study (Chang, et al., 2004) used computational methods to define the 
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different pharmacologically relevant components of the substrate and combined this 
information with inhibition data to detennine the molecular requirements for 
substrates/inhibitors of some of the human nucleoside transporters. 
HYPOXANTIDNE 
LlGo = -35.1 kl/mol 
H H 
'N / 12.5 
ADENINE 
LlGo = -30.5 kl/mol 
Figure 9.1. Model of the interactions between purines and the L. major NBT1 transporter. 
Estimations of the Gibbs free energy of these interactions are given in kJ/mol. This model 
is reproduced from AI-Salabi et al. (2003). 
The aim of the study in Chapter 3 was not so much to identify purine antimetabolites with 
strong trypan cidal activity. Rather, the intention was to prove the principle, that selective 
accumulati n by the parasite is possible and such purines can be designed or selected based 
on our sub trate-recognition models. The list of purine analogues tested for this study was 
therefor n t exhau tive and there remains a large number of molecules that could still be 
tested both fc r uptake by the various T. b. brucei transporters and for trypanocidal activity 
in vitro and in vivo. One potentially interesting purine-like molecule of interest is the 
immuno uppressant azathioprine, which has been administered to mouse models of late 
stage trypan ffila 1 to modulate the severe post-treatment reactive encephalopathy 
(PTRE) that devel p following non-curative berenil treatment (Hunter, et aI., 1992; 
Kennedy 1999). hi sub tance is a purine analogue (Figure 9.2) and it would be 
intere ing t determine if it has any anti-trypanosomal activity and if this activity is related 
to th pr enti n f PTRE or jf the anti-inflammatory effect of the drug is an 
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immunological one only. The use of azathioprine in a recent case of HAT misdiagnosed as 
systemic lupus erythrematosus in a Western hospital did not lead to an improvement in the 
patient's condition ahhougb the treatment schedules used may not have been ideal to 
detennine any effect on the parasites (K,irrstetter, et 01., 2004). The H2 transporter is not 
fond of bulky substitutions so it is unclear if azathioprine would be taken up by this 
transporter. However, this compound is very lipophilic and is therefore likely to diffuse 
across most biomembranes. 
N ) 
~ 
Fi"ure 9.2. Structure of the immUOOSUP.PfeSS8Ilt azathioprine. 
Chapter 6 details the attempts to design tools for functional complementation as a means of 
gene identification in T. b. brucei. It was intended to induce a null background for purine 
nucleobase transport by gradually increasing exposure to a toxic purine nucleobase, 
allopurinol. The growth conditions, on inosine as sole purine source, were designed to 
select for transporter-related allopurinol resistance. This mechanism is widely held to be 
the main cause of drug resistance in African trypanosomes (De Koning, 2001; Miser, et 
01., 2(03). A clonal population of nucleobase transport-deficient trypanosomes would be 
an ideal expression system for a genomic expression library following selection on 
hypoxanthine as sole purine source. A similar strategy has worked very well for the 
cloning of the first protoman nucleoside transporters, from Leishmania donovani, where 
LdNTl and LdNT2 were identified after complementing strains resistant to tubercidin and 
fonnycin B. respectively (Vasudevan, et 01., 1998; Carter, et 01., 2000). However we found 
allopurinol resistance impossible to induce by stepwise increasing exposure and that this 
was due to the fact that allopurinol uptake in T. b. brucei is mediated by two sets of 
transporters (Natto, et 01., submitted), in contrast to the situation for tubercidin (Aronow, et 
01 .• 1987), fonnycin B (Aronow, et 01., 1987) or allopurinol in Leishmania promastigotes 
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(AI-Salabi, et 01., 2(03). Functional complementation of T. b. brucei transporters in yeast 
is certainly possible, as demonstrated by the cloning of TbATl (Mliser, et 01., 1999) and an 
expression library of genomic ftagments was constructed and validated. However, the 
availability of increasing amounts of genomic information that were becoming available at 
the time meant that direct cloning by PCR of novel T. b. brucei nucleosidelnucleobase 
transport genes was becoming possible. 
One of the genes we cloned in this filshion, TbNBT1, and expressed in pmine transport-
deficient S. cerevis;ae, displayed excellent activity as a nucleobase transporter as 
demonstrated by its ability to mediate accumulation of eH] hypoxanthine, eH] adenine 
and eH] allopwinol. Similar results were obtained for TbNBTl using the Xenopus laevis 
oocyte expression system. Moreover. a nucleobase transporter with identical kinetic 
characteristics was identified in T. b. brucei procyclics and its activity knocked down by 
9()OA, using RNAi fragments of TbNBT1. These results not only represent the cloning of the 
fll'st protozoan nucleobase transporter they also establish the validity of the yeast 
expression system chosen. Since the publication of these results, another very similar gene 
from T. b. brucei and a related gene from L. major have also been shown to encode 
nucleobase transporters (Henriques, et 01 .• 2003; Sanchez, et 01 .• 2004), indicating that 
TbNBT J is likely to be the first of a subfamily of nucleobase transporters within the ENT 
family. 
We have now cloned and characterised several additional ENT-family genes from T. b. 
bruce; (Chapter 8) and are aiming to further investigate the molecular requirements that 
determine substrate specificity. Such studies will employ the construction of chimeric 
transporters to identify sequences determining recognition of nucleosides over nucleobases 
(and vice versa) and site directed mutagenesis based on our detailed kinetic analysis 
coupled with multiple-gene alignments. The dataset of well-characterised ENT transporters 
in T. b. brucei is highly suited to this purpose, and the yeast expression system allows 
positive and negative selection based on growth phenotype. It is possible that some of the 
ENT transporter genes may not encode purine transporters but one of the T. b. bruce; 
pyrimidine transport activities (De Koning and Jarvis, 1998; De Koning, unpublished), or 
one of the pentamidine transport activities, HAPTI and LAPTI (De Koning, 200lb; 
Matovu, et aI., 2(03). The cloning of the first protozoan pyrimidine transporter is one of 
the important next challenges. 
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The presence of up to 17 ENT family genes in the T. b. brucei genome clearly poses some 
interesting questions. There are at least 6 genes encoding functional P I-type transporters 
alone. Kinetically, the PI activities in procyclics (De Koning, et 01., 1998) and Iong-
slender bloodstream forms (De Koning & Jarvis, 1999) are indistinguishable. In short-
stumpy bloodstream forms, a PI-type adenosine transport activity is also present (De 
Koning, unpublished), but is less well characterised, partially due to the difficulty in 
obtaining large numbers of these cells. Recently, Sanchez and colleagues (2004) presented 
evidence that "TbNTIO", which is AT-like B in our annotation, is expressed exclusively in 
short-stumpy forms, but the evidence rested entirely on the presence of mRNA, rather than 
transport assays with short-stumpy trypanosomes. Still, it is possible that the numerous 
different life-cycle stages express subtly different purine nucleoside transporters. Certainly 
this seems to be true for nucleobase transporters ofprocyclics (De Koning & Jarvis, 1997a) 
and long-slender bloodstream forms (De Koning & Jarvis, 1997b) and a P2-type activity is 
not expressed in short-stumpy forms (De Koning, unpublished) or procyclics (De Koning, 
et 01., 1998). Furthermore, it is possible that some nucleoside transporters are located in 
organellar membranes, such as the mitochondrial membrane, rather than in the plasma 
membrane. 
Dissecting the individual physiological roles of this confusing array of similar but non-
identical transporters is a major challenge. RNAi can be part of the overall strategy but in 
some cases the transporter genes are too similar for this approach and targeted gene 
deletion would be necessary. Nor is it likely that sufficiently specific antibodies could be 
raised to each individual transporter, but epitope tagging of particular genes should be 
possible. Such strategies may also aid in the elucidation of any functional role for ENT 
transporters that so far have not shown any ability to transport purine or pyrimidines in 
heterologous syste~ including ThNT3, ThNT4 and AT-like A. 
In this new century, African trypanosomiasis continues to be a major heahh threat both to 
humans and. through their livestock, their livelihood The uhimate driving force behind 
many research studies involving T. brucei spp. is the very real need for novel therapeutics. 
The quest for new drugs is not inexpensive or straightforward, requiring expertise drawn 
from several disciplines. Beyond the discovery of any new drugs are problems of 
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production and distribution. And yet still the search for these life-saving compounds goes 
on. 
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Appendix A: Media. Buffers and Solutions 
LBmedium 
Tryptone 10 gil 
Yeast extract 5 gil 
NaCI 10 gil 
pH 7.0 
Sterilisation by autoclaving 
SOC medium 
Bactotryptone 
Yeast extract 
NaCI 
KCl 
MgCh 
MgS04 
Glucose 
20 gil 
5 gil 
10mM 
2.5mM 
10mM} 
10mM 
20mM 
Twanosome assay buffer 
HEPES 
NaCI 
KCI 
CaCh 
MgS04 
NaH2P04 
MgC12 
NaHCO) 
Glucose 
pH 7.3 
33mM 
98mM 
4.6mM 
0.55 mM 
0.07mM 
5.8mM 
0.3mM 
23mM 
14mM 
Erythrocyte assaY buffer 
NaCI 140mM 
KCl 5mM 
Tris 20mM 
MgCh 2mM 
EDTA 0.1 mM 
pH 7.4 
added after sterilisation by autoclaving 
A2 
Yeast assaY buffer 
HEPES 
NaCI 
KCI 
CaCh 
MgSO .. 
NaH2PO .. 
MgCI2 
NaHCO) 
pH 7.3 
33mM 
98mM 
4.6mM 
O.sS mM 
0.07 mM 
S.8mM 
0.3mM 
23mM 
Appendix A: Media, Buffers and Solutions 
PSG fDhosphate-buffered saline plus glucose) 
PS butTer: 
Na2HPO .. (anhydrous) 13.48 g 
NafhPO ... 2H20 0.78 g 
NaCI 4.2S g 
Make to one litre with dH20 
Add six volumes of PS to four volumes of glucose solution to give final glucose 
concentration of 1 % 
pH 8.0 exactly 
CBSS (Carte"s balanced salt solution) 
HEPES 
NaC) 
KCI 
CaCh 
MgSO .. 
Na2HPO .. 
D-gJucose 
pH 7.4 
25mM 
120mM 
S.4mM 
0.55 mM 
0.4mM 
5.6mM 
11.1 mM 
A3 
Appendix A: Media, Buffers and Solutions 
HMI-9 (and purine nucleobase-free HMI-9) 
(For SOOmI of medium) 
IIcovcs MEM 
Hypoxanthine (or adenosine for purine nucleobase-free) 
Kanamycin 
Penicillin 
Streptomycin 
Bathocuprione disulphonic acid 
Thymidine 
Pyruvate 
p-mercaptoethanol 
Cysteine 
FCS (or dialysed FCS for purine nucleobase-free) 
SDM-79 
(For 1 litre of medium) 
S-MEM FI4 powder 
Medium 199 TC4S powder 
MEM amino acids (SOX) 
MEM non-essential Amino acids (100) 
Glucose 
HEPES 
MOPS 
NaHCO) 
Sodium pyruvate 
L-alanine 
L-arginine 
L-glutamine 
L-methionine 
L-phenylalanine 
L-proline 
L-serine 
L-taurine 
L-threonine 
L-tyrosine 
Adenosine 
Guanosine 
Glucosamine Hel 
Folic acid 
Para-aminobenzoic acid 
Biotin 
FCS 
pH 7.3 
A4 
7g 
2g 
8ml 
6ml 
1 g 
8g 
5g 
2g 
100mg 
200mg 
100mg 
300mg 
70mg 
80rng 
600mg 
60rng 
160mg 
359mg 
lOOmg 
10mg 
10mg 
50mg 
4mg 
2mg 
0.2mg 
10% 
365ml 
ImM 
30 J.Lglml 
50 ulrnl 
50 J.Lglml 
50 J.LM 
160 J.LM 
lmM 
2mM 
lmM 
20% 
PETM (Purine""" tryoanO§Omfl medium) 
(For 1 litre of medium) 
RPMI 1640 medium 
8-MEM powder 
8m1 MEM (SOx) amino acids 
6m1 MEM non-essential amino acids (100) 
CaCh.2H20 
Glucose 
HEPES 
MOPS 
NaHCOJ 
Sodium pyruvate 
L-alanine 
L-arginine 
L-glutamine 
L-methionine 
L-phenylalanine 
L-proline 
L-serine 
L-threonine 
L-tyrosine 
L-taurine 
Glucosamine 
Folic acid 
p-aminobenzoic acid 
Biotin 
Sodium acetate 
pH 7.3 
Appendix A: Media, Buffers and Solutions 
130ml 
7g 
8ml 
6ml 
39mg 
1 g 
8g 
Sg 
2g 
0.2 g 
0.2 g 
0.1 g 
0.3 g 
70mg 
80rng 
0.6 g 
60rng 
0.35 g 
0.1 g 
0.3 g 
SOmg 
Smg 
20mg 
0.2mg 
6.Smg 
Supplement with 7.S mgtl bovine hemin, S% dialysed FCS and inosine (0.2 mM final) 
reAD (yeast extract - DfDtone - dextrose and adenine medium) 
(For 600 ml of medium) 
Yeast extract 
Peptone 
Glucose 
Adenine hemisulphate 
dH20 
6g 
12 g 
12 g 
60mg 
to 600 ml 
(For solid medium -+ Bacto-agar 109) 
pH 5.6 
Autoclave 
AS 
Appendix A: Media, Buffers and Solutions 
SC-URA (synthetic como/ere medium minus uracil) 
(For 600 ml of medium) 
Difco Yeast Nitrogen Base w/o amino acids 
Glucose 
Synthetic complete drop out mix 
dH20 
(For solid medium --+ Bacto-agar 109) 
pHS.6 
Autoclave 
Synthetic comoltte drop out mix minus uracil 
4g 
12g 
O.S g 
t0600ml 
Adenine hemisulphate 
Arginine Hel 
Histidine Hel 
Isoleucine 
2 g (or 1.47 g adenine free base) 
2g 
Leucine 
Lysine Hel 
Methionine 
Phenylalanine 
Homoserine 
Tryptophan 
Tyrosine 
Valine 
NaCI 5 gil 
Yeast extract 20 gil 
Bactotryptone 3 S gil 
[S.O M] NaOH I mVl 
DNA extraction buffer 
[1.0 M] Tris (pHS) 
[O.S M] EDTA 
[S.O M] NaCI 
dH20 
2g 
2g 
4g 
2g 
2g 
3g 
6g 
3g 
2g 
9g 
10ml 
2 ml 
4ml 
to 200 ml 
A6 
;1--
TBE running buffer 
Tria 
Boric acid 
BDTA 
d1120 
TEbuffsr 
pH 8.0 
TEB1 
S3.9 g 
27.S g 
2.3 g 
to S htres 
10 mM (0.605 g) 
1 mM (0.186 g) 
to SOOmI 
Potassium acetate 
CaCh 
30mM 
10mM 
SOmM 
lOOmM 
MnCh 
RbCI 
15% glycerol 
pHS.8 
TE82 
MOPS 
CaCh 
RbCI 
1S% glycerol 
pH6.S 
IOmM 
7SmM 
10mM 
ZOx Northern at' buffer 
Appendix A: Media, Buffers and Solutions 
0.36 M (96.S g heptahydrate per litre) 
0.04 M (S.S g monohydrate per litre) 
1x Northern gel buffer, 3% formaldehYde 
20X Northern gel buffer 
Stock fonnaldehyde (37%) 
dH20 
25 ml 
44ml 
430ml 
A7 
RNA load/no buffer 
50-;(, glycerol 
lmMEDTA 
0.4% bromphenol blue 
Made up with DEPC adH;!O and autoclaved 
DEPC-dHzO 
0.1% DEPC in dHl0 
IDcubated at room temperature overnight 
Autoclaved 
20xSSC 
Sodium citrate 0.3 M 
NaCJ 3.0M 
pH 7.0 
Autoclave 
Dtahardt's solution (x lQQ) 
(For SOO ml) 
FicoU 400 109 
Polyvinylpyrrolidone 109 
BSA 109 
TIVDBOosomt slabi/'tes 
Appendix A: Media, Buffers and Solutions 
50 mJ of culture (I x 106 cells/ml) centrifuged at 1200 rpm for 10 minutes and resuspended 
pntly in 3-4 ml of fresh medium. An equal volume of freezing medium (l0% glycerol in 
beat-inactivated FCS) mixed thoroughly but gently. Cell suspension transferred into 
cryotubes and placed in cotton wool-lined container. Container placed in -70 °c freezer 
overnight and then transferred to liquid nitrogen storage container. 
"'cled,/ stabi/'tes 
600 J11 of overnight LB culture mixed with 400 J11 of 40% glycerol in LB broth. Tubes 
ftozen at -20 °C and then stored at -70 °C until required. 
AS 
Appendix A: Media, Buffers and Solutions 
Yeast slabi/ales 
850 J.l1 of overnight broth culture mixed with I SO J.l1 of sterile glycerol. Tubes frozen at -20 
°C IIId then stored at -·70 °c. 
A9 
Appendix B: Restriction Enzyme Recognition and Incision Sites 
Appendix B: Restriction Enzyme Recognition and Incision Sites 
BamHI G-l.-GATCC 
EeoRl G-l.-AATTC 
HindIII A-l.-AGCTT 
Not! Gc-l.-GGCCGC 
Pst! CTGCA-l.-G 
Sal! G-l.-TCGAC 
Sau3AI -l.-GATC 
XbaI T-l.-CTAGA 
XhoI C-l.-TCGAG 
AIO 
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AI-Salabi, M. I., Wallace, L. J. M., & De Koning, H. P. (2003) A Leishmania major 
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